Patent Application
20180228780
This disclosure relates to inhibitors of one or more proteins in the Wnt pathway, including inhibitors of one or more Wnt proteins, and compositions comprising the same. More particularly, it concerns the use of an indazole compound or salts or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
The Wnt growth factor family includes more than 10 genes identified in the mouse and at least 19 genes identified in the human. Members of the Wnt family of signaling molecules mediate many short- and long-range patterning processes during invertebrate and vertebrate development. The Wnt signaling pathway is known for its role in the inductive interactions that regulate growth and differentiation, and it also plays roles in the homeostatic maintenance of post-embryonic tissue integrity. Wnt stabilizes cytoplasmic β-catenin, which stimulates the expression of genes including c-myc, c jun, fra-1, and cyclin Dl. In addition, misregulation of Wnt signaling can cause developmental defects and is implicated in the genesis of several human cancers. The Wnt pathway has also been implicated in the maintenance of stem or progenitor cells in a growing list of adult tissues including skin, blood, gut, prostate, muscle, and the nervous system.
The present disclosure provides methods and reagents, involving contacting a cell with an agent, such as an indazole compound, in a sufficient amount to antagonize a Wnt activity, e.g., to reverse or control an aberrant growth state or correct a genetic disorder due to mutations in Wnt signaling components.
Some embodiments disclosed herein include Wnt inhibitors containing an indazole core. Other embodiments disclosed herein include pharmaceutical compositions and methods of treatment using these compounds.
One embodiment disclosed herein includes a compound having the structure of Formula I:
as well as prodrugs and pharmaceutically acceptable salts thereof.
In some embodiments of Formula (I):
R1, R2, and R4 are independently selected from the group consisting of H and halide;
R3 is selected from the group consisting of -heteroaryl optionally substituted with 1-4 R6 and -heterocyclyl optionally substituted with 1-10 R7;
R5 is selected from the group consisting of H, -heteroaryl optionally substituted with 1-4 R8, -heterocyclyl optionally substituted with 1-10 R9, and -aryl optionally substituted with 1-5 R10;
each R6 is independently selected from the group consisting of halide, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R11, —(C2-4 alkenylene)pheterocyclyl optionally substituted with 1-10 R11, —(C2-4 alkynylene)pheterocyclyl optionally substituted with 1-10 R11, —(C1-4 alkylene)pcarbocyclyl optionally substituted with 1-12 R12, —(C2-4 alkenylene)pcarbocyclyl optionally substituted with 1-12 R12, —(C2-4alkynylene)pcarbocyclyl optionally substituted with 1-12 R12, —(C1-4 alkylene)paryl optionally substituted with 1-5 R13, —(C2-4 alkenylene)paryl optionally substituted with 1-5 R13, —(C2-4 alkynylene)paryl optionally substituted with 1-5 R13, —NHC(═O)R14, —NR15R16, —(C1-6 alkylene)NR17R18, —(C2-6 alkenylene)NR17R18, —(C2-6 alkynylene)NR17R18, and —(C1-4alkylene)pOR24;
each R7 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
each R8 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), halide, —CF3, —OCH3, —CN, and —C(═O)R19;
each R9 is independently selected from the group consisting of —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), halide, —CF3, —CN, and —OCH3;
each R10 is independently selected from the group consisting of —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), halide, —CF3, —CN, —(C1-6 alkylene)pNHSO2R19, —(C2-6 alkenylene)pNHSO2R19, —(C2-6 alkynylene)pNHSO2R19, —NR15(C1-6 alkylene)NR15R16, —NR15(C2-6 alkenylene)NR15R16, —NR15(C2-6 alkynylene)NR15R16, —(C1-6 alkylene)pNR15R16, —(C2-6 alkenylene)pNR15R16, —(C2-6 alkynylene)pNR15R16, and —OR27;
each R11 is independently selected from the group consisting of amino, —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
each R12 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
each R13 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
each R14 is independently selected from the group consisting of —(C1-9 alkyl), —(C1-4 haloalkyl), —(C2-9 alkenyl), —(C2-9 alkynyl), -heteroaryl optionally substituted with 1-4 R20, -aryl optionally substituted with 1-5 R21, —CH2aryl optionally substituted with 1-5 R21, -carbocyclyl optionally substituted with 1-12 R22, —CH2carbocyclyl optionally substituted with 1-12 R22, —(C1-4 alkylene)pNR25R26, —(C2-4 alkenylene)pNR25R26, —(C2-4 alkynylene)PNR25R26, -heterocyclyl optionally substituted with 1-10 R23, and —CH2heterocyclyl optionally substituted with 1-10 R23; each R15 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl);
each R16 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —CH2aryl optionally substituted with 1-5 R21, and —CH2carbocyclyl optionally substituted with 1-12 R22;
each R17 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl);
each R18 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —CH2aryl optionally substituted with 1-5 R21 and —CH2carbocyclyl optionally substituted with 1-12 R22;
each R19 is independently selected from the group consisting of —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl);
each R20 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
each R21 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
each R22 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
each R23 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
R24 is selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R23, —(C2-4 alkenylene)pheterocyclyl optionally substituted with 1-10 R23, —(C2-4 alkynylene)pheterocyclyl optionally substituted with 1-10 R23, —(C1-4 alkylene)pcarbocyclyl optionally substituted with 1-12 R22, —(C2-4alkenylene)pcarbocyclyl optionally substituted with 1-12 R22, —(C2-4 alkynylene)pcarbocyclyl optionally substituted with 1-12 R22, —(C1-4 alkylene)Paryl optionally substituted with 1-5 R21, —(C2-4 alkenylene)paryl optionally substituted with 1-5 R21, —(C2-4 alkynylene)paryl optionally substituted with 1-5 R21, —(C1-6 alkylene)pNR25R26, —(C2-4 alkenylene)PNR25R26, and —(C2-4alkynylene)pNR25R26;
each R25 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl);
each R26 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl);
R27 is selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R23, —(C2-4 alkenylene)pheterocyclyl optionally substituted with 1-10 R23, —(C2-4 alkynylene)pheterocyclyl optionally substituted with 1-10 R23, —(C1-6 alkylene)pNR25R26, —(C2-6 alkenylene)pNR25R26, and —(C2-6 alkynylene)PNR25R26; and
each p is independently an integer of 0 or 1.
In some embodiments of Formula (I):
R1, R2, and R4 are independently selected from the group consisting of H and halide;
R3 is selected from the group consisting of -heteroaryl optionally substituted with 1-4 R6 and -heterocyclyl optionally substituted with 1-10 R7;
R5 is selected from the group consisting of H, -heteroaryl optionally substituted with 1-4 R8, -heterocyclyl optionally substituted with 1-10 R9, and -aryl optionally substituted with 1-5 R10;
each R6 is independently selected from the group consisting of halide, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R11, —(C2-4 alkenylene)pheterocyclyl optionally substituted with 1-10 R11, —(C2-4 alkynylene)pheterocyclyl optionally substituted with 1-10 R11, —(C1-4 alkylene)pcarbocyclyl optionally substituted with 1-12 R12, —(C2-4 alkenylene)pcarbocyclyl optionally substituted with 1-12 R12, —(C2-4alkynylene)pcarbocyclyl optionally substituted with 1-12 R12, —(C1-4 alkylene)paryl optionally substituted with 1-5 R13, —(C2-4 alkenylene)paryl optionally substituted with 1-5 R13, —(C2-4 alkynylene)paryl optionally substituted with 1-5 R13, —NHC(═O)R14, —NR15R16, —(C1-6 alkylene)NR17R18, —(C2-4 alkenylene)NR17R18, and —(C1-4 alkynylene)NR17R18, —OR24;
each R7 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
each R8 is independently selected from the group consisting of —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), halide, —CF3, —OCH3, —CN, and —C(═O)R19;
each R9 is independently selected from the group consisting of —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), halide, —CF3, —CN, and —OCH3;
each R10 is independently selected from the group consisting of —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), halide, —CF3, —CN, —(C1-6 alkylene)pNHSO2R19, —(C2-6 alkenylene)pNHSO2R19, —(C2-6 alkynylene)pNHSO2R19, —NR15(C1-6 alkylene)NR15R16, —NR15(C2-6 alkenylene)NR15R16, —NR15(C2-6 alkynylene)NR15R16, —(C1-6 alkylene)pNR15R16, —(C2-6 alkenylene)pNR15R16, —(C2-6 alkynylene)pNR15R16, and —OR27;
each R11 is independently selected from the group consisting of amino, —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
each R12 is independently selected from the group consisting of —(C1-4 alkyl), —(C1-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
each R13 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
each R14 is independently selected from the group consisting of —(C1-9 alkyl), —(C2-4 alkenyl), —(C2-9 alkynyl), -heteroaryl optionally substituted with 1-4 R20, -aryl optionally substituted with 1-5 R21, —CH2aryl optionally substituted with 1-5 R21, -carbocyclyl optionally substituted with 1-12 R22, —CH2carbocyclyl optionally substituted with 1-12 R22, —(C1-4 alkylene)pNR25R26, —(C2-4 alkenylene)pNR25R26, —(C2-4 alkynylene)PNR25R26, -heterocyclyl optionally substituted with 1-10 R23, and —CH2heterocyclyl optionally substituted with 1-10 R23;
each R15 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl);
each R16 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —CH2aryl optionally substituted with 1-5 R21, and —CH2carbocyclyl optionally substituted with 1-12 R22;
each R17 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl);
each R18 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —CH2aryl optionally substituted with 1-5 R21 and —CH2carbocyclyl optionally substituted with 1-12 R22;
each R19 is independently selected from the group consisting of —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl);
each R20 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF2, and —CN;
each R21 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF2, and —CN;
each R22 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF2, and —CN;
each R23 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF2, and —CN;
R24 is selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R23, —(C2-4 alkenylene)pheterocyclyl optionally substituted with 1-10 R23, —(C2-4 alkynylene)pheterocyclyl optionally substituted with 1-10 R23, —(C1-4 alkylene)pcarbocyclyl optionally substituted with 1-12 R22, —(C2-4alkenylene)pcarbocyclyl optionally substituted with 1-12 R22, —(C2-4 alkynylene)pcarbocyclyl optionally substituted with 1-12 R22, —(C1-4 alkylene)Paryl optionally substituted with 1-5 R21, —(C2-4 alkenylene)paryl optionally substituted with 1-5 R21, —(C2-4 alkynylene)paryl optionally substituted with 1-5 R21, —(C1-6 alkylene)pNR25R26, —(C2-4 alkenylene)PNR25R26, and —(C2-4alkynylene)pNR25R26;
each R25 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl);
each R26 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl);
R27 is selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl). —(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R23, —(C2-4 alkenylene)pheterocyclyl optionally substituted with 1-10 R23, —(C2-4 alkynylene)pheterocyclyl optionally substituted with 1-10 R23, —(C1-6 alkylene)pNR25R26, —(C2-6 alkenylene)pNR25R26, and —(C2-6 alkynylene)PNR25R26; and each p is independently an integer of 0 or 1.
Some embodiments include stereoisomers and pharmaceutically acceptable salts of a compound of Formula (I).
Some embodiments include pro-drugs of a compound of Formula (I).
Some embodiments of the present disclosure include pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier, diluent, or excipient.
Other embodiments disclosed herein include methods of inhibiting one or more members of the Wnt pathway, including one or more Wnt proteins by administering to a patient affected by a disorder or disease in which aberrant Wnt signaling is implicated, such as cancer and other diseases associated with abnormal angiogenesis, cellular proliferation, cell cycling and mutations in Wnt signaling components, a compound according to Formula (I). Accordingly, the compounds and compositions provided herein can be used to treat cancer, to reduce or inhibit angiogenesis, to reduce or inhibit cellular proliferation and correct a genetic disorder due to mutations in Wnt signaling components.
Non-limiting examples of diseases which can be treated with the compounds and compositions provided herein include a variety of cancers, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis, scleroderma, mycotic and viral infections, osteochondrodysplasia, Alzheimer's disease, lung disease, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), polyposis coli, osteoporosis-pseudoglioma syndrome, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia syndrome, Müllerian-duct regression and virilization, SERKAL syndrome, diabetes mellitus type 2, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication syndrome, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease, and Rett syndrome.
Some embodiments of the present disclosure include methods to prepare compounds of Formula (I).
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the disclosure, as claimed.
Provided herein are compositions and methods for inhibiting one or more members of the Wnt pathway, including one or more Wnt proteins. Other Wnt inhibitors and methods for using the same are disclosed in U.S. application Ser. Nos. 12/852,706; 12/968,505; 13/552,188; 13/800,963; 13/855,874; 13/887,177 13/938,691; 13/938,692; 14/019,103; 14/019,147; 14/019,940; 14/149,948; 14/178,749; 14/331,427; 14/334,005; and 14/664,517 and U.S. Provisional Application Ser. Nos. 61/232,603; 61/288,544; 61/305,459; 61/620,107; 61/642,915; 61/750,221; 61/968,350; 62/047,324; 62/047,371; 62/047,395; 62/047,401; 62/047,406; 62/047,438; 62/047,509; 62/047,575; 62/047,567, all of which are incorporated by reference in their entirety herein.
Some embodiments provided herein relate to a method for treating a disease or disorder including, but not limited to, cancers, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis, scleroderma, mycotic and viral infections, bone and cartilage diseases, Alzheimer's disease, lung disease, osteoarthritis, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), polyposis coli, bone density and vascular defects in the eye (Osteoporosis-pseudoglioma Syndrome, OPPG), familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia, Müllerian-duct regression and virilization, SERKAL syndrome, type II diabetes, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease, and Rett syndrome.
In some embodiments, non-limiting examples of bone and cartilage diseases which can be treated with the compounds and compositions provided herein include bone spur (osteophytes), craniosynostosis, fibrodysplasia ossificans progressiva, fibrous dysplasia, giant cell tumor of bone, hip labral tear, meniscal tears, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), osteochondritis dissecans, osteochondroma (bone tumor), osteopetrosis, relapsing polychondritis, and Salter-Harris fractures.
In some embodiments, pharmaceutical compositions are provided that are effective for treatment of a disease of an animal, e.g., a mammal, caused by the pathological activation or mutations of the Wnt pathway. The composition includes a pharmaceutically acceptable carrier and a compound as described herein.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents, applications, published applications, and other publications are incorporated by reference in their entirety. In the event that there is a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.
As used herein, “alkyl” means a branched, or straight chain chemical group containing only carbon and hydrogen, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, sec-pentyl and neo-pentyl. Alkyl groups can either be unsubstituted or substituted with one or more substituents. In some embodiments, alkyl groups include 1 to 9 carbon atoms (for example, 1 to 6 carbon atoms, 1 to 4 carbon atoms, or 1 to 2 carbon atoms).
As used herein, “alkenyl” means a straight or branched chain chemical group containing only carbon and hydrogen and containing at least one carbon-carbon double bond, such as ethenyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, and the like. In various embodiments, alkenyl groups can either be unsubstituted or substituted with one or more substituents. Typically, alkenyl groups will comprise 2 to 9 carbon atoms (for example, 2 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 carbon atoms).
“Exocyclic double bond” means a carbon-carbon double bond connected to and hence external to, a ring structure.
As used herein, “alkynyl” means a straight or branched chain chemical group containing only carbon and hydrogen and containing at least one carbon-carbon triple bond, such as ethynyl, 1-propynyl, 1-butynyl, 2-butynyl, and the like. In various embodiments, alkynyl groups can either be unsubstituted or substituted with one or more substituents. Typically, alkynyl groups will comprise 2 to 9 carbon atoms (for example, 2 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 carbon atoms).
As used herein, “alkylene” means a bivalent branched, or straight chain chemical group containing only carbon and hydrogen, such as methylene, ethylene, n-propylene, iso-propylene, n-butylene, iso-butylene, sec-butylene, tert-butylene, n-pentylene, iso-pentylene, sec-pentylene and neo-pentylene. Alkylene groups can either be unsubstituted or substituted with one or more substituents. Alkylene groups can be saturated or unsaturated (e.g., containing —C═C— or —C≡C— subunits), at one or several positions. In some embodiments, alkylene groups include 1 to 9 carbon atoms (for example, 1 to 6 carbon atoms, 1 to 4 carbon atoms, or 1 to 2 carbon atoms).
As used herein, “alkenylene” means a bivalent branched, or straight chain chemical group containing only carbon and hydrogen and containing at least one carbon-carbon double bond, such as ethenylene, 1-propenylene, 2-propenylene, 2-methyl-1-propenylene, 1-butenylene, 2-butenylene, and the like. In various embodiments, alkenylene groups can either be unsubstituted or substituted with one or more substituents. Typically, alkenylene groups will comprise 2 to 9 carbon atoms (for example, 2 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 carbon atoms).
As used herein, “alkynylene” means a bivalent branched, or straight chain chemical group containing only carbon and hydrogen and containing at least one carbon-carbon triple bond, such as ethynylene, 1-propynylene, 1-butynylene, 2-butynylene, and the like. In various embodiments, alkynylene groups can either be unsubstituted or substituted with one or more substituents. Typically, alkynylene groups will comprise 2 to 9 carbon atoms (for example, 2 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 carbon atoms).
As used herein, “carbocyclyl” means a cyclic ring system containing only carbon atoms in the ring system backbone, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclohexenyl. Carbocyclyls may include multiple fused rings. Carbocyclyls may have any degree of saturation provided that at least one ring in the ring system is not aromatic. Carbocyclyl groups can either be unsubstituted or substituted with one or more substituents. In some embodiments, carbocyclyl groups include 3 to 10 carbon atoms, for example, 3 to 6 carbon atoms.
As used herein, “aryl” means a mono-, bi-, tri- or polycyclic group with only carbon atoms present in the ring backbone having 5 to 14 ring atoms, alternatively 5, 6, 9, or 10 ring atoms; and having 6, 10, or 14 pi electrons shared in a cyclic array; wherein at least one ring in the system is aromatic. Aryl groups can either be unsubstituted or substituted with one or more substituents. Examples of aryl include phenyl, naphthyl, tetrahydronaphthyl, 2,3-dihydro-1H-indenyl, and others. In some embodiments, the aryl is phenyl.
As used herein, “arylalkylene” means an aryl-alkylene-group in which the aryl and alkylene moieties are as previously described. In some embodiments, arylalkylene groups contain C1-4 (Aralkylene moiety. Exemplary arylalkylene groups include benzyl and 2-phenethyl.
As used herein, the term “heteroaryl” means a mono-, bi-, tri- or polycyclic group having 5 to 14 ring atoms, alternatively 5, 6, 9, or 10 ring atoms; and having 6, 10, or 14 pi electrons shared in a cyclic array; wherein at least one ring in the system is aromatic, and at least one ring in the system contains one or more heteroatoms independently selected from the group consisting of N, O, and S. Heteroaryl groups can either be unsubstituted or substituted with one or more substituents. Examples of heteroaryl include thienyl, pyridinyl, furyl, oxazolyl, oxadiazolyl, pyrrolyl, imidazolyl, triazolyl, thiodiazolyl, pyrazolyl, isoxazolyl, thiadiazolyl, pyranyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thiazolyl benzothienyl, benzoxadiazolyl, benzofuranyl, benzimidazolyl, benzotriazolyl, cinnolinyl, indazolyl, indolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, purinyl, thienopyridinyl, pyrido[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyridinyl, quinazolinyl, quinolinyl, thieno[2,3-c]pyridinyl, pyrazolol[3,4-b]pyridinyl, pyrazolo[3,4-c]pyridinyl, pyrazolo[4,3-c]pyridine, pyrazolo[4,3-b]pyridinyl, tetrazolyl, chromane, 2,3-dihydrobenzo[b][1,4]dioxine, benzo[d][1,3]dioxole, 2,3-dihydrobenzofuran, tetrahydroquinoline, 2,3-dihydrobenzo[b][1,4]oxathiine, and others. In some embodiments, the heteroaryl is selected from thienyl, pyridinyl, furyl, pyrazolyl, imidazolyl, pyranyl, pyrazinyl, and pyrimidinyl.
As used herein, “halo”, “halide” or “halogen” is a chloro, bromo, fluoro, or iodo atom radical. In some embodiments, a halo is a chloro, bromo or fluoro. For example, a halide can be fluoro.
As used herein, “haloalkyl” means a hydrocarbon substituent, which is a linear or branched, alkyl, alkenyl or alkynyl substituted with one or more chloro, bromo, fluoro, and/or iodo atom(s). In some embodiments, a haloalkyl is a fluoroalkyls, wherein one or more of the hydrogen atoms have been substituted by fluoro. In some embodiments, haloalkyls are of 1 to about 3 carbons in length (e.g., 1 to about 2 carbons in length or 1 carbon in length). The term “haloalkylene” means a diradical variant of haloalkyl, and such diradicals may act as spacers between radicals, other atoms, or between a ring and another functional group.
As used herein, “heterocyclyl” means a nonaromatic cyclic ring system comprising at least one heteroatom in the ring system backbone. Heterocyclyls may include multiple fused rings. Heterocyclyls may be substituted or unsubstituted with one or more substituents. In some embodiments, heterocycles have 5-7 members. In six membered monocyclic heterocycles, the heteroatom(s) are selected from one to three of O, N or S, and wherein when the heterocycle is five membered, it can have one or two heteroatoms selected from O, N, or S. Examples of heterocyclyl include azirinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl, 1,4,2-dithiazolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, morpholinyl, thiomorpholinyl, piperazinyl, pyranyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyridinyl, oxazinyl, thiazinyl, thiinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, piperidinyl, pyrazolidinyl imidazolidinyl, thiomorpholinyl, and others. In some embodiments, the heterocyclyl is selected from azetidinyl, morpholinyl, piperazinyl, pyrrolidinyl, and tetrahydropyridinyl.
As used herein, “monocyclic heterocyclyl” means a single nonaromatic cyclic ring comprising at least one heteroatom in the ring system backbone. Heterocyclyls may be substituted or unsubstituted with one or more substituents. In some embodiments, heterocycles have 5-7 members. In six membered monocyclic heterocycles, the heteroatom(s) are selected from one to three of O, N or S, and wherein when the heterocycle is five membered, it can have one or two heteroatoms selected from O, N, or S. Examples of heterocyclyl include azirinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl, 1,4,2-dithiazolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, morpholinyl, thiomorpholinyl, piperazinyl, pyranyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyridinyl, oxazinyl, thiazinyl, thiinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, piperidinyl, pyrazolidinyl imidazolidinyl, thiomorpholinyl, and others.
The term “substituted” refers to moieties having substituents replacing a hydrogen on one or more non-hydrogen atoms of the molecule. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. Substituents can include, for example, —(C1-9 alkyl) optionally substituted with one or more of hydroxyl, —NH2, —NH(C1-3 alkyl), and —N(C1-3 alkyl)2; —(C1-9 haloalkyl); a halide; a hydroxyl; a carbonyl [such as —C(O)OR, and —C(O)R]; a thiocarbonyl [such as —C(S)OR, —C(O)SR, and —C(S)R]; —(C1-9 alkoxyl) optionally substituted with one or more of halide, hydroxyl, —NH2. —NH(C1-3 alkyl), and —N(C1-3 alkyl)2: —OPO(OH)2; a phosphonate [such as —PO(OH)2 and —PO(OR′)2]; —OPO(OR′)R″; —NRR′; —C(O)NRR′; —C(NR)NR′R″; —C(NR′)R″; a cyano; a nitro; an azido; —SH; —S—R; —OSO2(OR); a sulfonate [such as —SO2(OH) and —SO2(OR)]; —SO2NR′R″; and —SO2R; in which each occurrence of R, R′ and R″ are independently selected from H; —(C1-9 alkyl); C6-10 aryl optionally substituted with from 1-3R′″; 5-10 membered heteroaryl having from 1-4 heteroatoms independently selected from N, O, and S and optionally substituted with from 1-3 R′″; C3-7 carbocyclyl optionally substituted with from 1-3 R′″; and 3-8 membered heterocyclyl having from 1-4 heteroatoms independently selected from N, O, and S and optionally substituted with from 1-3 R′″; wherein each R′″ is independently selected from —(C1-6 alkyl), —(C1-6 haloalkyl), a halide (e.g., F), a hydroxyl, —C(O)OR, —C(O)R, —(C1-6 alkoxyl), —NRR′, —C(O)NRR′, and a cyano, in which each occurrence of R and R′ is independently selected from H and —(C1-6 alkyl). In some embodiments, the substituent is selected from —(C1-6 alkyl), —(C1-6 haloalkyl), a halide (e.g., F), a hydroxyl, —C(O)OR, —C(O)R, —(C1-6 alkoxyl), —NRR′, —C(O)NRR′, and a cyano, in which each occurrence of R and R′ is independently selected from H and —(C1-6 alkyl).
As used herein, when two groups are indicated to be “linked” or “bonded” to form a “ring”, it is to be understood that a bond is formed between the two groups and may involve replacement of a hydrogen atom on one or both groups with the bond, thereby forming a carbocyclyl, heterocyclyl, aryl, or heteroaryl ring. The skilled artisan will recognize that such rings can and are readily formed by routine chemical reactions. In some embodiments, such rings have from 3-7 members, for example, 5 or 6 members.
The skilled artisan will recognize that some structures described herein may be resonance forms or tautomers of compounds that may be fairly represented by other chemical structures, even when kinetically, the artisan recognizes that such structures are only a very small portion of a sample of such compound(s). Such compounds are clearly contemplated within the scope of this disclosure, though such resonance forms or tautomers are not represented herein.
The compounds provided herein may encompass various stereochemical forms. The compounds also encompass diastereomers as well as optical isomers, e.g., mixtures of enantiomers including racemic mixtures, as well as individual enantiomers and diastereomers, which arise as a consequence of structural asymmetry in certain compounds. Separation of the individual isomers or selective synthesis of the individual isomers is accomplished by application of various methods which are well known to practitioners in the art. Unless otherwise indicated, when a disclosed compound is named or depicted by a structure without specifying the stereochemistry and has one or more chiral centers, it is understood to represent all possible stereoisomers of the compound.
The term “administration” or “administering” refers to a method of providing a dosage of a compound or pharmaceutical composition to a vertebrate or invertebrate, including a mammal, a bird, a fish, or an amphibian, where the method is, e.g., orally, subcutaneously, intravenously, intralymphatic, intranasally, topically, transdermally, intraperitoneally, intramuscularly, intrapulmonarily, vaginally, rectally, ontologically, neuro-otologically, intraocularly, subconjuctivally, via anterior eye chamber injection, intravitreally, intraperitoneally, intrathecally, intracystically, intrapleurally, via wound irrigation, intrabuccally, intra-abdominally, intra-articularly, intra-aurally, intrabronchially, intracapsularly, intrameningeally, via inhalation, via endotracheal or endobronchial instillation, via direct instillation into pulmonary cavities, intraspinally, intrasynovially, intrathoracically, via thoracostomy irrigation, epidurally, intratympanically, intracistemally, intravascularly, intraventricularly, intraosseously, via irrigation of infected bone, or via application as part of any admixture with a prosthetic device. The method of administration can vary depending on various factors, e.g., the components of the pharmaceutical composition, the site of the disease, the disease involved, and the severity of the disease.
A “diagnostic” as used herein is a compound, method, system, or device that assists in the identification or characterization of a health or disease state. The diagnostic can be used in standard assays as is known in the art.
The term “mammal” is used in its usual biological sense. Thus, it specifically includes humans, cattle, horses, monkeys, dogs, cats, mice, rats, cows, sheep, pigs, goats, and non-human primates, but also includes many other species.
The term “pharmaceutically acceptable carrier”, “pharmaceutically acceptable diluent” or “pharmaceutically acceptable excipient” includes any and all solvents, co-solvents, complexing agents, dispersion media, coatings, isotonic and absorption delaying agents and the like which are not biologically or otherwise undesirable. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions. In addition, various adjuvants such as are commonly used in the art may be included. These and other such compounds are described in the literature, e.g., in the Merck Index, Merck & Company, Rahway, N.J. Considerations for the inclusion of various components in pharmaceutical compositions are described, e.g., in Gilman et al. (Eds.) (2010); Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 12th Ed., The McGraw-Hill Companies.
The term “pharmaceutically acceptable salt” refers to salts that retain the biological effectiveness and properties of the compounds provided herein and, which are not biologically or otherwise undesirable. In many cases, the compounds provided herein are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto. Many such salts are known in the art, for example, as described in WO 87/05297. Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.
“Solvate” refers to the compound formed by the interaction of a solvent and a compound as provided herein or a salt thereof. Suitable solvates are pharmaceutically acceptable solvates including hydrates.
“Patient” as used herein, means a human or a non-human mammal, e.g., a dog, a cat, a mouse, a rat, a cow, a sheep, a pig, a goat, a non-human primate, or a bird, e.g., a chicken, as well as any other vertebrate or invertebrate. In some embodiments, the patient is a human.
A “therapeutically effective amount” of a compound as provided herein is one which is sufficient to achieve the desired physiological effect and may vary according to the nature and severity of the disease condition, and the potency of the compound. “Therapeutically effective amount” is also intended to include one or more of the compounds of Formula I in combination with one or more other agents that are effective to treat the diseases and/or conditions described herein. The combination of compounds can be a synergistic combination. Synergy, as described, for example, by Chou and Talalay, Advances in Enzyme Regulation (1984), 22, 27-55, occurs when the effect of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent. In general, a synergistic effect is most clearly demonstrated at sub-optimal concentrations of the compounds. It will be appreciated that different concentrations may be employed for prophylaxis than for treatment of an active disease. This amount can further depend upon the patient's height, weight, sex, age and medical history.
A therapeutic effect relieves, to some extent, one or more of the symptoms of the disease.
“Treat,” “treatment,” or “treating,” as used herein refers to administering a compound or pharmaceutical composition as provided herein for therapeutic purposes. The term “therapeutic treatment” refers to administering treatment to a patient already suffering from a disease thus causing a therapeutically beneficial effect, such as ameliorating existing symptoms, ameliorating the underlying metabolic causes of symptoms, postponing or preventing the further development of a disorder, and/or reducing the severity of symptoms that will or are expected to develop.
“Drug-eluting” and/or controlled release as used herein refers to any and all mechanisms, e.g., diffusion, migration, permeation, and/or desorption by which the drug(s) incorporated in the drug-eluting material pass therefrom over time into the surrounding body tissue.
“Drug-eluting material” and/or controlled release material as used herein refers to any natural, synthetic or semi-synthetic material capable of acquiring and retaining a desired shape or configuration and into which one or more drugs can be incorporated and from which incorporated drug(s) are capable of eluting overtime.
“Elutable drug” as used herein refers to any drug or combination of drugs having the ability to pass over time from the drug-eluting material in which it is incorporated into the surrounding areas of the body.
Compounds
The compounds and compositions described herein can be used as anti-proliferative agents, e.g., anti-cancer and anti-angiogenesis agents, and/or as inhibitors of the Wnt signaling pathway, e.g., for treating diseases or disorders associated with aberrant Wnt signaling. In addition, the compounds can be used as inhibitors of one or more kinases, kinase receptors, or kinase complexes. Such compounds and compositions are also useful for controlling cellular proliferation, differentiation, and/or apoptosis.
Some embodiments of the present disclosure include compounds of Formula I:
or salts, pharmaceutically acceptable salts, or prodrugs thereof.
In some embodiments, R1, R2, and R4 are independently selected from the group consisting of H and halide (e.g., F, Cl, Br, I).
In some embodiments, R1 and R2 are H, and R4 is F.
In some embodiments, R1 is H, and R2 and R4 are F.
In some embodiments, R1 and R4 are H, and R2 is F.
In some embodiments, R2 is H, and R1 and R4 are F.
In some embodiments, R1 and R2 are F, and R4 is H.
In some embodiments, R1, R2, and R4 are all H.
In some embodiments, R1, R2, and R4 are all F.
In some embodiments, R3 is selected from the group consisting of -heteroaryl optionally substituted with 1-4 (e.g., 1-3, 1-2, 1) R6 and -heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R7.
In some embodiments, R3 is selected from the group consisting of -heteroaryl optionally substituted with 1-2 (e.g., 1) R6 and -heterocyclyl optionally substituted with 1-2 (e.g., 1) R7.
In some embodiments, the heteroaryl of R3 is selected from the group consisting of -pyridinyl, -pyrimidinyl, -pyrazolyl, -imidazolyl, -thiazolyl, and -oxazolyl.
In some embodiments, the heteroaryl of R3 is selected from the group consisting of -pyridin-3-yl, -pyrimidin-5-yl, -pyrazol-4-yl, -imidazol-5-yl, -thiazol-2-yl, -thiazol-5-yl, -oxazol-2-yl, and -oxazol-5-yl.
In some embodiments, the -heterocyclyl of R3 is selected from the group consisting of -tetrahydropyridinyl and -piperidinyl.
In some embodiments, the -heterocyclyl of R3 is selected from the group consisting of -1,2,3,6-tetrahydropyridinyl and -piperidin-4-yl.
In some embodiments, R3 is -pyridinyl optionally substituted with 1 R6.
In some embodiments, R3 is -pyridin-3-yl optionally substituted with 1 R6.
In some embodiments, R3 is -pyrimidinyl optionally substituted with 1 R6.
In some embodiments, R3 is -pyrimidin-5-yl optionally substituted with 1 R6.
In some embodiments, R3 is -pyrazolyl optionally substituted with 1 R6.
In some embodiments, R3 is -pyrazolyl substituted with 1 R6.
In some embodiments, R3 is -pyrazolyl substituted with 1 methyl.
In some embodiments, R3 is -pyrazolyl optionally substituted with 2 R6.
In some embodiments, R3 is -pyrazolyl substituted with 2 R6.
In some embodiments, R3 is -pyrazolyl substituted with 1 methyl and 1 —CH2OH.
In some embodiments, R3 is -pyrazol-4-yl optionally substituted with 1 R6.
In some embodiments, R3 is -pyrazol-4-yl substituted with 1 R6.
In some embodiments, R3 is -pyrazol-4-yl substituted with 1 methyl.
In some embodiments, R3 is -pyrazol-4-yl optionally substituted with 2 R6.
In some embodiments, R3 is -pyrazol-4-yl substituted with 2 R6.
In some embodiments, R3 is -pyrazol-4-yl substituted with 1 methyl and 1 —CH2OH.
In some embodiments, R3 is -imidazolyl optionally substituted with 1-2 R6.
In some embodiments, R3 is -imidazolyl substituted with 1-2 R6.
In some embodiments, R3 is -imidazolyl substituted with 1-2 methyls.
In some embodiments, R3 is -imidazolyl substituted with 1 methyl.
In some embodiments, R3 is -imidazolyl substituted with 2 methyls.
In some embodiments, R3 is -imidazol-5-yl optionally substituted with 1-2 R6.
In some embodiments, R3 is -imidazol-5-yl substituted with 1-2 R6.
In some embodiments, R3 is -imidazol-5-yl substituted with 1-2 methyls.
In some embodiments, R3 is -imidazol-5-yl substituted with 1 methyl.
In some embodiments, R3 is -imidazol-5-yl substituted with 2 methyls.
In some embodiments, R3 is -thiazolyl optionally substituted with 1 R6.
In some embodiments, R3 is -thiazol-2-yl optionally substituted with 1 R6.
In some embodiments, R3 is thiazol-5-yl optionally substituted with 1 R6.
In some embodiments, R3 is -oxazolyl optionally substituted with 1 R6.
In some embodiments, R3 is -oxazol-2-yl optionally substituted with 1 R6.
In some embodiments, R3 is -oxazol-5-yl optionally substituted with 1 R6.
In some embodiments, R5 is selected from the group consisting of H, -heteroaryl optionally substituted with 1-4 (e.g., 1-3, 1-2, 1) R8, -heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R9, and -aryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R10.
In some embodiments, R5 is selected from the group consisting of H, -heteroaryl optionally substituted with 1-2 (e.g., 1) R8, -heterocyclyl optionally substituted with 1-2 (e.g., 1) R9, and -phenyl optionally substituted with 1-2 (e.g., 1) R10.
In some embodiments, R5 is H.
In some embodiments, R5 is -heteroaryl optionally substituted with 1-2 (e.g., 1) R8.
In some embodiments, R5 is-heterocyclyl optionally substituted with 1-2 (e.g., 1) R9.
In some embodiments, R5 is -piperidinyl optionally substituted with 1-2 (e.g., 1) R9.
In some embodiments, R5 is -piperazinyl optionally substituted with 1-2 (e.g., 1) R9.
In some embodiments, R5 is -aryl optionally substituted with 1-2 (e.g., 1) R10.
In some embodiments, R5 is -phenyl optionally substituted with 1-2 (e.g., 1)
R10.
In some embodiments, R5 is -pyridinyl optionally substituted with 1-2 (e.g., 1) R8.
In some embodiments, R5 is -pyridin-3-yl optionally substituted with 1-2 (e.g., 1) R8.
In some embodiments, R5 is -pyridin-4-yl optionally substituted with 1-2 (e.g., 1) R8.
In some embodiments, R5 is -pyridin-5-yl optionally substituted with 1-2 (e.g., 1) R8.
In some embodiments, R5 is -imidazolyl optionally substituted with 1-2 (e.g., 1) R8.
In some embodiments, R5 is -imidazolyl substituted with 1-2 (e.g., 1) R8.
In some embodiments, R5 is -imidazolyl substituted with 1 R8.
In some embodiments, R5 is -imidazolyl substituted with 1 methyl.
In some embodiments, R5 is -imidazol-1-yl optionally substituted with 1-2 (e.g., 1) R8.
In some embodiments, R5 is -imidazol-1-yl substituted with 1-2 (e.g., 1) R8.
In some embodiments, R5 is -imidazol-1-yl substituted with 1 R8.
In some embodiments, R5 is -imidazol-1-yl substituted with 1 methyl.
In some embodiments, R5 is -furanyl optionally substituted with 1-2 (e.g., 1) R8.
In some embodiments, R5 is -furan-2-yl optionally substituted with 1-2 (e.g., 1) R8.
In some embodiments, R5 is -furan-3-yl optionally substituted with 1-2 (e.g., 1) R8.
In some embodiments, R5 is -thiophenyl optionally substituted with 1-2 (e.g., 1) R8.
In some embodiments, R5 is -thiophen-2-yl optionally substituted with 1-2 (e.g., 1) R8.
In some embodiments, R5 is -thiophen-2-yl optionally substituted with 1-2 (e.g., 1) R8, and each R8 is independently halide.
In some embodiments, R5 is -thiophen-2-yl optionally substituted with 1-2 (e.g., 1) F.
In some embodiments, R5 is -thiophen-2-yl optionally substituted with 1-2 (e.g., 1) Cl.
In some embodiments, R5 is -thiophen-2-yl optionally substituted with 1-2 (e.g., 1) R8, and each R8 is independently —(C1-6 alkyl).
In some embodiments, R5 is -thiophen-2-yl optionally substituted with 1-2 (e.g., 1) R8, and each R8 is independently —(C1-2 alkyl).
In some embodiments, R5 is -thiophen-2-yl optionally substituted with 1-2 (e.g., 1) methyls.
In some embodiments, R5 is -thiophen-2-yl optionally substituted with 1-2 (e.g., 1) —CF3.
In some embodiments, R5 is -thiophen-2-yl optionally substituted with 1-2 (e.g., 1) —CN.
In some embodiments, R5 is -thiophen-2-yl optionally substituted with 1 —C(═O)R19.
In some embodiments, R5 is -thiophen-2-yl optionally substituted with 1 —C(═O)R19, and R19 is —(C1-6 alkyl).
In some embodiments, R5 is -thiophen-2-yl optionally substituted with 1 —C(═O)R19, and R19 is —(C1-4 alkyl).
In some embodiments, R5 is -thiophen-2-yl optionally substituted with 1 —C(═O)R19, and R19 is —(C1-2 alkyl).
In some embodiments, R5 is -thiophen-2-yl optionally substituted with 1 —C(═O)R19, and R19 is methyl.
In some embodiments, R5 is -thiophen-3-yl optionally substituted with 1-2 (e.g., 1) R8.
In some embodiments, R5 is -thiophen-3-yl optionally substituted with 1-2 (e.g., 1) R8 and each R8 is independently halide.
In some embodiments, R5 is -thiophen-3-yl optionally substituted with 1-2 (e.g., 1) F.
In some embodiments, R5 is -thiophen-3-yl optionally substituted with 1-2 (e.g., 1) Cl.
In some embodiments, R5 is -thiophen-3-yl optionally substituted with 1-2 (e.g., 1) R8, and each R8 is independently —(C1-6 alkyl).
In some embodiments, R5 is -thiophen-3-yl optionally substituted with 1-2 (e.g., 1) R8, and each R8 is independently —(C1-2 alkyl).
In some embodiments, R5 is -thiophen-3-yl optionally substituted with 1-2 (e.g., 1) methyls.
In some embodiments, R5 is -thiophen-3-yl optionally substituted with 1-2 (e.g., 1) —CF3.
In some embodiments, R5 is -thiophen-3-yl optionally substituted with 1-2 (e.g., 1) —CN.
In some embodiments, R5 is -thiophen-3-yl optionally substituted with 1 —C(═O)R19.
In some embodiments, R5 is -thiophen-3-yl optionally substituted with 1 —C(═O)R19, and R19 is —(C1-6 alkyl).
In some embodiments, R5 is -thiophen-3-yl optionally substituted with 1 —C(═O)R19, and R19 is —(C1-4 alkyl).
In some embodiments, R5 is -thiophen-3-yl optionally substituted with 1 —C(═O)R19, and R19 is —(C1-2 alkyl).
In some embodiments, R5 is -thiophen-3-yl optionally substituted with 1 —C(═O)R19, and R19 is methyl.
In some embodiments, R5 is selected from the group consisting of:
In some embodiments, R5 is -phenyl optionally substituted with 1-2 (e.g., 1) R10, and each R10 is independently halide.
In some embodiments, R5 is -phenyl optionally substituted with 1-2 (e.g., 1) F.
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —(C1-4 alkylene)NHSO2R19.
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —(C1-4 alkylene)NHSO2R19.
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —(C1-2 alkylene)NHSO2R19.
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —CH2NHSO2R19.
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —CH2NHSO2R19, R19 is —(C1-4 alkyl).
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —CH2NHSO2R19, R19 is —(C1-2 alkyl).
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —CH2NHSO2R19, R19 is methyl.
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is F and the other R10 is —CH2NHSO2R19, R19 is —(C1-2 alkyl).
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is F and the other R10 is —CH2NHSO2R19, R19 is methyl.
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —NR15(C1-6 alkylene)NR15R16.
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —NR15(C1-5 alkylene)NR15R16.
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —NR15(C1-4 alkylene)NR15R16.
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —NR15(C1-3 alkylene)NR15R16.
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —NR15CH2CH2NR15R16.
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —NHCH2CH2NR15R16.
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —NHCH2CH2NR15R16, and R15 and R16 are independently selected from —(C1-6 alkyl).
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —NHCH2CH2NR15R16, and R15 and R16 are independently selected from —(C1-4 alkyl).
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —NHCH2CH2NR15R16, and R15 and R16 are independently selected from —(C1-2 alkyl).
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —NHCH2CH2NR15R16, and both R15 and R16 are methyls.
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is F and the other R10 is —NHCH2CH2NR15R16, and R15 and R16 are independently selected from —(C1-2 alkyl).
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is F and the other R10 is —NHCH2CH2NR15R16, and both R15 and R16 are methyls.
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —OR27.
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —OCH2CH2NR25R26.
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —OCH2CH2NR25R26, and R25 and R26 are independently —(C1-2 alkyl).
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —OCH2CH2NR25R26, and R25 and R26 are both methyl.
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is F and the other R10 is —OCH2CH2NR25R26, and R25 and R26 are both methyl.
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —OCH2CH2heterocyclyl optionally substituted with 1-2 (e.g., 1) R23.
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is F and the other R10 is —OCH2CH2heterocyclyl optionally substituted with 1-2 (e.g., 1) R23.
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —OH.
In some embodiments, R5 is -phenyl optionally substituted with 2 R10, one R10 is halide and the other R10 is —OMe.
In some embodiments, R5 is -phenyl optionally substituted with 1 —OMe.
In some embodiments, R5 is selected from the group consisting of:
In some embodiments, R5 is -piperidin-1-yl optionally substituted with 1-2 (e.g., 1) R9.
In some embodiments, R5 is -piperidin-1-yl optionally substituted with 1-2 (e.g., 1) R9, and each R9 is independently halide.
In some embodiments, R5 is -piperazin-1-yl optionally substituted with 1-2 (e.g., 1) R9.
In some embodiments, R5 is -piperazin-1-yl optionally substituted with 1 C1-3alkyl.
In some embodiments, R5 is -piperazin-1-yl optionally substituted with 1 methyl.
In some embodiments, R5 is -morpholinyl optionally substituted with 1-2 (e.g., 1) R9.
In some embodiments, R5 is -morpholin-1-yl optionally substituted with 1-2 (e.g., 1) R9.
In some embodiments, R5 is selected from the group consisting of:
In some embodiments, each R6 is independently selected from the group consisting of halide, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R11, —(C2-4 alkenylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R11, —(C2-4 alkynylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R11, —(C1-4 alkylene)pcarbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R12, —(C2-4 alkenylene)pcarbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R12, —(C2-4 alkynylene)pcarbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R12, —(C1-4 alkylene)paryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R13, —(C2-4 alkenylene)paryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R13, —(C2-4 alkynylene)paryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R13, —NHC(═O)R14, —NR15R16, —(C1-6 alkylene)NR17R18, —(C2-6 alkenylene)NR17R18, —(C2-6 alkynylene)NR17R18, and —OR24.
In some embodiments, each R6 is independently selected from the group consisting of halide, —(C1-4 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R11, —(C2-4 alkenylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R11, —(C2-4 alkynylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R11, —(C1-4 alkylene)pcarbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R12, —(C2-4 alkenylene)pcarbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R12, —(C2-4 alkynylene)pcarbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R12, —(C1-4 alkylene)Paryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R13, —(C2-4 alkenylene)paryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R13, —(C2-4 alkynylene)paryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R13, —NHC(═O)R14, —NR15R16, —(C1-6 alkylene)NR17R18, —(C2-6 alkenylene)NR17R18, —(C2-6 alkynylene)NR17R18, and —(Cu 4 alkylene)pOR24.
In some embodiments, each R6 is independently selected from the group consisting of F, Cl, —(C1-3 alkyl), -heterocyclyl optionally substituted with 1-2 (e.g., 1) R11, —CH2heterocyclyl optionally substituted with 1-2 (e.g., 1) R11, -carbocyclyl optionally substituted with 1-2 (e.g., 1) R12, —CH2carbocyclyl optionally substituted with 1-2 (e.g., 1) R12, -aryl optionally substituted with 1-2 (e.g., 1) R13, —CH2aryl optionally substituted with 1-2 (e.g., 1) R13, —NHC(═O)R14, —NR15R16, —CH2NR17R18, and —OR24.
In some embodiments, each R6 is independently selected from the group consisting of F, Cl, —(C1-3 alkyl), -heterocyclyl optionally substituted with 1-2 (e.g., 1) R11, —CH2heterocyclyl optionally substituted with 1-2 (e.g., 1) R11, -carbocyclyl optionally substituted with 1-2 (e.g., 1) R12, —CH2carbocyclyl optionally substituted with 1-2 (e.g., 1) R12, -aryl optionally substituted with 1-2 (e.g., 1) R13, —CH2aryl optionally substituted with 1-2 (e.g., 1) R13, —NHC(═O)R14, —NR15R16, —CH2NR17R18, —CH2OR24, and —OR24.
In some embodiments, each R6 is independently selected from the group consisting of F, -Me, -heterocyclyl optionally substituted with 1-2 (e.g., 1) halides, -heterocyclyl optionally substituted with 1-2 (e.g., 1) methyls, —CH2heterocyclyl optionally substituted with 1-2 (e.g., 1) halides, —CH2heterocyclyl optionally substituted with 1-2 (e.g., 1) methyls, -carbocyclyl optionally substituted with 1-2 (e.g., 1) halides, —CH2carbocyclyl optionally substituted with 1-2 (e.g., 1) halides, -aryl optionally substituted with 1-2 (e.g., 1) halides, —CH2aryl optionally substituted with 1-2 (e.g., 1) halides, —NHC(═O)R14, —NH2, —NHMe, —NHEt, —NHPr, —NMe2, —CH2NMe2, —CH2NHMe, —CH2NHEt, —CH2NHCH2phenyl, —CH2NHCH2carbocylyl, —CH2OH, and —OR24.
In some embodiments, R6 is selected from the group consisting of —(C1-3 alkyl), —CH2heterocyclyl optionally substituted with 1-2 R11, —NHC(═O)R14, —NR15R16, —CH2NR17R18, —CH2OH, and —OR24.
In some embodiments, at least one R6 is —(C1-3 alkyl).
In some embodiments, at least one R6 is —(C1-2 alkyl).
In some embodiments, at least one R6 is -Me.
In some embodiments, at least one R6 is halide.
In some embodiments, at least one R6 is F.
In some embodiments, at least one R6 is —(C1-4 alkylene)heterocyclyl optionally substituted with 1-2 R11.
In some embodiments, at least one R6 is —(C1-3 alkylene)heterocyclyl optionally substituted with 1-2 R11.
In some embodiments, at least one R6 is —(C1-2 alkylene)heterocyclyl optionally substituted with 1-2 R11.
In some embodiments, at least one R6 is —CH2pyrrolidinyl optionally substituted with 1-2 R11.
In some embodiments, R6 is —CH2pyrrolidinyl optionally substituted with 1-2 R11.
In some embodiments, R6 is —CH2pyrrolidinyl optionally substituted with 1-2 R11, and each R11 is independently halide.
In some embodiments, R6 is —CH2pyrrolidinyl optionally substituted with 1-2 F.
In some embodiments, R6 is -dipyrrolidinyl substituted with 1-2 F.
In some embodiments, R6 is -dipyrrolidinyl substituted with 2 F.
In some embodiments, at least one R6 is —CH2piperidinyl optionally substituted with 1-2 R11.
In some embodiments, R6 is —CH2piperidinyl optionally substituted with 1-2 R11.
In some embodiments, R6 is —CH2piperidinyl optionally substituted with 1-2 R11, and each R11 is independently halide.
In some embodiments, R6 is —CH2piperidinyl optionally substituted with 1-2 F.
In some embodiments, R6 is
In some embodiments, at least one R6 is —(C1-4 alkylene)carbocyclyl optionally substituted with 1-2 (e.g., 1) R12.
In some embodiments, at least one R6 is —(C1-3 alkylene)carbocyclyl optionally substituted with 1-2 (e.g., 1) R12.
In some embodiments, at least one R6 is —(C1-2 alkylene)carbocyclyl optionally substituted with 1-2 (e.g., 1) R12.
In some embodiments, at least one R6 is —CH2carbocyclyl optionally substituted with 1-2 (e.g., 1) R12.
In some embodiments, R6 is —CH2carbocyclyl optionally substituted with 1-2 (e.g., 1) R12.
In some embodiments, at least one R6 is —CH2aryl optionally substituted with 1-2 (e.g., 1) R13,
In some embodiments, at least one R6 is —CH2phenyl optionally substituted with 1-2 (e.g., 1) R13,
In some embodiments, R6 is —CH2phenyl optionally substituted with 1-2 (e.g., 1) R13,
In some embodiments, at least one R6 is —NHC(═O)R14.
In some embodiments, R6 is —NHC(═O)R14.
In some embodiments, at least one R6 is —NHC(═O)R14 and R14 is —(C1-9 alkyl).
In some embodiments, at least one R6 is —NHC(═O)R14 and R14 is —(C1-8 alkyl).
In some embodiments, at least one R6 is —NHC(═O)R14 and R14 is —(C1-7 alkyl).
In some embodiments, at least one R6 is —NHC(═O)R14 and R14 is —(C1-6 alkyl).
In some embodiments, at least one R6 is —NHC(═O)R14 and R14 is —(C1-5 alkyl).
In some embodiments, R6 is —NHC(═O)R14 and R14 is —(C1-5 alkyl).
In some embodiments, at least one R6 is —NHC(═O)R14 and R14 is —(C1-4 alkyl).
In some embodiments, R6 is —NHC(═O)R14 and R14 is —(C1-4 alkyl).
In some embodiments, at least one R6 is —NHC(═O)R14 and R14 is —(C1-3 alkyl).
In some embodiments, R6 is —NHC(═O)R14 and R14 is —(C1-3 alkyl).
In some embodiments, at least one R6 is —NHC(═O)R14 and R14 is —(C1-2 alkyl).
In some embodiments, R6 is —NHC(═O)R14 and R14 is —(C1-2 alkyl).
In some embodiments, R6 is —NHC(═O)R14 and R14 is —CF3.
In some embodiments, at least one R6 is —NHC(═O)R14 and R14 is —(C2-5 alkyl).
In some embodiments, R6 is —NHC(═O)R14 and R14 is —(C2-5 alkyl).
In some embodiments, at least one R6 is —NHC(═O)R14 and R14 is —(C3-4 alkyl).
In some embodiments, at least one R6 is —NHC(═O)R14, R14 is -aryl optionally substituted with 1-2 (e.g., 1) R21.
In some embodiments, at least one R6 is —NHC(═O)R14, R14 is -phenyl optionally substituted with 1-2 (e.g., 1) R21.
In some embodiments, at least one R6 is —NHC(═O)R14, R14 is —CH2aryl optionally substituted with 1-2 (e.g., 1) R21.
In some embodiments, at least one R6 is —NHC(═O)R14, R14 is —CH2phenyl optionally substituted with 1-2 (e.g., 1) R21.
In some embodiments, at least one R6 is —NHC(═O)R14, R14 is -heteroaryl optionally substituted with 1-2 (e.g., 1) R20.
In some embodiments, at least one R6 is —NHC(═O)R14, R14 is -carbocyclyl optionally substituted with 1-2 (e.g., 1) R22.
In some embodiments, at least one R6 is —NHC(═O)R14, R14 is -cyclopropyl optionally substituted with 1-2 (e.g., 1) R22.
In some embodiments, at least one R6 is —NHC(═O)R14, R14 is -cyclobutyl optionally substituted with 1-2 (e.g., 1) R22.
In some embodiments, at least one R6 is —NHC(═O)R14, R14 is -cyclopentyl optionally substituted with 1-2 (e.g., 1) R22.
In some embodiments, at least one R6 is —NHC(═O)R14, R14 is -cyclohexyl optionally substituted with 1-2 (e.g., 1) R22.
In some embodiments, at least one R6 is —NHC(═O)R14, R14 is —CH2carbocyclyl optionally substituted with 1-2 (e.g., 1) R22.
In some embodiments, at least one R6 is —NHC(═O)R14, R14 is —CH2cyclopropyl optionally substituted with 1-2 (e.g., 1) R22.
In some embodiments, at least one R6 is —NR15R16.
In some embodiments, at least one R6 is —NR15R16, and R15 and R16 are independently selected from the group consisting of H and —(C1-6 alkyl).
In some embodiments, at least one R6 is —NR15R16, and R15 and R16 are independently selected from the group consisting of H and —(C1-5 alkyl).
In some embodiments, at least one R6 is —NR15R16, and R15 and R16 are independently selected from the group consisting of H and —(C1-4 alkyl).
In some embodiments, at least one R6 is —NR15R16, and R15 and R16 are independently selected from the group consisting of H and —(C1-3 alkyl).
In some embodiments, at least one R6 is —NR15R16, and R15 and R16 are independently selected from the group consisting of H and —(C1-2 alkyl).
In some embodiments, at least one R6 is —NR15R16, and R15 and R16 are independently selected from the group consisting of H and methyl.
In some embodiments, at least one R6 is —NH2.
In some embodiments, R6 is —NH2.
In some embodiments, at least one R6 is —NHR16 and R16 is —(C1-4 alkyl).
In some embodiments, at least one R6 is —NHR16 and R16 is —(C1-3 alkyl).
In some embodiments, at least one R6 is —NHR16 and R16 is —(C1-2 alkyl).
In some embodiments, R6 is —NHR16 and R16 is —(C1-2 alkyl).
In some embodiments, at least one R6 is —NHR16 and R16 is -diaryl optionally substituted with 1-2 (e.g., 1) R21.
In some embodiments, at least one R6 is —NHR16 and R16 is —CH2phenyl optionally substituted with 1-2 (e.g., 1) R21.
In some embodiments, at least one R6 is —NHR16 and R16 is —CH2carbocyclyl optionally substituted with 1-2 (e.g., 1) R22.
In some embodiments, at least one R6 is —NHR16 and R16 is —CH2cyclopropyl optionally substituted with 1-2 (e.g., 1) R22.
In some embodiments, at least one R6 is —NHR16 and R16 is —CH2cyclobutyl optionally substituted with 1-2 (e.g., 1) R22.
In some embodiments, at least one R6 is —NHR16 and R16 is -dicyclopentyl optionally substituted with 1-2 (e.g., 1) R22.
In some embodiments, at least one R6 is —NHR16 and R16 is -Oxcyclohexyl optionally substituted with 1-2 (e.g., 1) R22.
In some embodiments, at least one R6 is —(C1-6 alkylene)NR17R18.
In some embodiments, at least one R6 is —(C1-5 alkylene)NR17R18.
In some embodiments, at least one R6 is —(C1-4 alkylene)NR17R18.
In some embodiments, at least one R6 is —(C1-3 alkylene)NR17R18.
In some embodiments, at least one R6 is —(C1-2 alkylene)NR17R18.
In some embodiments, at least one R6 is —CH2NR17R18.
In some embodiments, R6 is —CH2NR17R18.
In some embodiments, at least one R6 is —CH2NR17R18, and R17 and R18 are independently selected from the group consisting of H and —(C1-6 alkyl).
In some embodiments, at least one R6 is —CH2NR17R18, and R17 and R18 are independently selected from the group consisting of H and —(C1-5 alkyl).
In some embodiments, at least one R6 is —CH2NR17R18, and R17 and R18 are independently selected from the group consisting of H and —(C1-4 alkyl).
In some embodiments, at least one R6 is —CH2NR17R18, and R17 and R18 are independently selected from the group consisting of H and —(C1-3 alkyl).
In some embodiments, at least one R6 is —CH2NR17R18, and R17 and R18 are independently selected from the group consisting of H and —(C1-2 alkyl).
In some embodiments, at least one R6 is —CH2NR17R18, and R17 and R18 are independently selected from the group consisting of H and methyl.
In some embodiments, R6 is —CH2NR17R18, and R17 and R18 are independently selected from the group consisting of H and methyl.
In some embodiments, at least one R6 is —CH2NH2.
In some embodiments, R6 is —CH2NH2.
In some embodiments, at least one R6 is —CH2NMe2.
In some embodiments, R6 is —CH2NMe2.
In some embodiments, at least one R6 is —CH2NHR18 and R18 is —(C1-4 alkyl).
In some embodiments, at least one R6 is —CH2NHR18 and R18 is —(C1-3 alkyl).
In some embodiments, at least one R6 is —CH2NHR18 and R18 is —(C1-2 alkyl).
In some embodiments, R6 is —CH2NHR18 and R18 is —(C1-2 alkyl).
In some embodiments, at least one R6 is —CH2NHR18 and R18 is -diaryl optionally substituted with 1-2 (e.g., 1) R21.
In some embodiments, at least one R6 is —CH2NHR18 and R18 is —CH2phenyl optionally substituted with 1-2 (e.g., 1) R21.
In some embodiments, R6 is —CH2NHR18 and R18 is —CH2phenyl optionally substituted with 1-2 (e.g., 1) R21.
In some embodiments, at least one R6 is —CH2NHR18 and R18 is —CH2carbocyclyl optionally substituted with 1-2 (e.g., 1) R22.
In some embodiments, at least one R6 is —CH2NHR18 and R18 is —CH2cyclopropyl optionally substituted with 1-2 (e.g., 1) R22.
In some embodiments, R6 is —CH2NHR18 and R18 is —CH2cyclopropyl optionally substituted with 1-2 (e.g., 1) R22.
In some embodiments, at least one R6 is —CH2NHR18 and R18 is —CH2cyclobutyl optionally substituted with 1-2 (e.g., 1) R22.
In some embodiments, R6 is —CH2NHR18 and R18 is —CH2cyclobutyl optionally substituted with 1-2 (e.g., 1) R22.
In some embodiments, at least one R6 is —CH2NHR18 and R18 is —CH2cyclopentyl optionally substituted with 1-2 (e.g., 1) R22.
In some embodiments, R6 is —CH2NHR18 and R18 is —CH2cyclopentyl optionally substituted with 1-2 (e.g., 1) R22.
In some embodiments, at least one R6 is —CH2NHR18 and R18 is —CH2cyclohexyl optionally substituted with 1-2 (e.g., 1) R22.
In some embodiments, R6 is —CH2NHR18 and R18 is —CH2cyclohexyl optionally substituted with 1-2 (e.g., 1) R22.
In some embodiments, at least one R6 is —OR24.
In some embodiments, at least one R6 is —OH.
In some embodiments, R6 is —OH.
In some embodiments, at least one R6 is —(C1-4 alkylene)OR24.
In some embodiments, R6 is —(C1-4 alkylene)OR24.
In some embodiments, R6 is —(C1-3 alkylene)OR24.
In some embodiments, R6 is —(C1-2 alkylene)OR24.
In some embodiments, R6 is —CH2OR24.
In some embodiments, R6 is —CH2OH.
In some embodiments, at least one R6 is —OR24 and R24 is —(C1-3 alkyl).
In some embodiments, at least one R6 is —OR24 and R24 is —(C1-2 alkyl).
In some embodiments, at least one R6 is —OMe.
In some embodiments, R6 is —OMe.
In some embodiments, at least one R6 is —OR24 and R24 is -heterocyclyl optionally substituted with 1-2 (e.g., 1) R23.
In some embodiments, R6 is —OR24 and R24 is -heterocyclyl optionally substituted with 1-2 (e.g., 1) R23.
In some embodiments, at least one R6 is —OR24 and R24 is -carbocyclyl optionally substituted with 1-2 (e.g., 1) R22.
In some embodiments, R6 is —OR24 and R24 is -carbocyclyl optionally substituted with 1-2 (e.g., 1) R22.
In some embodiments, at least one R6 is —OR24 and R24 is —(C1-4alkylene)heterocyclyl optionally substituted with 1-2 (e.g., 1) R23.
In some embodiments, at least one R6 is —OR24 and R24 is —(CH2CH2)heterocyclyl optionally substituted with 1-2 (e.g., 1) R23.
In some embodiments, R6 is —OR24 and R24 is —(CH2CH2)heterocyclyl optionally substituted with 1-2 (e.g., 1) R23.
In some embodiments, at least one R6 is —OR24 and R24 is —(C1-4alkylene)NR25R26 and R25 and R26 are independently —(C1-4 alkyl).
In some embodiments, at least one R6 is —OR24 and R24 is —(CH2CH2)NR25R26 and R25 and R26 are independently —(C1-2 alkyl).
In some embodiments, at least one R6 is —OR24 and R24 is —(CH2CH2)NMe2.
In some embodiments, R6 is —OR24 and R24 is —(CH2CH2)NMe2.
In some embodiments, at least one R6 is —OR24 and R24 is —(C1-4 alkylene)aryl optionally substituted with 1-2 (e.g., 1) R21, and each R21 is independently halide.
In some embodiments, at least one R6 is —OR24 and R24 is —(CH2CH2)phenyl optionally substituted with 1-2 (e.g., 1) R21, and each R21 is independently halide.
In some embodiments, R6 is —OR24 and R24 is —(CH2CH2)phenyl optionally substituted with 1-2 (e.g., 1) R21, and each R21 is independently halide.
In some embodiments, at least one R6 is —OR24 and R24 is —(CH2)phenyl optionally substituted with 1-2 (e.g., 1) R21, and each R21 is independently halide.
In some embodiments, R6 is —OR24 and R24 is —(CH2)phenyl optionally substituted with 1-2 (e.g., 1) R21, and each R21 is independently halide.
In some embodiments, each R7 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl). —(C2-4 alkynyl), halide, —CF3, and —CN.
In some embodiments, each R7 is independently selected from the group consisting of methyl, F, Cl, —CF3, and —CN.
In some embodiments, at least one R7 is —(C1-4 alkyl).
In some embodiments, at least one R7 is —(C1-3 alkyl).
In some embodiments, at least one R7 is —(C1-2 alkyl).
In some embodiments, at least one R7 is methyl.
In some embodiments, at least one R7 is halide.
In some embodiments, at least one R7 is F.
In some embodiments, each R8 is independently selected from the group consisting of —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), halide, —CF3, —OCH3, —CN, and —C(═O)R19.
In some embodiments, each R8 is independently selected from the group consisting of methyl, F, Cl, —CF3, —OCH3, —CN, and —C(═O)Me.
In some embodiments, at least one R8 is halide.
In some embodiments, at least one R8 is F.
In some embodiments, at least one R8 is —(C1-4 alkyl).
In some embodiments, at least one R8 is —(C1-3 alkyl).
In some embodiments, at least one R8 is —(C1-2 alkyl).
In some embodiments, at least one R8 is methyl.
In some embodiments, R8 is methyl.
In some embodiments, at least one R8 is —C(═O)(C1-3 alkyl).
In some embodiments, at least one R8 is —C(═O)Me.
In some embodiments, R8 is —C(═O)Me.
In some embodiments, each R9 is independently selected from the group consisting of —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), halide, —CF3, —CN, and —OCH3.
In some embodiments, each R9 is independently selected from the group consisting of methyl, F, Cl, —CF3, —CN, and —OCH3.
In some embodiments, each R10 is independently selected from the group consisting of —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), halide, —CF3, —CN, —(C1-6 alkylene)pNHSO2R19, —(C2-6 alkenylene)pNHSO2R19, —(C2-6 alkynylene)pNHSO2R19, —NR15(C1-6 alkylene)NR15R16, —NR15(C2-6 alkenylene)NR15R16, —NR15(C2-6 alkynylene)NR15R16, —(C1-6 alkylene)pNR15R16, —(C2-6 alkenylene)pNR15R16, —(C2-6 alkynylene)PNR15R16, and —OR27.
In some embodiments, each R11 is independently selected from the group consisting of amino, —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN.
In some embodiments, each R11 is independently selected from the group consisting of amino, methyl, F, Cl, —CF3, and —CN.
In some embodiments, each R12 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN.
In some embodiments, each R12 is independently selected from the group consisting of methyl, F, Cl, —CF3, and —CN.
In some embodiments, each R13 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN.
In some embodiments, each R13 is independently selected from the group consisting of methyl, F, Cl, —CF3, and —CN.
In some embodiments, each R14 is independently selected from the group consisting of —(C1-9 alkyl), —(C1-4 haloalkyl), —(C2-9 alkenyl), —(C2-9 alkynyl), -heteroaryl optionally substituted with 1-4 (e.g., 1-3, 1-2, 1) R20, -aryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R21, —CH2aryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R21, -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R22, —CH2carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R22, —(C1-4 alkylene)pNR25R26, —(C2-4 alkenylene)pNR25R26, —(C2-4 alkynylene)pNR25R26, -heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R23, and —CH2heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R23.
In some embodiments, each R15 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl).
In some embodiments, each R16 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —CH2aryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R21, and —CH2carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R22.
In some embodiments, each R17 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl).
In some embodiments, each R18 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —CH2aryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R21 and —CH2carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R22.
In some embodiments, each R19 is independently selected from the group consisting of —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl).
In some embodiments, each R20 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN.
In some embodiments, each R20 is independently selected from the group consisting of methyl, F, Cl, —CF3, and —CN.
In some embodiments, each R21 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN.
In some embodiments, each R21 is independently selected from the group consisting of methyl, F, Cl, —CF3, and —CN.
In some embodiments, each R22 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN.
In some embodiments, each R22 is independently selected from the group consisting of methyl, F, Cl, —CF3, and —CN.
In some embodiments, each R23 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN.
In some embodiments, each R23 is independently selected from the group consisting of methyl, F, Cl, —CF3, and —CN.
In some embodiments, R24 is selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R23, —(C2-4 alkenylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R23, —(C2-4alkynylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R23, —(C1-4 alkylene)pcarbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R22, —(C2-4 alkenylene)pcarbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R22, —(C2-4 alkynylene)pcarbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R22, —(C1-4 alkylene)paryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R21, —(C2-4 alkenylene)paryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R21, —(C2-4 alkynylene)paryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R21, —(C1-6 alkylene)pNR25R26, —(C2-4 alkenylene)pNR25R26, and —(C2-4 alkynylene)pNR25R26.
In some embodiments, each R25 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl).
In some embodiments, each R26 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl).
In some embodiments, R27 is selected from the group consisting of H, —(C1-6alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R23, —(C2-4 alkenylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R23, —(C2-4alkynylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R23, —(C1-6 alkylene)pNR25R26, —(C2-6 alkenylene)PNR25R26, and —(C2-6 alkynylene)PNR25R26.
In some embodiments, each p is independently an integer of 0 or 1.
In some embodiments, p is 0.
In some embodiments, p is 1.
Illustrative compounds of Formula (I) are shown in Table 1.
Some embodiments include pharmaceutical compositions comprising: (a) a therapeutically effective amount of a compound provided herein, or its corresponding enantiomer, diastereoisomer or tautomer, or pharmaceutically acceptable salt; and (b) a pharmaceutically acceptable carrier.
The compounds provided herein may also be useful in combination (administered together or sequentially) with other known agents.
Non-limiting examples of diseases which can be treated with a combination of a compound of Formula (I) and other known agents are colorectal cancer, ovarian cancer, retinitis pigmentosa, macular degeneration, diabetic retinopathy, idiopathic pulmonary fibrosis/pulmonary fibrosis, and osteoarthritis.
In some embodiments, colorectal cancer can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: 5-Fluorouracil (5-FU), which can be administered with the vitamin-like drug leucovorin (also called folinic acid); capecitabine (XELODA®), irinotecan (CAMPOSTAR®), oxaliplatin (ELOXATIN®). Examples of combinations of these drugs which could be further combined with a compound of Formula (I) are FOLFOX (5-FU, leucovorin, and oxaliplatin), FOLFIRI (5-FU, leucovorin, and irinotecan), FOLFOXIRI (leucovorin, 5-FU, oxaliplatin, and irinotecan) and CapeOx (Capecitabine and oxaliplatin). For rectal cancer, chemo with 5-FU or capecitabine combined with radiation may be given before surgery (neoadjuvant treatment).
In some embodiments, ovarian cancer can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: Topotecan, Liposomal doxorubicin (DOXIL®), Gemcitabine (GEMZAR®), Cyclophosphamide (CYTOXAN®), Vinorelbine (NAVELBINE®), Ifosfamide (IFEX®), Etoposide (VP-16), Altretamine (HEXALEN®), Capecitabine (XELODA®), Irinotecan (CPT-11, CAMPTOSAR®), Melphalan, Pemetrexed (ALIMTA®) and Albumin bound paclitaxel (nab-paclitaxel, ABRAXANE®). Examples of combinations of these drugs which could be further combined with a compound of Formula (I) are TIP (paclitaxel [Taxol], ifosfamide, and cisplatin), VeIP (vinblastine, ifosfamide, and cisplatin) and VIP (etoposide [VP-16], ifosfamide, and cisplatin).
In some embodiments, a compound of Formula (I) can be used to treat cancer in combination with any of the following methods: (a) Hormone therapy such as aromatase inhibitors, LHRH [luteinizing hormone-releasing hormone] analogs and inhibitors, and others; (b) Ablation or embolization procedures such as radiofrequency ablation (RFA), ethanol (alcohol) ablation, microwave thermotherapy and cryosurgery (cryotherapy); (c) Chemotherapy using alkylating agents such as cisplatin and carboplatin, oxaliplatin, mechlorethamine, cyclophosphamide, chlorambucil and ifosfamide; (d) Chemotherapy using anti-metabolites such as azathioprine and mercaptopurine; (e) Chemotherapy using plant alkaloids and terpenoids such as vinca alkaloids (i.e. Vincristine, Vinblastine, Vinorelbine and Vindesine) and taxanes; (f) Chemotherapy using podophyllotoxin, etoposide, teniposide and docetaxel; (g) Chemotherapy using topoisomerase inhibitors such as irinotecan, topotecan, amsacrine, etoposide, etoposide phosphate, and teniposide; (h) Chemotherapy using cytotoxic antibiotics such as actinomycin, anthracyclines, doxorubicin, daunorubicin, valrubicin, idarubicin, epirubicin, bleomycin, plicamycin and mitomycin; (i) Chemotherapy using tyrosine-kinase inhibitors such as Imatinib mesylate (GLEEVEC®, also known as STI-571), Gefitinib (Iressa, also known as ZD 1839), Erlotinib (marketed as TARCEVA®), Bortezomib (VELCADE®), tamoxifen, tofacitinib, crizotinib, Bcl-2 inhibitors (e.g. obatoclax in clinical trials, ABT-263, and Gossypol), PARP inhibitors (e.g. Iniparib, Olaparib in clinical trials), PI3K inhibitors (e.g. perifosine in a phase III trial), VEGF Receptor 2 inhibitors (e.g. Apatinib), AN-152, (AEZS-108), Braf inhibitors (e.g. vemurafenib, dabrafenib and LGX818), MEK inhibitors (e.g. trametinib and MEK 162), CDK inhibitors, (e.g. PD-0332991), salinomycin and Sorafenib; (j) Chemotherapy using monoclonal antibodies such as Rituximab (marketed as MABTHERA® or RITUXAN®), Trastuzumab (Herceptin also known as ErbB2), Cetuximab (marketed as ERBITUX®), and Bevacizumab (marketed as AVASTIN®); and (k) radiation therapy.
In some embodiments, diabetic retinopathy can be treated with a combination of a compound of Formula (I) and one or more of the following natural supplements: Bilberry, Butcher's broom, Ginkgo, Grape seed extract, and Pycnogenol (Pine bark).
In some embodiments, idiopathic pulmonary fibrosis/pulmonary fibrosis can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: pirfenidone (pirfenidone was approved for use in 2011 in Europe under the brand name Esbriet®), prednisone, azathioprine, N-acetylcysteine, interferon-γ 1b, bosentan (bosentan is currently being studied in patients with IPF, [The American Journal of Respiratory and Critical Care Medicine (2011), 184(1), 92-9]), Nintedanib (BIBF 1120 and Vargatef), QAX576 [British Journal of Pharmacology (2011), 163(1), 141-172], and anti-inflammatory agents such as corticosteroids.
In some embodiments, a compound of Formula (I) can be used to treat idiopathic pulmonary fibrosis/pulmonary fibrosis in combination with any of the following methods: oxygen therapy, pulmonary rehabilitation and surgery.
In some embodiments, a compound of Formula (I) can be used to treat osteoarthritis in combination with any of the following methods: (a) Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, aspirin and acetaminophen; (b) physical therapy; (c) injections of corticosteroid medications; (d) injections of hyaluronic acid derivatives (e.g. Hyalgan, Synvisc); (e) narcotics, like codeine; (f) in combination with braces and/or shoe inserts or any device that can immobilize or support your joint to help you keep pressure off it (e.g., splints, braces, shoe inserts or other medical devices); (g) realigning bones (osteotomy); (h) joint replacement (arthroplasty); and (i) in combination with a chronic pain class.
In some embodiments, macular degeneration can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: Bevacizumab (Avastin®), Ranibizumab (Lucentis®), Pegaptanib (Macugen), Aflibercept (Eylea®), verteporfin (Visudyne®) in combination with photodynamic therapy (PDT) or with any of the following methods: (a) in combination with laser to destroy abnormal blood vessels (photocoagulation); and (b) in combination with increased vitamin intake of antioxidant vitamins and zinc.
In some embodiments, retinitis pigmentosa can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: UF-021 (Ocuseva™), vitamin A palmitate and pikachurin or with any of the following methods: (a) with the Argus® II retinal implant; and (b) with stem cell and/or gene therapy.
Administration of the compounds disclosed herein or the pharmaceutically acceptable salts thereof can be via any of the accepted modes of administration, including, but not limited to, orally, subcutaneously, intravenously, intranasally, topically, transdermally, intraperitoneally, intramuscularly, intrapulmonarilly, vaginally, rectally, ontologically, neuro-otologically, intraocularly, subconjuctivally, via anterior eye chamber injection, intravitreally, intraperitoneally, intrathecally, intracystically, intrapleurally, via wound irrigation, intrabuccally, intra-abdominally, intra-articularly, intra-aurally, intrabronchially, intracapsularly, intrameningeally, via inhalation, via endotracheal or endobronchial instillation, via direct instillation into pulmonary cavities, intraspinally, intrasynovially, intrathoracically, via thoracostomy irrigation, epidurally, intratympanically, intracistemally, intravascularly, intraventricularly, intraosseously, via irrigation of infected bone, or via application as part of any admixture with a prosthetic devices. In some embodiments, the administration method includes oral or parenteral administration.
Compounds provided herein intended for pharmaceutical use may be administered as crystalline or amorphous products. Pharmaceutically acceptable compositions may include solid, semi-solid, liquid, solutions, colloidal, liposomes, emulsions, suspensions, complexes, coacervates and aerosols. Dosage forms, such as, e.g., tablets, capsules, powders, liquids, suspensions, suppositories, aerosols, implants, controlled release or the like. They may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, milling, grinding, supercritical fluid processing, coacervation, complex coacervation, encapsulation, emulsification, complexation, freeze drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose. The compounds can also be administered in sustained or controlled release dosage forms, including depot injections, osmotic pumps, pills (tablets and or capsules), transdermal (including electrotransport) patches, implants and the like, for prolonged and/or timed, pulsed administration at a predetermined rate.
The compounds can be administered either alone or in combination with a conventional pharmaceutical carrier, excipient or the like. Pharmaceutically acceptable excipients include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-α-tocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens, poloxamers or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, tris, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium-chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-poly oxypropylene-block polymers, and wool fat. Cyclodextrins such as α-, β, and γ-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-β-cyclodextrins, or other solubilized derivatives can also be used to enhance delivery of compounds described herein. Dosage forms or compositions containing a compound as described herein in the range of 0.005% to 100% with the balance made up from non-toxic carrier may be prepared. The contemplated compositions may contain 0.001%-100% of a compound provided herein, in one embodiment 0.1-95%, in another embodiment 75-85%, in a further embodiment 20-80%. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington: The Science and Practice of Pharmacy, 22nd Edition (Pharmaceutical Press, London, UK. 2012).
In one embodiment, the compositions will take the form of a unit dosage form such as a pill or tablet and thus the composition may contain, along with a compound provided herein, a diluent such as lactose, sucrose, dicalcium phosphate, or the like; a lubricant such as magnesium stearate or the like; and a binder such as starch, gum acacia, polyvinylpyrrolidine, gelatin, cellulose, cellulose derivatives or the like. In another solid dosage form, a powder, marume, solution or suspension (e.g., in propylene carbonate, vegetable oils, PEG's, poloxamer 124 or triglycerides) is encapsulated in a capsule (gelatin or cellulose base capsule). Unit dosage forms in which one or more compounds provided herein or additional active agents are physically separated are also contemplated; e.g., capsules with granules (or tablets in a capsule) of each drug; two-layer tablets; two-compartment gel caps, etc. Enteric coated or delayed release oral dosage forms are also contemplated.
Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. a compound provided herein and optional pharmaceutical adjuvants in a carrier (e.g., water, saline, aqueous dextrose, glycerol, glycols, ethanol or the like) to form a solution, colloid, liposome, emulsion, complexes, coacervate or suspension. If desired, the pharmaceutical composition can also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, co-solvents, solubilizing agents, pH buffering agents and the like (e.g., sodium acetate, sodium citrate, cyclodextrin derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate, and the like).
In some embodiments, the unit dosage of compounds of Formula (I) is about 0.25 mg/Kg to about 50 mg/Kg in humans.
In some embodiments, the unit dosage of compounds of Formula (I) is about 0.25 mg/Kg to about 20 mg/Kg in humans.
In some embodiments, the unit dosage of compounds of Formula (I) is about 0.50 mg/Kg to about 19 mg/Kg in humans.
In some embodiments, the unit dosage of compounds of Formula (I) is about 0.75 mg/Kg to about 18 mg/Kg in humans.
In some embodiments, the unit dosage of compounds of Formula (I) is about 1.0 mg/Kg to about 17 mg/Kg in humans.
In some embodiments, the unit dosage of compounds of Formula (I) is about 1.25 mg/Kg to about 16 mg/Kg in humans.
In some embodiments, the unit dosage of compounds of Formula (I) is about 1.50 mg/Kg to about 15 mg/Kg in humans.
In some embodiments, the unit dosage of compounds of Formula (I) is about 1.75 mg/Kg to about 14 mg/Kg in humans.
In some embodiments, the unit dosage of compounds of Formula (I) is about 2.0 mg/Kg to about 13 mg/Kg in humans.
In some embodiments, the unit dosage of compounds of Formula (I) is about 3.0 mg/Kg to about 12 mg/Kg in humans.
In some embodiments, the unit dosage of compounds of Formula (I) is about 4.0 mg/Kg to about 11 mg/Kg in humans.
In some embodiments, the unit dosage of compounds of Formula (I) is about 5.0 mg/Kg to about 10 mg/Kg in humans.
In some embodiments, the compositions are provided in unit dosage forms suitable for single administration.
In some embodiments, the compositions are provided in unit dosage forms suitable for twice a day administration.
In some embodiments, the compositions are provided in unit dosage forms suitable for three times a day administration.
Injectables can be prepared in conventional forms, either as liquid solutions, colloid, liposomes, complexes, coacervate or suspensions, as emulsions, or in solid forms suitable for reconstitution in liquid prior to injection. The percentage of a compound provided herein contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the patient. However, percentages of active ingredient of 0.01% to 10% in solution are employable, and could be higher if the composition is a solid or suspension, which could be subsequently diluted to the above percentages.
In some embodiments, the composition will comprise about 0.1-10% of the active agent in solution.
In some embodiments, the composition will comprise about 0.1-5% of the active agent in solution.
In some embodiments, the composition will comprise about 0.1-4% of the active agent in solution.
In some embodiments, the composition will comprise about 0.15-3% of the active agent in solution.
In some embodiments, the composition will comprise about 0.2-2% of the active agent in solution.
In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-96 hours.
In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-72 hours.
In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-48 hours.
In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-24 hours.
In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-12 hours.
In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-6 hours.
In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 5 mg/m2 to about 300 mg/m2.
In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 5 mg/m2 to about 200 mg/m2.
In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 5 mg/m2 to about 100 mg/m2.
In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 10 mg/m2 to about 50 mg/m2.
In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 50 mg/m2 to about 200 mg/m2.
In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 75 mg/m2 to about 175 mg/m2.
In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 100 mg/m2 to about 150 mg/m2.
It is to be noted that concentrations and dosage values may also vary depending on the specific compound and the severity of the condition to be alleviated. It is to be further understood that for any particular patient, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.
In one embodiment, the compositions can be administered to the respiratory tract (including nasal and pulmonary) e.g., through a nebulizer, metered-dose inhalers, atomizer, mister, aerosol, dry powder inhaler, insufflator, liquid instillation or other suitable device or technique.
In some embodiments, aerosols intended for delivery to the nasal mucosa are provided for inhalation through the nose. For optimal delivery to the nasal cavities, inhaled particle sizes of about 5 to about 100 microns are useful, with particle sizes of about 10 to about 60 microns being preferred. For nasal delivery, a larger inhaled particle size may be desired to maximize impaction on the nasal mucosa and to minimize or prevent pulmonary deposition of the administered formulation. In some embodiments, aerosols intended for delivery to the lung are provided for inhalation through the nose or the mouth. For delivery to the lung, inhaled aerodynamic particle sizes of about less than 10 μm are useful (e.g., about 1 to about 10 microns). Inhaled particles may be defined as liquid droplets containing dissolved drug, liquid droplets containing suspended drug particles (in cases where the drug is insoluble in the suspending medium), dry particles of pure drug substance, drug substance incorporated with excipients, liposomes, emulsions, colloidal systems, coacervates, aggregates of drug nanoparticles, or dry particles of a diluent which contain embedded drug nanoparticles.
In some embodiments, compounds of Formula (I) disclosed herein intended for respiratory delivery (either systemic or local) can be administered as aqueous formulations, as non-aqueous solutions or suspensions, as suspensions or solutions in halogenated hydrocarbon propellants with or without alcohol, as a colloidal system, as emulsions, coacervates, or as dry powders. Aqueous formulations may be aerosolized by liquid nebulizers employing either hydraulic or ultrasonic atomization or by modified micropump systems (like the soft mist inhalers, the Aerodose® or the AERx® systems). Propellant-based systems may use suitable pressurized metered-dose inhalers (pMDIs). Dry powders may use dry powder inhaler devices (DPIs), which are capable of dispersing the drug substance effectively. A desired particle size and distribution may be obtained by choosing an appropriate device.
In some embodiments, the compositions of Formula (I) disclosed herein can be administered to the ear by various methods. For example, a round window catheter (e.g., U.S. Pat. Nos. 6,440,102 and 6,648,873) can be used.
Alternatively, formulations can be incorporated into a wick for use between the outer and middle ear (e.g., U.S. Pat. No. 6,120,484) or absorbed to collagen sponge or other solid support (e.g., U.S. Pat. No. 4,164,559).
If desired, formulations of the disclosure can be incorporated into a gel formulation (e.g., U.S. Pat. Nos. 4,474,752 and 6,911,211).
In some embodiments, compounds of Formula (I) disclosed herein intended for delivery to the ear can be administered via an implanted pump and delivery system through a needle directly into the middle or inner ear (cochlea) or through a cochlear implant stylet electrode channel or alternative prepared drug delivery channel such as but not limited to a needle through temporal bone into the cochlea.
Other options include delivery via a pump through a thin film coated onto a multichannel electrode or electrode with a specially imbedded drug delivery channel (pathways) carved into the thin film for this purpose. In other embodiments the acidic or basic solid compound of Formula (I) can be delivered from the reservoir of an external or internal implanted pumping system.
Formulations of the disclosure also can be administered to the ear by intratympanic injection into the middle ear, inner ear, or cochlea (e.g., U.S. Pat. No. 6,377,849 and Ser. No. 11/337,815).
Intratympanic injection of therapeutic agents is the technique of injecting a therapeutic agent behind the tympanic membrane into the middle and/or inner ear. In one embodiment, the formulations described herein are administered directly onto the round window membrane via transtympanic injection. In another embodiment, the ion channel modulating agent auris-acceptable formulations described herein are administered onto the round window membrane via a non-transtympanic approach to the inner ear. In additional embodiments, the formulation described herein is administered onto the round window membrane via a surgical approach to the round window membrane comprising modification of the crista fenestrae cochleae.
In some embodiments, the compounds of Formula (I) are formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas, containing conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, PEG (like PEG ointments), and the like.
Suppositories for rectal administration of the drug (either as a solution, colloid, suspension or a complex) can be prepared by mixing a compound provided herein with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt or erode/dissolve in the rectum and release the compound. Such materials include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, poloxamers, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol. In suppository forms of the compositions, a low-melting wax such as, but not limited to, a mixture of fatty acid glycerides, optionally in combination with cocoa butter, is first melted.
Solid compositions can be provided in various different types of dosage forms, depending on the physicochemical properties of the compound provided herein, the desired dissolution rate, cost considerations, and other criteria. In one of the embodiments, the solid composition is a single unit. This implies that one unit dose of the compound is comprised in a single, physically shaped solid form or article. In other words, the solid composition is coherent, which is in contrast to a multiple unit dosage form, in which the units are incoherent.
Examples of single units which may be used as dosage forms for the solid composition include tablets, such as compressed tablets, film-like units, foil-like units, wafers, lyophilized matrix units, and the like. In one embodiment, the solid composition is a highly porous lyophilized form. Such lyophilizates, sometimes also called wafers or lyophilized tablets, are particularly useful for their rapid disintegration, which also enables the rapid dissolution of the compound.
On the other hand, for some applications the solid composition may also be formed as a multiple unit dosage form as defined above. Examples of multiple units are powders, granules, microparticles, pellets, mini-tablets, beads, lyophilized powders, and the like. In one embodiment, the solid composition is a lyophilized powder. Such a dispersed lyophilized system comprises a multitude of powder particles, and due to the lyophilization process used in the formation of the powder, each particle has an irregular, porous microstructure through which the powder is capable of absorbing water very rapidly, resulting in quick dissolution. Effervescent compositions are also contemplated to aid the quick dispersion and absorption of the compound.
Another type of multiparticulate system which is also capable of achieving rapid drug dissolution is that of powders, granules, or pellets from water-soluble excipients which are coated with a compound provided herein so that the compound is located at the outer surface of the individual particles. In this type of system, the water-soluble low molecular weight excipient may be useful for preparing the cores of such coated particles, which can be subsequently coated with a coating composition comprising the compound and, for example, one or more additional excipients, such as a binder, a pore former, a saccharide, a sugar alcohol, a film-forming polymer, a plasticizer, or other excipients used in pharmaceutical coating compositions.
Also provided herein are kits. Typically, a kit includes one or more compounds or compositions as described herein. In certain embodiments, a kit can include one or more delivery systems, e.g., for delivering or administering a compound as provided herein, and directions for use of the kit (e.g., instructions for treating a patient). In another embodiment, the kit can include a compound or composition as described herein and a label that indicates that the contents are to be administered to a patient with cancer. In another embodiment, the kit can include a compound or composition as described herein and a label that indicates that the contents are to be administered to a patient with one or more of hepatocellular carcinoma, colon cancer, leukemia, lymphoma, sarcoma, ovarian cancer, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis, scleroderma, mycotic and viral infections, bone and cartilage diseases, Alzheimer's disease, lung disease, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), polyposis coli, bone density and vascular defects in the eye (Osteoporosis-pseudoglioma Syndrome, OPPG), familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia, Müllerian-duct regression and virilization, SERKAL syndrome, type II diabetes, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICE syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease, and Rett syndrome.
The compounds and compositions provided herein can be used as inhibitors and/or modulators of one or more components of the Wnt pathway, which may include one or more Wnt proteins, and thus can be used to treat a variety of disorders and diseases in which aberrant Wnt signaling is implicated, such as cancer and other diseases associated with abnormal angiogenesis, cellular proliferation, and cell cycling. Accordingly, the compounds and compositions provided herein can be used to treat cancer, to reduce or inhibit angiogenesis, to reduce or inhibit cellular proliferation, to correct a genetic disorder, and/or to treat a neurological condition/disorder/disease due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Non-limiting examples of diseases which can be treated with the compounds and compositions provided herein include a variety of cancers, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, scleroderma, mycotic and viral infections, bone and cartilage diseases, neurological conditions/diseases such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), motor neuron disease, multiple sclerosis or autism, lung disease, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, polyposis coli, bone density and vascular defects in the eye (Osteoporosis-pseudoglioma Syndrome, OPPG), familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia, Müllerian-duct regression and virilization, SERKAL syndrome, type II diabetes, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICE syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease and Rett syndrome.
The compounds and compositions described herein can be used to treat tendinopathy includes all tendon pathologies (tendinitis, tendinosis and paratenonitis) localized in and around the tendons and is characterized by pain, swelling and impaired performance due to the degeneration of the tendon's collagen in response tendon overuse, often referred to as tendinosis. Tendinopathy may be categorized into two histopathologic entities—tendonitis, which results from acute injury to the tendon accompanied by intratendinous inflammation, and more commonly, tendinosis, which is a degenerative response to repetitive microtrauma resulting from overuse. Tendinosis may be accompanied by paratenonitis, an inflammatory condition of the lining of the tendon.
With respect to cancer, the Wnt pathway is known to be constitutively activated in a variety of cancers including, for example, colon cancer, hepatocellular carcinoma, lung cancer, ovarian cancer, prostate cancer, pancreatic cancer and leukemias such as CMF, CLL and T-ALL. Accordingly, the compounds and compositions described herein may be used to treat these cancers in which the Wnt pathway is constitutively activated. In certain embodiments, the cancer is chosen from hepatocellular carcinoma, colon cancer, leukemia, lymphoma, sarcoma and ovarian cancer.
Other cancers can also be treated with the compounds and compositions described herein.
More particularly, cancers that may be treated by the compounds, compositions and methods described herein include, but are not limited to, the following:
1) Breast cancers, including, for example ER+ breast cancer, ER− breast cancer, her2− breast cancer, her2+ breast cancer, stromal tumors such as fibroadenomas, phyllodes tumors, and sarcomas, and epithelial tumors such as large duct papillomas; carcinomas of the breast including in situ (noninvasive) carcinoma that includes ductal carcinoma in situ (including Paget's disease) and lobular carcinoma in situ, and invasive (infiltrating) carcinoma including, but not limited to, invasive ductal carcinoma, invasive lobular carcinoma, medullary carcinoma, colloid (mucinous) carcinoma, tubular carcinoma, and invasive papillary carcinoma; and miscellaneous malignant neoplasms. Further examples of breast cancers can include luminal A, luminal B, basal A, basal B, and triple negative breast cancer, which is estrogen receptor negative (ER), progesterone receptor negative, and her2 negative (her2). In some embodiments, the breast cancer may have a high risk Oncotype score.
2) Cardiac cancers, including, for example sarcoma, e.g., angiosarcoma, fibrosarcoma, rhabdomyosarcoma, and liposarcoma; myxoma; rhabdomyoma; fibroma; lipoma and teratoma.
3) Lung cancers, including, for example, bronchogenic carcinoma, e.g., squamous cell, undifferentiated small cell, undifferentiated large cell, and adenocarcinoma; alveolar and bronchiolar carcinoma; bronchial adenoma; sarcoma; lymphoma; chondromatous hamartoma; and mesothelioma.
4) Gastrointestinal cancer, including, for example, cancers of the esophagus, e.g., squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, and lymphoma; cancers of the stomach, e.g., carcinoma, lymphoma, and leiomyosarcoma; cancers of the pancreas, e.g., ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, and vipoma; cancers of the small bowel, e.g., adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, and fibroma; cancers of the large bowel, e.g., adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, and leiomyoma.
5) Genitourinary tract cancers, including, for example, cancers of the kidney, e.g., adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, and leukemia; cancers of the bladder and urethra, e.g., squamous cell carcinoma, transitional cell carcinoma, and adenocarcinoma; cancers of the prostate, e.g., adenocarcinoma, and sarcoma; cancer of the testis, e.g., seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, and lipoma.
6) Liver cancers, including, for example, hepatoma, e.g., hepatocellular carcinoma; cholangiocarcinoma; hepatoblastoma; angiosarcoma; hepatocellular adenoma; and hemangioma.
7) Bone cancers, including, for example, osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochrondroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors.
8) Nervous system cancers, including, for example, cancers of the skull, e.g., osteoma, hemangioma, granuloma, xanthoma, and osteitis deformans; cancers of the meninges, e.g., meningioma, meningiosarcoma, and gliomatosis; cancers of the brain, e.g., astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, and congenital tumors; and cancers of the spinal cord, e.g., neurofibroma, meningioma, glioma, and sarcoma.
9) Gynecological cancers, including, for example, cancers of the uterus, e.g., endometrial carcinoma; cancers of the cervix, e.g., cervical carcinoma, and pre tumor cervical dysplasia; cancers of the ovaries, e.g., ovarian carcinoma, including serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma, granulosa theca cell tumors, Sertoli Leydig cell tumors, dysgerminoma, and malignant teratoma; cancers of the vulva, e.g., squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, and melanoma; cancers of the vagina, e.g., clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma, and embryonal rhabdomyosarcoma; and cancers of the fallopian tubes, e.g., carcinoma.
10) Hematologic cancers, including, for example, cancers of the blood, e.g., acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, and myelodysplastic syndrome, Hodgkin's lymphoma, non-Hodgkin's lymphoma (malignant lymphoma) and Waldenström's macroglobulinemia.
11) Skin cancers and skin disorders, including, for example, malignant melanoma and metastatic melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, and scleroderma.
12) Adrenal gland cancers, including, for example, neuroblastoma.
Cancers may be solid tumors that may or may not be metastatic. Cancers may also occur, as in leukemia, as a diffuse tissue. Thus, the term “tumor cell,” as provided herein, includes a cell afflicted by any one of the above identified disorders.
A method of treating cancer using a compound or composition as described herein may be combined with existing methods of treating cancers, for example by chemotherapy, irradiation, or surgery (e.g., oophorectomy). In some embodiments, a compound or composition can be administered before, during, or after another anticancer agent or treatment.
The compounds and compositions described herein can be used as anti-angiogenesis agents and as agents for modulating and/or inhibiting the activity of protein kinases, thus providing treatments for cancer and other diseases associated with cellular proliferation mediated by protein kinases. For example, the compounds described herein can inhibit the activity of one or more kinases. Accordingly, provided herein is a method of treating cancer or preventing or reducing angiogenesis through kinase inhibition.
In addition, and including treatment of cancer, the compounds and compositions described herein can function as cell-cycle control agents for treating proliferative disorders in a patient. Disorders associated with excessive proliferation include, for example, cancers, scleroderma, immunological disorders involving undesired proliferation of leukocytes, and restenosis and other smooth muscle disorders. Furthermore, such compounds may be used to prevent de-differentiation of post-mitotic tissue and/or cells.
Diseases or disorders associated with uncontrolled or abnormal cellular proliferation include, but are not limited to, the following:
The compounds and compositions described herein can be used to treat neurological conditions, disorders and/or diseases caused by dysfunction in the Wnt signaling pathway. Non-limiting examples of neurological conditions/disorders/diseases which can be treated with the compounds and compositions provided herein include Alzheimer's disease, aphasia, apraxia, arachnoiditis, ataxia telangiectasia, attention deficit hyperactivity disorder, auditory processing disorder, autism, alcoholism, Bell's palsy, bipolar disorder, brachial plexus injury, Canavan disease, carpal tunnel syndrome, causalgia, central pain syndrome, central pontine myelinolysis, centronuclear myopathy, cephalic disorder, cerebral aneurysm, cerebral arteriosclerosis, cerebral atrophy, cerebral gigantism, cerebral palsy, cerebral vasculitis, cervical spinal stenosis, Charcot-Marie-Tooth disease, Chiari malformation, chronic fatigue syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic pain, Coffin-Lowry syndrome, complex regional pain syndrome, compression neuropathy, congenital facial diplegia, corticobasal degeneration, cranial arteritis, craniosynostosis, Creutzfeldt-Jakob disease, cumulative trauma disorder, Cushing's syndrome, cytomegalic inclusion body disease (CIBD), Dandy-Walker syndrome, Dawson disease, de Morsier's syndrome, Dejerine-Klumpke palsy, Dejerine-Sottas disease, delayed sleep phase syndrome, dementia, dermatomyositis, developmental dyspraxia, diabetic neuropathy, diffuse sclerosis, Dravet syndrome, dysautonomia, dyscalculia, dysgraphia, dyslexia, dystonia, empty sella syndrome, encephalitis, encephalocele, encephalotrigeminal angiomatosis, encopresis, epilepsy, Erb's palsy, erythromelalgia, essential tremor, Fabry's disease, Fahr's syndrome, familial spastic paralysis, febrile seizure, Fisher syndrome, Friedreich's ataxia, fibromyalgia, Foville's syndrome, Gaucher's disease, Gerstmann's syndrome, giant cell arteritis, giant cell inclusion disease, globoid cell leukodystrophy, gray matter heterotopia, Guillain-Barré syndrome, HTFV-1 associated myelopathy, Hallervorden-Spatz disease, hemifacial spasm, hereditary spastic paraplegia, heredopathia atactica polyneuritiformis, herpes zoster oticus, herpes zoster, Hirayama syndrome, holoprosencephaly, Huntington's disease, hydranencephaly, hydrocephalus, hypercortisolism, hypoxia, immune-mediated encephalomyelitis, inclusion body myositis, incontinentia pigmenti, infantile phytanic acid storage disease, infantile Refsum disease, infantile spasms, inflammatory myopathy, intracranial cyst, intracranial hypertension, Joubert syndrome, Karak syndrome, Keams-Sayre syndrome, Kennedy disease, Kinsboume syndrome, Klippel Fed syndrome, Krabbe disease, Kugelberg-Welander disease, kuru, Fafora disease, Lambert-Eaton myasthenic syndrome, Landau-Kleffner syndrome, lateral medullary (Wallenberg) syndrome, Leigh's disease, Lennox-Gastaut syndrome, Lesch-Nyhan syndrome, leukodystrophy, Lewy body dementia, lissencephaly, locked-in syndrome, Lou Gehrig's disease, lumbar disc disease, lumbar spinal stenosis, Lyme disease, Machado-Joseph disease (Spinocerebellar ataxia type 3), macrencephaly, macropsia, megalencephaly, Melkersson-Rosenthal syndrome, Meniere's disease, meningitis, Menkes disease, metachromatic leukodystrophy, microcephaly, micropsia, Miller Fisher syndrome, misophonia, mitochondrial myopathy, Mobius syndrome, monomelic amyotrophy, motor neuron disease, motor skills disorder, Moyamoya disease, mucopolysaccharidoses, multi-infarct dementia, multifocal motor neuropathy, multiple sclerosis, multiple system atrophy, muscular dystrophy, myalgic encephalomyelitis, myasthenia gravis, myelinoclastic diffuse sclerosis, myoclonic Encephalopathy of infants, myoclonus, myopathy, myotubular myopathy, myotonia congenital, narcolepsy, neurofibromatosis, neuroleptic malignant syndrome, lupus erythematosus, neuromyotonia, neuronal ceroid lipofuscinosis, Niemann-Pick disease, O'Sullivan-McLeod syndrome, occipital Neuralgia, occult Spinal Dysraphism Sequence, Ohtahara syndrome, olivopontocerebellar atrophy, opsoclonus myoclonus syndrome, optic neuritis, orthostatic hypotension, palinopsia, paresthesia, Parkinson's disease, paramyotonia congenita, paraneoplastic diseases, paroxysmal attacks, Parry-Romberg syndrome, Pelizaeus-Merzbacher disease, periodic paralyses, peripheral neuropathy, photic sneeze reflex, phytanic acid storage disease, Pick's disease, polymicrogyria (PMG), polymyositis, porencephaly, post-polio syndrome, postherpetic neuralgia (PHN), postural hypotension, Prader-Willi syndrome, primary lateral sclerosis, prion diseases, progressive hemifacial atrophy, progressive multifocal leukoencephalopathy, progressive supranuclear palsy, pseudotumor cerebri, Ramsay Hunt syndrome type I, Ramsay Hunt syndrome type II, Ramsay Hunt syndrome type III, Rasmussen's encephalitis, reflex neurovascular dystrophy, Refsum disease, restless legs syndrome, retrovirus-associated myelopathy, Rett syndrome, Reye's syndrome, rhythmic movement disorder, Romberg syndrome, Saint Vitus dance, Sandhoff disease, schizophrenia, Schilder's disease, schizencephaly, sensory integration dysfunction, septo-optic dysplasia, Shy-Drager syndrome, Sjögren's syndrome, snatiation, Sotos syndrome, spasticity, spina bifida, spinal cord tumors, spinal muscular atrophy, spinocerebellar ataxia, Steele-Richardson-Olszewski syndrome, Stiff-person syndrome, stroke, Sturge-Weber syndrome, subacute sclerosing panencephalitis, subcortical arteriosclerotic encephalopathy, superficial siderosis, Sydenham's chorea, syncope, synesthesia, syringomyelia, tarsal tunnel syndrome, tardive dyskinesia, tardive dysphrenia, Tarlov cyst, Tay-Sachs disease, temporal arteritis, tetanus, tethered spinal cord syndrome, Thomsen disease, thoracic outlet syndrome, tic douloureux, Todd's paralysis, Tourette syndrome, toxic encephalopathy, transient ischemic attack, transmissible spongiform encephalopathies, transverse myelitis, tremor, trigeminal neuralgia, tropical spastic paraparesis, trypanosomiasis, tuberous sclerosis, ubisiosis, Von Hippel-Lindau disease (VHL), Viliuisk Encephalomyelitis (VE), Wallenberg's syndrome, Werdnig, Hoffman disease, west syndrome, Williams syndrome, Wilson's disease and Zellweger syndrome.
The compounds and compositions may also be useful in the inhibition of the development of invasive cancer, tumor angiogenesis and metastasis.
In some embodiments, the disclosure provides a method for treating a disease or disorder associated with aberrant cellular proliferation by administering to a patient in need of such treatment an effective amount of one or more of the compounds of Formula (I), in combination (simultaneously or sequentially) with at least one other agent.
In some embodiments, the disclosure provides a method of treating or ameliorating in a patient a disorder or disease selected from the group consisting of: cancer, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), degenerative disc disease, bone/osteoporotic fractures, bone or cartilage disease, and osteoarthritis, the method comprising administering to the patient a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.
In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
In some embodiments, the method of treats a disorder or disease in which aberrant Wnt signaling is implicated in a patient, the method comprises administering to the patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
In some embodiments, the disorder or disease is cancer.
In some embodiments, the disorder or disease is systemic inflammation.
In some embodiments, the disorder or disease is metastatic melanoma.
In some embodiments, the disorder or disease is fatty liver disease.
In some embodiments, the disorder or disease is liver fibrosis.
In some embodiments, the disorder or disease is tendon regeneration.
In some embodiments, the disorder or disease is diabetes.
In some embodiments, the disorder or disease is degenerative disc disease.
In some embodiments, the disorder or disease is osteoarthritis.
In some embodiments, the disorder or disease is diabetic retinopathy.
In some embodiments, the disorder or disease is pulmonary fibrosis.
In some embodiments, the disorder or disease is idiopathic pulmonary fibrosis (IPF).
In some embodiments, the disorder or disease is degenerative disc disease.
In some embodiments, the disorder or disease is rheumatoid arthritis.
In some embodiments, the disorder or disease is scleroderma.
In some embodiments, the disorder or disease is a mycotic or viral infection.
In some embodiments, the disorder or disease is a bone or cartilage disease.
In some embodiments, the disorder or disease is Alzheimer's disease.
In some embodiments, the disorder or disease is osteoarthritis.
In some embodiments, the disorder or disease is lung disease.
In some embodiments, the disorder or disease is tendinitis.
In some embodiments, the disorder or disease is tendinosis.
In some embodiments, the disorder or disease is paratenonitis.
In some embodiments, the disorder or disease is degeneration of the tendon's collagen.
In some embodiments, the disorder or disease is tendinopathy.
In some embodiments, the disorder or disease is a genetic disease caused by mutations in Wnt signaling components, wherein the genetic disease is selected from: polyposis coli, osteoporosis-pseudoglioma syndrome, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia syndrome, Müllerian-duct regression and virilization, SERKAL syndrome, diabetes mellitus type 2, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication syndrome, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICE syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease and Rett syndrome.
In some embodiments, the patient is a human.
In some embodiments, the cancer is chosen from: hepatocellular carcinoma, colon cancer, breast cancer, pancreatic cancer, chronic myeloid leukemia (CML), chronic myelomonocytic leukemia, chronic lymphocytic leukemia (CLL), acute myeloid leukemia, acute lymphocytic leukemia, Hodgkin lymphoma, lymphoma, sarcoma and ovarian cancer.
In some embodiments, the cancer is chosen from: lung cancer—non-small cell, lung cancer—small cell, multiple myeloma, nasopharyngeal cancer, neuroblastoma, osteosarcoma, penile cancer, pituitary tumors, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer—basal and squamous cell, skin cancer—melanoma, small intestine cancer, stomach (gastric) cancers, testicular cancer, thymus cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, laryngeal or hypopharyngeal cancer, kidney cancer, Kaposi sarcoma, gestational trophoblastic disease, gastrointestinal stromal tumor, gastrointestinal carcinoid tumor, gallbladder cancer, eye cancer (melanoma and lymphoma), Ewing tumor, esophagus cancer, endometrial cancer, colorectal cancer, cervical cancer, brain or spinal cord tumor, bone metastasis, bone cancer, bladder cancer, bile duct cancer, anal cancer and adrenal cortical cancer.
In some embodiments, the cancer is hepatocellular carcinoma.
In some embodiments, the cancer is colon cancer.
In some embodiments, the cancer is colorectal cancer.
In some embodiments, the cancer is breast cancer.
In some embodiments, the cancer is pancreatic cancer.
In some embodiments, the cancer is chronic myeloid leukemia (CML).
In some embodiments, the cancer is chronic myelomonocytic leukemia.
In some embodiments, the cancer is chronic lymphocytic leukemia (CLL).
In some embodiments, the cancer is acute myeloid leukemia.
In some embodiments, the cancer is acute lymphocytic leukemia.
In some embodiments, the cancer is Hodgkin lymphoma.
In some embodiments, the cancer is lymphoma.
In some embodiments, the cancer is sarcoma.
In some embodiments, the cancer is ovarian cancer.
In some embodiments, the cancer is lung cancer—non-small cell.
In some embodiments, the cancer is lung cancer—small cell.
In some embodiments, the cancer is multiple myeloma.
In some embodiments, the cancer is nasopharyngeal cancer.
In some embodiments, the cancer is neuroblastoma.
In some embodiments, the cancer is osteosarcoma.
In some embodiments, the cancer is penile cancer.
In some embodiments, the cancer is pituitary tumors.
In some embodiments, the cancer is prostate cancer.
In some embodiments, the cancer is retinoblastoma.
In some embodiments, the cancer is rhabdomyosarcoma.
In some embodiments, the cancer is salivary gland cancer.
In some embodiments, the cancer is skin cancer—basal and squamous cell.
In some embodiments, the cancer is skin cancer—melanoma.
In some embodiments, the cancer is small intestine cancer.
In some embodiments, the cancer is stomach (gastric) cancers.
In some embodiments, the cancer is testicular cancer.
In some embodiments, the cancer is thymus cancer.
In some embodiments, the cancer is thyroid cancer.
In some embodiments, the cancer is uterine sarcoma.
In some embodiments, the cancer is vaginal cancer.
In some embodiments, the cancer is vulvar cancer.
In some embodiments, the cancer is Wilms tumor.
In some embodiments, the cancer is laryngeal or hypopharyngeal cancer.
In some embodiments, the cancer is kidney cancer.
In some embodiments, the cancer is Kaposi sarcoma.
In some embodiments, the cancer is gestational trophoblastic disease.
In some embodiments, the cancer is gastrointestinal stromal tumor.
In some embodiments, the cancer is gastrointestinal carcinoid tumor.
In some embodiments, the cancer is gallbladder cancer.
In some embodiments, the cancer is eye cancer (melanoma and lymphoma).
In some embodiments, the cancer is Ewing tumor.
In some embodiments, the cancer is esophagus cancer.
In some embodiments, the cancer is endometrial cancer.
In some embodiments, the cancer is colorectal cancer.
In some embodiments, the cancer is cervical cancer.
In some embodiments, the cancer is brain or spinal cord tumor.
In some embodiments, the cancer is bone metastasis.
In some embodiments, the cancer is bone cancer.
In some embodiments, the cancer is bladder cancer.
In some embodiments, the cancer is bile duct cancer.
In some embodiments, the cancer is anal cancer.
In some embodiments, the cancer is adrenal cortical cancer.
In some embodiments, the disorder or disease is a neurological condition, disorder or disease, wherein the neurological condition/disorder/disease is selected from: Alzheimer's disease, frontotemporal dementias, dementia with lewy bodies, prion diseases, Parkinson's disease, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, amyotrophic lateral sclerosis (ALS), inclusion body myositis, autism, degenerative myopathies, diabetic neuropathy, other metabolic neuropathies, endocrine neuropathies, orthostatic hypotension, multiple sclerosis and Charcot-Marie-Tooth disease.
In some embodiments, the compound of Formula (I) inhibits one or more proteins in the Wnt pathway.
In some embodiments, the compound of Formula (I) inhibits signaling induced by one or more Wnt proteins.
In some embodiments, the Wnt proteins are chosen from: WNT1, WNT2, WNT2B, WNT3, WNT3A, WNT4. WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, and WNT16.
In some embodiments, the compound of Formula (I) inhibits a kinase activity.
In some embodiments, the method treats a disease or disorder mediated by the Wnt pathway in a patient, the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.
In some embodiments, the compound of Formula (I) inhibits one or more Wnt proteins.
In some embodiments, the method treats a disease or disorder mediated by kinase activity in a patient, the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.
In some embodiments, the disease or disorder comprises tumor growth, cell proliferation, or angiogenesis.
In some embodiments, the method inhibits the activity of a protein kinase receptor, the method comprises contacting the receptor with an effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.
In some embodiments, the method treats a disease or disorder associated with aberrant cellular proliferation in a patient; the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.
In some embodiments, the method prevents or reduces angiogenesis in a patient; the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.
In some embodiments, the method prevents or reduces abnormal cellular proliferation in a patient; the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.
In some embodiments, the method treats a disease or disorder associated with aberrant cellular proliferation in a patient, the method comprises administering to the patient a pharmaceutical composition comprising one or more of the compounds of claim 1 in combination with a pharmaceutically acceptable carrier and one or more other agents.
Moreover, the compounds and compositions, for example, as inhibitors of the cyclin-dependent kinases (CDKs), can modulate the level of cellular RNA and DNA synthesis and therefore are expected to be useful in the treatment of viral infections such as HIV, human papilloma virus, herpes virus, Epstein-Barr virus, adenovirus, Sindbis virus, pox virus and the like.
Compounds and compositions described herein can inhibit the kinase activity of, for example, CDK/cyclin complexes, such as those active in the G0. or G.1 stage of the cell cycle, e.g., CDK2, CDK4, and/or CDK6 complexes.
The biological activity of the compounds described herein can be tested using any suitable assay known to those of skill in the art, see, e.g., WO 2001/053268 and WO 2005/009997. For example, the activity of a compound may be tested using one or more of the test methods outlined below.
In one example, tumor cells may be screened for Wnt independent growth. In such a method, tumor cells of interest are contacted with a compound (i.e. inhibitor) of interest, and the proliferation of the cells, e.g. by uptake of tritiated thymidine, is monitored. In some embodiments, tumor cells may be isolated from a candidate patient who has been screened for the presence of a cancer that is associated with a mutation in the Wnt signaling pathway. Candidate cancers include, without limitation, those listed above.
In another example, one may utilize in vitro assays for Wnt biological activity, e.g. stabilization of β-catenin and promoting growth of stem cells. Assays for biological activity of Wnt include stabilization of β-catenin, which can be measured, for example, by serial dilutions of a candidate inhibitor composition. An exemplary assay for Wnt biological activity contacts a candidate inhibitor with cells containing constitutively active Wnt/β-catenin signaling. The cells are cultured for a period of time sufficient to stabilize β-catenin, usually at least about 1 hour, and lysed. The cell lysate is resolved by SDS PAGE, then transferred to nitrocellulose and probed with antibodies specific for β-catenin.
In a further example, the activity of a candidate compound can be measured in a Xenopus secondary axis bioassay (Leyns, L. et al. Cell (1997), 88(6), 747-756).
To further illustrate this disclosure, the following examples are included. The examples should not, of course, be construed as specifically limiting the disclosure. Variations of these examples within the scope of the claims are within the purview of one skilled in the art and are considered to fall within the scope of the disclosure as described, and claimed herein. The reader will recognize that the skilled artisan, armed with the present disclosure, and skill in the art is able to prepare and use the disclosure without exhaustive examples.
The starting materials used in preparing the compounds of the disclosure are known, made by known methods, or are commercially available. It will be apparent to the skilled artisan that methods for preparing precursors and functionality related to the compounds claimed herein are generally described in the literature. The skilled artisan given the literature and this disclosure is well equipped to prepare any of the compounds.
It is recognized that the skilled artisan in the art of organic chemistry can readily carry out manipulations without further direction, that is, it is well within the scope and practice of the skilled artisan to carry out these manipulations. These include reduction of carbonyl compounds to their corresponding alcohols, oxidations, acylations, aromatic substitutions, both electrophilic and nucleophilic, etherifications, esterification and saponification and the like. These manipulations are discussed in standard texts such as March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure 7th Ed., John Wiley & Sons (2013), Carey and Sundberg, Advanced Organic Chemistry 5th Ed., Springer (2007), Comprehensive Organic Transformations: A Guide to Functional Group Transformations, 2nd Ed., John Wiley & Sons (1999) (incorporated herein by reference in its entirety) and the like.
The skilled artisan will readily appreciate that certain reactions are best carried out when other functionality is masked or protected in the molecule, thus avoiding any undesirable side reactions and/or increasing the yield of the reaction. Often the skilled artisan utilizes protecting groups to accomplish such increased yields or to avoid the undesired reactions. These reactions are found in the literature and are also well within the scope of the skilled artisan. Examples of many of these manipulations can be found for example in T. Greene and P. Wuts Protective Groups in Organic Synthesis, 4th Ed., John Wiley & Sons (2007), incorporated herein by reference in its entirety.
Trademarks used herein are examples only and reflect illustrative materials used at the time of the disclosure. The skilled artisan will recognize that variations in lot, manufacturing processes, and the like, are expected. Hence the examples, and the trademarks used in them are non-limiting, and they are not intended to be limiting, but are merely an illustration of how a skilled artisan may choose to perform one or more of the embodiments of the disclosure.
(1H) nuclear magnetic resonance spectra (NMR) were measured in the indicated solvents on a Bruker NMR spectrometer (Avance™ DRX300, 300 MHz for 1H or Avance™ DRX500, 500 MHz for 1H) or Varian NMR spectrometer (Mercury 400BB, 400 MHz for 1H). Peak positions are expressed in parts per million (ppm) downfield from tetramethylsilane. The peak multiplicities are denoted as follows, s, singlet; d, doublet; t, triplet; q, quartet; ABq, AB quartet; quin, quintet; sex, sextet; sep, septet; non, nonet; dd, doublet of doublets; ddd, doublet of doublets of doublets; d/ABq, doublet of AB quartet; dt, doublet of triplets; td, triplet of doublets; dq, doublet of quartets; m, multiplet.
The following abbreviations have the indicated meanings:
Ac2O=acetic anhydride
BH3-Me2S=borane dimethyl sulfide complex
B(i-PrO)3=triisopropyl borate
(BOC)2O=di-tert-butyl dicarbonate
brine=saturated aqueous sodium chloride
CDCl3=deuterated chloroform
CD3OD=deuterated methanol
mCPBA=meta-chloroperoxybenzoic acid
Cy3P=tricyclohexylphosphine
DCAD=di-(4-chlorobenzyl)azodicarboxylate
DCE=dichloroethane
DCM=dichloromethane
DEAD=diethyl azodicarboxylate
DHP=dihydropyran
DIPEA=diisopropylethylamine
DMAP=4-dimethylaminopyridine
DMF=N,N-dimethylformamide
DMSO-d6=deuterated dimethylsulfoxide
ESIMS=electron spray mass spectrometry
EtOAc=ethyl acetate
EtOH=ethanol
HCl=hydrochloric acid
HOAc=acetic acid
K2CO3=potassium carbonate
KOAc=potassium acetate
LC/MS=liquid chromatography-mass spectrometry
LDA=lithium diisopropylamide
MeOH=methanol
MgSO4=magnesium sulfate
MPLC=Medium pressure liquid chromatography
MsCl=methanesulfonyl chloride or mesyl chloride
MTBE=methyl tert-butyl ether
MW=microwave
NaBH4=sodium borohydride
NaBH(OAc)3=sodium triacetoxyborohydride
NaCNBH3=sodium cyanoborohydride
NaHCO3=sodium bicarbonate
NaH2PO4=monosodium phosphate
Na2HPO4=disodium phosphate
NaIO4=sodium periodate
NaOH=sodium hydroxide
Na2SO4=sodium sulfate
NBS=N-bromo succinimide
NMR=nuclear magnetic resonance
ON=overnight
Pd2(dba)3=tris(dibenzylideneacetone)dipalladium(0)
Pd(dppf)Cl2=1,1′-bis(diphenylphosphino)ferrocene]palladium(II) chloride
Pd(PPh3)4=tetrakis(triphenylphosphine)palladium(0)
PE=petroleum ether
PhMe=toluene
Pin2B2=bis(pinacolato)diboron
POCl3=phosphorus oxychloride
PPh3=triphenylphosphine
prep-HPLC=preparative High-performance liquid chromatography
r.t=room temperature
SEM-Cl=2-(trimethylsilyl)ethoxymethyl chloride
TEA=triethylamine
TFA=trifluoroacetic acid
THF=tetrahydrofuran
THP=tetrahydropyran
TLC=thin layer chromatography
p-TsOH=p-toluenesulfonic acid
XPhos=2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl
The following example schemes are provided for the guidance of the reader, and collectively represent an example method for making the compounds provided herein. Furthermore, other methods for preparing compounds of the disclosure will be readily apparent to the person of ordinary skill in the art in light of the following reaction schemes and examples. The skilled artisan is thoroughly equipped to prepare these compounds by those methods given the literature and this disclosure. The compound numberings used in the synthetic schemes depicted below are meant for those specific schemes only, and should not be construed as or confused with same numberings in other sections of the application. Unless otherwise indicated, all variables are as defined above.
Compounds of Formula (I) of the present disclosure can be prepared as depicted in Scheme 1a.
Compound I, wherein PG is a protecting group such as THP, undergoes Suzuki coupling with Compound II to provide Compound III. In certain embodiments, Compound I (X=Br) undergoes Suzuki coupling with Compound II (Y=—B(OH)2 or boronate ester) to provide Compound III after removal of the protecting group. In other embodiments, Compound I (X=Br) is first converted to the corresponding boronic acid or boronate ester (not shown), which in turn undergoes Suzuki coupling with Compound II (Y=Br) to provide Compound III after removal of the protecting group. Treatment of Compound III with KOH and I2 followed by Boc2O affords the protected iodide IV.
In certain embodiments, when R* is R5 (e.g., a six-membered ring), Suzuki coupling between iodide (IV) and boronic acid (V) followed by removal of the protecting groups affords the desired hi-heteroaryl product VI (see, for example, conditions A above).
In other embodiments, when R* is Br or Cl, the resultant Suzuki product can further undergo a second Suzuki coupling to install the R5 substituent. In some cases, this procedure is useful when the R5 substituent is a five-membered ring. In these embodiments, removal of the protecting groups affords the desired bi-heteroaryl product VI. See, for example, conditions B above.
Compounds of Formula (I) of the present disclosure can be prepared as depicted in Scheme 1.
Scheme 1 describes a method for preparation of 3-(1H-pyrrolo[2,3-c]pyridin-2-yl)-1H-indazole compounds (X) by converting the N-protected 5-bromo-1H-indazole (I) to the boronate (II) followed by Suzuki coupling with various bromo compounds to produce compound (III) analogs. (Ill) is then deprotected to form (IV). Iodination with iodine and potassium hydroxide can either be performed directly on (IV) to form (V) followed by Boc protection (Path A) or (IV) can be first protected with Boc to give (VI) followed by iodination (Path B) to produce compound (VII) analogs. The protected 3-iodo-1H-indazole (VII) is then reacted with the Boc/SEM protected (1H-pyrrolo[2,3-c]pyridin-2-yl)boronic acid (VIII) using Suzuki coupling to form the protected 3-(1H-pyrrolo[2,3-c]pyridin-2-yl)-1H-indazole compounds (IX). Final deprotection of the pyrazole nitrogen yields the desired substituted 3-(1H-pyrrolo[2,3-c]pyridin-2-yl)-1H-indazole compounds (X).
Alternatively, compounds of Formula (I) of the present disclosure can be prepared as depicted in Scheme 2,
Scheme 2 describes an alternative method for preparation of 3-(1H-pyrrolo[2,3-c]pyridin-2-yl)-1H-indazole compounds (XIV) by reacting Boc protected 3-iodo-1H-indazole (VII) with the Boc/SEM protected (4-bromo-1H-pyrrolo[2,3-c]pyridin-2-ylboronic acid (XI) by Suzuki coupling. A second Suzuki coupling with various boronic acids yields the protected 3-(1H-pyrrolo[2,3-c]pyridin-2-yl)-1H-indazole (XIII). Final deprotection of the pyrazole nitrogen yields the desired substituted 3-(1H-pyrrolo[2,3-c]pyridin-2-yl)-1H-indazole analogs (XIV).
Preparation of intermediate 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (XVII) is depicted below in Scheme 3.
A mixture of 5-bromo-1H-indazole (XV) (500 g, 2.54 mol), DHP (256 g, 3.05 mol), and p-TsOH (48.3 g, 254 mmol) in DCM (4 F) was stirred at 25° C. for 4 h. TLC (PE:EtOAc=2:1, Rf=0.83) showed that the reaction was complete. The mixture was washed with a saturated NaHCO3 solution (1000 mL), brine, dried over Na2SO4, and concentrated to give 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (XVI) (700 g, crude) as a yellow oil. ESIMS found for C12H13BrN2O m/z 281.1 (M+H).
A mixture of 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (XVI) (200 g, 711 mmol), bis(pinacolato)diboron (217 g, 854 mmol), KOAc (279 g, 2.85 mol) and Pd(dppf)Cl2 (10.4 g, 14.23 mmol) in dioxane (2 L) was stirred at 85° C. for 16 h. TLC (PE:EtOAc=2:1, Rf=0.78) showed that the reaction was complete. The mixture was filtered and the filtrate was concentrated. The residue was purified by column chromatography on silica gel (PE:EtOAc=20:1) to give 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (XVII) (110 g, 335 mmol, 47.1% yield) as a white solid. 1H NMR (CDCl3, 400 MHz) δ ppm 1.26 (s, 12H), 1.36 (s, 12H), 1.60-1.84 (m, 3H), 2.06 (dd, J=3.2 Hz, J=13.2 Hz, 1H), 2.15 (br s, 1H), 2.49-2.66 (m, 1H), 3.74 (t, J=8.8 Hz, 1H), 4.03 (d, J=12 Hz, 1H), 5.72 (dd, J=2.8 Hz, J=11.2 Hz, 1H), 7.56 (d, J=8.4 Hz, 1H), 7.80 (d, J=8.4 Hz, 1H), 8.03 (s, 1H), 8.25 (s, 1H); ESIMS found for C18H25BN2O3 m/z 329.1 (M+H).
Preparation of the 7-fluoro-substituted indazole intermediate (XXIII) is depicted below in Scheme 4.
To a stirred solution of 2,3-difluorobenzaldehyde (XVIII) (75.0 g, 528 mmol, 1.0 eq) in H2SO4 (565 mL) was added NBS (113 g, 633 mmol, 1.2 eq) in portions at 60° C. The resulting mixture was stirred at 60° C. for 12 hr. LC/MS showed the reaction was completed. The reaction mixture was poured into ice water and petroleum ether (500 mL) and stirred for 10 min, the organic layer was separated and concentrated under vacuum to give crude product. The residue was purified column chromatography silica gel (100% petroleum ether) to give 5-bromo-2,3-difluorobenzaldehyde (XIX) (120 g, 543.0 mmol, quantitative yield). ESIMS found C7H3BrF2O m/z 221.1 (M+1).
To a solution of 5-bromo-2,3-difluorobenzaldehyde (XIX) (115 g, 520 mmol, 1.0 eq), MeONH2.HCl (47.8 g, 572 mmol, 1.1 eq) and K2CO3 (86.3 g, 624 mmol, 1.20 eq) was in DME (1.30 L) was heated to 40° C. for 15 h. TLC (petroleum ether) showed (XIX) was consumed. The reaction was filtered and the filtrate was concentrated under vacuum to give crude product. The residue was purified by column chromatography on silica gel (100% petroleum ether) to give (E)-5-bromo-2,3-difluorobenzaldehyde O-methyl oxime (XX) (74 g, 56.9% yield). 1H NMR (CDCl3, 400 MHz) δ ppm 4.04 (s, 3H), 7.37-7.32 (m, 1H), 7.77 (s, 1H), 8.23 (s, 1H); ESIMS found C8H6BrF2NO m/z 250.2 (M+1).
A solution of (E)-5-bromo-2,3-difluorobenzaldehyde O-methyl oxime (XX) (150 g, 600 mmol, 1.0 eq), NH2NH2H2O (600 mL) in dry THF (600 mL) was heated to 90° C. for 84 h. LC/MS showed the reaction was completed. The solvent was evaporated and the resulting mixture was diluted with EtOAc, washed with water, dried over Na2SO4 and concentrated under vacuum to give crude product. The residue was purified by column chromatography on silica gel (PE:EtOAc=10:1) to give 5-bromo-7-fluoro-1H-indazole (XXI) as a white solid (78 g, 362.7 mmol, 60.5% yield). 1H NMR (DMSO-d6, 400 MHz) δ ppm 7.44 (d, J=9.6 Hz, 1H), 7.87 (d, J=1.6 Hz, 1H), 8.17 (s, 1H), 13.90 (s, 1H); ESIMS found C7H4BrFN2 m/z 215 (M+1).
Preparation of 5-bromo-7-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (XXII) was performed following the procedure listed in Scheme 3, Step 1. Light yellow solid (98 g, 327.6 mmol, 93.9% yield). 1H NMR (CDCl3, 400 MHz) δ ppm 1.78-1.62 (m, 3H), 2.17-2.09 (m, 2H), 2.63-2.58 (m, 1H), 3.76 (t, J=11.6 Hz, 1H), 4.05 (d, J=9.6 Hz, 1H), 5.85 (d, J=9.6 Hz, 1H), 7.22 (d, J=12.0 Hz, 1H), 7.65 (s, 1H), 8.00 (s, 1H); ESIMS found C12H12BrFN2O m/z 299.2 (M+1).
Preparation of 7-fluoro-1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (XXIII) was performed following the procedure listed in Scheme 3, Step 2. White solid (45 g, 130.0 mmol, 86.7% yield). ESIMS found C18H24BFN2O3 m/z 347.1 (M+1).
Preparation of the 6-fluoro-substituted indazole intermediate (XXX) is depicted below in Scheme 5.
A solution of 5-fluoro-2-methylaniline (XXIV) (100 g, 799 mmol, 1.0 eq) and AC2O (89 g, 879 mmol, 1.1 eq) in toluene (4.0 L) was stirred at 110° C. for 4 h. TLC (PE:EtOAc=2:1) showed (XXIV) was consumed. The reaction mixture was cooled to 25° C. The precipitated solid was filtered, washed with petro ether. The solid was dried in vacuo to give N-(5-fluoro-2-methylphenyl)acetamide (XXV) as a white solid (120 g, 717.8 mmol, 89.8% yield), which was used in step 2 without further purification. ESIMS found C9H10FNO m/z 168.1 (M+1).
To a solution of N-(5-fluoro-2-methylphenyl)acetamide (XXV) (120 g, 717 mmol, 1.0 eq) in HOAc (3 L) was added a solution of Bra (140 g, 876 mmol, 1.2 eq) in HOAc (1 L) dropwise. The mixture was stirred at 25° C. for 3 h. LC/MS showed compound 2 was (XXV) completely consumed. The reaction mixture was quenched with water (8 L). The solid was filtered, washed with water and petroleum ether. The solid was dried in vacuo to give N-(4-bromo-5-fluoro-2-methylphenyl)acetamide (XXVI) as a white solid (155 g, 629.9 mmol, 87.8% yield). 1H NMR (CDCl3, 400 MHz) δ ppm 2.20 (s, 6H), 7.07 (brs, 1H), 7.32 (d, J=7.2 Hz, 1H), 7.85 (d, J=10.8 Hz, 1H); ESIMS found C9H9BrFNO m/z 247.2 (M+1).
A solution of N-(4-bromo-5-fluoro-2-methylphenyl)acetamide (XXVI) (155 g, 629.9 mmol, 1.0 eq), Ac2O (192 g, 1.8 mol, 3.0 eq), KOAc (123 g, 1.26 mol, 2.0 eq), 18-CROWN-6 (8.3 g, 31 mmol, 0.05 eq) and isoamyl nitrite (147 g, 1.2 mol, 2.0 eq) in CHCl3 (7.0 L) was stirred at 65° C. for 12 h. TLC (PE:EtOAc=5:1, Rf=0.2) showed (XXVI) was consumed completely. The solvent was removed under reduced pressure. The residue was extracted with EtOAc (1.5 L) and water (1.5 L). The organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure to give 1-(5-bromo-6-fluoro-1H-indazol-1-yl)ethan-1-one (XXVII) as a white solid (170 g, crude, quantitative yield), which was used in step 4 without further purification. ESIMS found C9H6BrFN2O m/z 258.1 (M+1).
A solution of 1-(5-bromo-6-fluoro-1H-indazol-1-yl)ethan-1-one (XXVII) (170 g, 629.9 mmol, 1.0 eq) in 3 N HCl (6.6 mol, 10 eq) and MeOH (900 mL) was stirred at 60° C. for 12 h. TLC (PE:EtOAc=5:1, Rf=0.8) showed (XXVII) was consumed completely. The reaction mixture was cooled to room temperature and basified with 1N aq. NaOH to pH=10. The precipitated solid was filtered and dried in vacuo to afford 5-bromo-6-fluoro-1H-indazole (XXVIII) as a yellow solid (100 g, 465.1 mmol, 73.8% yield). ESIMS found C7H4BrFN2 m/z 215.1 (M+1).
To solution of a mixture of 5-bromo-6-fluoro-1H-indazole (XXVIII) (90 g, 418 mmol, 1.0 eq) and 3,4-dihydro-2H-pyran (70 g, 837 mmol, 2.0 eq) in DCM (2.0 L) was added p-TsOH (3.6 g, 20 mmol, 0.05 eq) at 25° C. The resulting mixture was stirred at 25° C. for 12 h. TLC (PE:EtOAc=5:1, Rf=0.7) showed (XXVIII) was completely consumed. To the reaction mixture was added saturated aqueous NaHCO3 (4 L). The organic layer was separated, dried over Na2SO4, concentrated in vacuo to give a residue, which was further purified by silica gel column (EtOAc:PE=20:1) to give 5-bromo-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (XXIX) as a brown oil (120 g, 401.1 mmol, 96.0% yield), which was used in step 6 without further purification. ESIMS found C12H12BrFN2O m/z 299.2 (M+1).
A solution of 5-bromo-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (XXIX) (30 g, 100 mmol, 1.0 eq), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (25 g, 100 mmol, 1.0 eq), Pd(dppf)Cl2 (3.6 g, 5.0 mmol, 0.05 eq), KOAc (19.6 g, 200 mmol, 2.0 eq) in dioxane (550 mL) was stirred at 100° C. for 12 h under N2. LC/MS showed (XXIX) was completely consumed. The reaction mixture was concentrated and then extracted with EtOAc (300 mL) and water (100 mL). The mixture was filtered and separated. The organic layer was dried over anhydrous Na2SO4, concentrated to give crude product, which was further purified by silica gel column (EtOAc:PE=20/1) to give 6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (XXX) as a green solid (13 g, 37.5 mmol, 37.4% yield). 1H NMR (CDCl3, 400 MHz) δ ppm 1.37 (s, 12H), 1.73-1.43 (m, 3H), 2.58-2.50 (m, 1H), 3.79-3.73 (m, 1H), 4.06-4.04 (m, 1H), 5.66-5.63 (m, 1H), 7.28-7.21 (m, 1H), 8.00 (s, 1H), 8.19 (d, J=5.6 Hz, 1H); ESIMS found C18H24BFN2O3 m/z 347.2 (M+1).
Preparation of the 4-fluoro-substituted indazole intermediate (XXXV) is depicted below in Scheme 6.
To a stirred solution of 3-fluoro-2-methylaniline (XXXI) (50 g, 399 mmol, 1.0 eq) in CH3CN (1.2 L) was added NBS (78 g, 439 mmol, 1.1 eq) in portions at 10° C., the resulting mixture was stirred at 25° C. for 1 h. LC/MS showed the reaction was completed. Saturated Na2S2O3 (1.2 L) was then added slowly to the reaction mixture at 10° C., extracted with EtOAc (2 L) and the organic layer was concentrated under vacuum to give crude product. The residue was washed with PE (1 L), the solid was filtered, washed again with PE (500 mL) and dried under vacuum to give 4-bromo-3-fluoro-2-methylaniline (XXXII) as a white solid (163.0 g, 798.9 mmol, 66.7% yield). ESIMS found C7H7BrFN m/z 204.1 (M+1).
To a stirred solution of 4-bromo-3-fluoro-2-methylaniline (XXXII) (40 g, 196 mmol, 1.0 eq) in HOAc (1.2 L) was added NaNO2 (16 g, 235 mmol, 1.2 eq) in portions at 10° C., the resulting mixture was stirred at 25° C. for 4 h. LC/MS showed the reaction was completed. Upon completion, aqueous NaOH (50%) was added to the reaction mixture until pH 7˜8, then the mixture was extracted with EtOAc (1.6 L), the organic layer was dried over Na2SO4, filtered; filtrate was concentrated under vacuum to give crude 5-bromo-4-fluoro-1H-indazole (XXXIII) (40 g, 186.0 mmol, 94.9% yield), which was used in step 3 without further purification. 1H NMR (CDCl3, 400 MHz) δ ppm 7.47-7.42 (m, 1H), 7.56-7.53 (m, 1H), 8.23 (s, 1H); ESIMS found C7H4BrFN2 m/z 215 (M+1).
Preparation of 5-bromo-4-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (XXXIV) was performed following the procedure listed in Scheme 4, Step 5. Brown oil (9.9 g, 33.1 mmol, 71.9% yield). 1H NMR (CDCl3, 400 MHz) δ ppm 1.75-1.67 (m, 3H), 2.10-1.76 (m, 2H), 2.52-2.14 (m, 1H), 3.76-3.71 (m, 1H), 4.01-3.97 (m, 1H), 5.70-5.69 (m, 1H), 7.30-7.26 (m, 1H), 7.47-7.45 (m, 1H), 8.06 (s, 1H); ESIMS found C12H12BrFN2O m/z 299 (M+1).
Preparation of 4-fluoro-1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (XXXV) was performed following the procedure listed in Scheme 4, Step 6. Red oil (25 g, 72.2 mmol, 72.2% yield). 1H NMR (CD3OD, 400 MHz) δ ppm 1.72 (s, 12H), 2.12-1.74 (m, 5H), 2.52-2.16 (m, 1H), 3.85-3.80 (m, 1H), 4.12-4.00 (m, 1H), 5.84-5.81 (m, 1H), 7.48 (d, J=8.0 Hz, 1H), 7.71-7.67 (m, 1H), 8.15 (s, 1H); ESIMS found C18H24BFN2O3 m/z 347 (M+1).
Preparation of intermediate N-(5-bromopyridin-3-yl)pivalamide (XXXVIII) is depicted below in Scheme 7.
To a solution of 3-amino-5-bromo pyridine (XXXVI) (1.0 g, 5.78 mmol) in dry pyridine (10 mL) was added pivaloyl chloride (XXXVII) (769 mg, 6.38 mmol). The reaction mixture was stirred at room temperature for 3 h. The reaction was poured into an ice water/saturated aqueous NaHCO3 mixture and stirred for 30 min. The precipitate was filtered, washed with cold water and dried at room temperature to yield N-(5-bromopyridin-3-yl)pivalamide (XXXVIII) as an off-white solid (1.082 g, 4.22 mmol, 73.1% yield). 1H NMR (DMSO-d6, 500 MHz) δ ppm 1.23 (s, 9H), 8.37 (d, J=2 Hz, 1H), 8.39 (t, J=2 Hz, 1H), 8.80 (d, H=2 Hz, 1H), 9.58 (brs, 1H); ESIMS found C10H13BrN2O m/z 258.9 (Br81M+H).
The following intermediates were prepared in accordance with the procedure described in the above Scheme 7.
N-(5-Bromopyridin-3-yl)isobutyramide (XXXIX): Off-white solid, (71% yield). 1H NMR (CDCl3) δ ppm 8.55-8.35 (m, 3H), 7.32 (s, 1H), 2.59-2.48 (m, 1H), 1.28-1.27 (d, 6H); ESIMS found C9H11BrN2O m/z 242.9 (Br79M+H).
N-(5-Bromopyridin-3-ylpropionamide (XL): Off white solid (92% yield). 1H NMR (DMSO-d6) δ ppm 1.09 (t, J=7.54 Hz, 3H), 2.36 (q, J=7.54 Hz, 2H), 8.36 (m, 2H), 8.65 (d, J=2.07 Hz, 1H), 10.26 (s, 1H); ESIMS found C8H9BrN2O m/z 231.1 (Br81M+H).
N-(5-Bromopyridin-3-yl)butyramide (XLI): Yellow solid (2.1 g, 8.64 mmol, 88.8% yield). 1H NMR(CD3OD, 400 MHz) δ ppm 1.02 (t, J=7.2 Hz, 3H), 1.74 (sxt, J=7.2 Hz, 2H), 2.40 (t, J=7.2 Hz, 2H), 8.35 (d, J=2 Hz, 1H), 8.46 (t, J=2 Hz, 1H), 8.63 (d, J=2 Hz, 1H); ESIMS found C9H11BrN2O m/z 243.1 (Br79M+H).
N-(5-Bromopyridin-3-ylpentanamide (XLII): Yellow solid (2.0 g, 7.78 mmol, 85.3% yield). 1H NMR(CD3OD, 400 MHz) δ ppm 0.98 (t, J=7.4 Hz, 3H), 1.43 (sxt, J=7.4 Hz, 2H), 1.70 (quin, J=7.4 Hz, 2H), 2.43 (t, J=7.6 Hz, 2H), 8.35 (s, 1H), 8.45 (d, J=2 Hz, 1H), 8.64 (d, J=2 Hz, 1H); ESIMS found C10H13BrN2O m/z 256.9 (Br79M+H).
N-(5-Bromopyridin-3-yl)-3-methylbutanamide (XLIII): Off white solid, (67% yield), 1H NMR (CDCl3, 500 MHz) δ ppm 8.55-8.42 (m, 3H), 7.62 (s, 1H), 2.31-2.18 (m, 3H), 1.02-1.01 (d, J=6 Hz, 6H); ESIMS found C10H13BrN2O m/z 258.9 (Br81M+H).
N-(5-Bromopyridin-3-yl)-3,3-dimethylbutanamide (XLIV): Yellow solid (1.7 g, 6.27 mmol, 78.6% yield). 1H NMR (CD3OD, 400 MHz) δ ppm 1.10 (s, 9H), 2.29 (s, 2H), 8.36 (d, J=1.6 Hz, 1H), 8.46 (d, J=2.0 Hz, 1H), 8.64 (d, J=2.0 Hz, 1H); ESIMS found C11H15BrN2O m/z 273.1 ((Br81M+H).
N-(5-Bromopyridin-3-yl)-2-phenylacetamide (XLV): White solid (2.5 g, 8.59 mmol, 77.9% yield). 1H NMR (CDCl3, 400 MHz) δ ppm 3.76 (s, 2H), 7.26-7.45 (m, 5H), 7.57 (brs, 1H), 8.33 (s, 1H), 8.37 (s, 2H); ESIMS found C13H11BrN2O m/z 292.8 (Br81M+H).
N-(5-Bromopyridin-3-ylbenzamide (XLVI): White solid (2.7 g, 9.74 mmol, 60% yield). 1H NMR (CDCl3, 400 MHz) δ ppm 7.40-7.52 (m, 2H), 7.52-7.62 (m, 1H), 7.86 (d, J=7.2 Hz, 2H), 8.39 (d, J=1.6 Hz, 1H), 8.46 (s, 1H), 8.55 (d, J=1.6 Hz, 1H), 8.57 (d, J=2.0 Hz, 1H); ESIMS found C12H9BrN2O m/z 278.8 (Br81M+H).
N-(5-Bromopyridin-3-yl)cyclopropanecarboxamide (XLVII): Off-white solid, (83% yield), 1H NMR (CDCl3, 500 MHz) δ ppm 8.46-8.39 (m, 3H), 7.54 (bs, 1H), 1.56-1.50 (m, 1H), 1.13-1.07 (m, 2H), 0.96-0.90 (m, 2H); ESIMS found for C9H9BrN2O m/z 240.9 (Br79M+H).
N-(5-Bromopyridin-3-yl)cyclobutanecarboxamide (XLVIII): Yellow solid (2.1 g, 6.27 mmol, 86.6% yield). 1H NMR(CD3OD, 400 MHz) δ ppm 1.80-1.99 (m, 1H), 1.99-2.15 (m, 1H), 2.16-2.30 (m, 2H), 2.30-2.45 (m, 2H), 3.25-3.35 (m, 1H), 8.34 (d, J=2.0 Hz, 1H), 8.47 (s, 1H), 8.64 (d, J=2.0 Hz, 1H); ESIMS found C10H11BrN2O m/z 257.1 (Br81M+H).
N-(5-Bromopyridin-3-yl)cyclopentanecarboxamide (XLIX): Yellow solid (1.9 g, 7.06 mmol, 80.2% yield). 1H NMR(CD3OD, 400 MHz) δ ppm 1.57-1.74 (m, 2H), 1.74-1.91 (m, 4H), 1.91-2.07 (m, 2H), 2.77-2.92 (m, 1H), 8.34 (d, J=1.6 Hz, 1H), 8.45 (s, 1H), 8.65 (d, J=2.0 Hz, 1H); ESIMS found C11H13BrN2O m/z 271.1 (Br81M+H).
N-(5-Bromopyridin-3-yl)cyclohexanecarboxamide (L): Yellow solid (2.0 g, 7.06 mmol, 84.3% yield). 1H NMR (CD3OD, 400 MHz) δ ppm 1.19-1.46 (m, 3H), 1.46-1.63 (m, 2H), 1.74 (d, J=11.6 Hz, 1H), 1.88 (t, J=14.0 Hz, 4H), 2.40 (tt, J=11.6 Hz, J=3.6 Hz, 1H), 8.34 (d, J=2.0 Hz, 1H), 8.44 (t, J=2.0 Hz, 1H), 8.64 (d, J=2.0 Hz, 1H); ESIMS found C12H15BrN2O m/z 285.1 (Br81M+H).
N-(5-Bromopyridin-3-yl)-2-cyclohexylacetamide (LI): Yellow solid (261 mg, 0.878 mmol, 84.4% yield). ESIMS found C13H17BrN2O m/z 297.1 (Br81M+H).
Preparation of intermediate 5-bromo-N,N-dimethylpyridin-3-amine (LIII) is depicted below in Scheme 8.
To a solution of 3,5-dibromopyridine (LII) (2.37 g, 10.0 mmol) in dry DMF (20.0 mL) was added K2CO3 (4.5 g, 33 mmol) and dimethylamino hydrochloride (1.79 g, 22 mmol). The mixture was heated overnight at 200° C. in a sealed tube. The solution was cooled to room temperature and excess DMF was removed under vacuum. The residue was partitioned between EtOAc and water. The organic phase was separated. The aqueous phase was washed with EtOAc and the combined organic phases were dried over MgSO4, and concentrated to afford 5-bromo-N,N-dimethylpyridin-3-amine (LIII) as an off-white solid (1.78 g, 8.85 mmol, 88% yield). 1H NMR (DMSO-d6, 500 MHz) δ ppm 2.94 (s, 6H), 7.25 (t, J=2 Hz, 1H), 7.91 (d, J=2 Hz, 1H), 8.07 (d, J=2 Hz, 1H); ESIMS found C7H9BrN2 m/z 201.1 (M+H).
Preparation of intermediate 5-bromo-N-isopropylpyridin-3-amine (LIV) is depicted below in Scheme 9.
To a solution of 5-bromopyridin-3-amine (XXXVI) (535 mg, 3.09 mmol) in MeOH (62 mL) was added acetone (296 μL, 4.02 mL). The pH was adjusted to 4 using HOAc and stirred for 30 min. NaCNBH3 (272 mg, 4.33 mmol) was added and stirred at room temperature overnight. The MeOH was removed under vacuum and the residue was partitioned between EtOAc and saturated aqueous NaHCO3. The organic layer was dried over MgSO4 and evaporated under vacuum. The crude product was purified on a silica gel column (100% hexanes→90:10 hexanes:EtOAc) to produce 5-bromo-N-isopropylpyridin-3-amine (LIV) as an oil which slowly solidified into an off-white solid (309 mg, 1.44 mmol, 47% yield). 1H NMR (DMSO-d6, 500 MHz) δ ppm 1.12 (d, J=6.3 Hz, 6H), 3.55-3.59 (m, 1H), 6.03 (d, J=7.9 Hz, 1H), 7.05-7.06 (m, 1H), 7.75 (d, J=2 Hz, 1H), 7.90 (d, J=2 Hz, 1H); ESIMS found C8H11BrN2 m/z 215.1 (M+H).
Preparation of intermediate 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine (LVI) is depicted below in Scheme 10.
Preparation of 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine (LVI) was performed following the procedure listed in Scheme 9, Step 1. Brown oil (1.20 g, 5.59 mmol, 45% yield). 1H NMR (DMSO-d6, 500 MHz) δ ppm 2.15 (s, 6H), 3.43 (s, 2H), 7.94 (s, 1H), 8.47 (d, J=1.1 Hz, 1H), 8.59 (d, J=2.2 Hz, 1H); ESIMS found C8H11BrN2 m/z 215 (MBr79+H) and 217 (MBr81+H).
Preparation of intermediate 3-bromo-5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridine (LVII) is depicted below in Scheme 11.
To a mixture of 5-bromopyridine-3-carbaldehyde (LV) (6.00 g, 32.26 mmol, 1.0 eq), 3,3-difluoropyrrolidine (5.56 g, 38.71 mmol, 1.20 eq) and TEA (5.39 mL, 38.71 mmol, 1.2 eq) in DCE (200 mL) was stirred at room temperature for 30 min, then added sodium triacetoxyborohydride (10.25 g, 48.38 mmol, 1.50 eq) in one portion at room temperature under N2. The mixture was stirred at room temperature for 6 h. TLC showed the reaction was complete. The reaction was quenched with 1N NaOH (100 mL), extracted with DCE (100 mL×2). The combined organic layers were washed with brine (100 mL), dried and concentrated. The residue was purified by silica gel chromatography (column height: 50 mm, diameter: 50 mm, 300-400 mesh silica gel, DCM/MeOH=30/1→20/1) to give 3-bromo-5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridine (LVII): Yellow oil (8.00 g, 28.9 mmol, 89.5% yield). 1H NMR (CDCl3, 400 MHz) δ ppm 2.30 (spt, J=7.2 Hz, 2H), 2.75 (t, J=6.8 Hz, 2H), 2.91 (t, J=13.2 Hz, 2H), 7.85 (s, 1H), 8.45 (s, 1H), 8.59 (d, J=2 Hz, 1H); ESIMS found for C10H11BrF2N2 m/z 277.0 (M+H).
The following intermediates were prepared in accordance with the procedure described in the above Schemes 9-11.
3-Bromo-5-(pyrrolidin-1-ylmethyl)pyridine (LVIII): Golden liquid (1.35 g, 97% yield). 1H NMR (DMSO-d6) δ ppm 1.68-1.71 (m, 4H), 2.42-2.44 (m, 4H), 3.60 (s, 2H), 7.96 (s, 1H), 8.48 (d, J=2 Hz, 1H), 8.58 (d, J=3 Hz, 1H); ESIMS found for C10H13BrN2 m/z 242.2 (M+H).
3-Bromo-5-(piperidin-1-ylmethyl)pyridine (LIX): Brown liquid (13.1 g, 94% yield). 1H NMR (DMSO-d6) δ ppm 1.36-1.39 (m, 2H), 1.46-1.51 (m, 4H), 2.31-2.32 (m, 4H), 3.46 (s, 2H), 7.94 (s, 1H), 8.47 (d, J=2 Hz, 1H), 8.58 (d, J=3 Hz, 1H); ESIMS found for C11H15BrN2 m/z 257.0 (M+H).
N-((5-Bromopyridin-3-yl)methyl)ethanamine (LX): Golden liquid (1.29 g, 6.00 mmol, 60% yield). 1H NMR(CDCl3, 400 MHz) δ ppm 1.14 (t, J=7.2 Hz, 3H), 2.67 (q, J=7.2 Hz, 2H), 3.79 (s, 2H), 7.85 (t, J=2 Hz, 1H), 8.46 (d, J=1.6 Hz, 1H), 8.56 (d, J=2.4 Hz, 1H); ESIMS found for C8H11BrN2 m/z 215.1 (M+H).
N-Benzyl-1-(5-bromopyridin-3-yl)methanamine (LXI): Yellow oil (8.0 g, 28.9 mmol, 89.5% yield). 1H NMR (DMSO-d6, 400 MHz) δ ppm 3.71 (s, 2H), 3.74 (s, 2H), 7.18-7.28 (m, 1H), 7.28-7.40 (m, 4H), 8.04 (s, 1H), 8.52 (s, 1H), 8.58 (s, 1H); ESIMS found for C13H13BrN2 m/z 277.1 (M+H).
Preparation of intermediate tert-butyl (5-bromopyridin-3-ylmethyl (cyclopentylmethyl)carbamate (LXVI) is depicted below in Scheme 12.
To a solution of 5-bromonicotinaldehyde (LV) (2.0 g, 10.8 mmol, 1 eq) in MeOH (20 mL) was added NaBH4 (2.4 g, 64.9 mmol, 6 eq) and the reaction mixture was stirred at room temperature for 3 h. The mixture was concentrated in vacuo and the residue was diluted in water (15 mL), the aqueous phase was extracted with DCM (10 mL×3). The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo to afford (5-bromopyridin-3-ylmethanol (LXII) (1.8 g, 9.57 mmol, 90.0% yield) as a colorless oil. 1H NMR (CDCl3, 500 MHz) δ ppm 4.73 (s, 2H), 7.90 (s, 1H), 8.47 (s, 1H), 8.57 (s, 1H). ESIMS found for C6H6BrNO m/z 188.0 (M+H).
To a stirred solution of (5-bromopyridin-3-ylmethanol (LXII) (1.60 g, 8.5 mmol, 1 eq), phthalimide (1.24 g, 8.5 mmol, 1 eq) and PPh3 (3.33 g, 12.75 mmol, 1.5 eq) in anhydrous THF (15 mL) was added DEAD (2.21 g, 12.75 mmol, 1.5 eq) dropwise at 0° C. under N2. Then the reaction mixture was stirred at room temperature for 6 h. The mixture was washed with saturated NaHCO3 solution (15 mL), water (15 mL) and brine (15 mL) subsequently. The organic layers were dried over MgSO4, concentrated under reduced pressure, the resultant residue was purified by flash chromatography on silica gel (PE:EtOAc=4:1) to give 2-((5-bromopyridin-3-yl)methyl)isoindoline-1,3-dione (LXIII) (2.5 g, 7.88 mmol, 82.3% yield) as a white solid. ESIMS found for C14H9BrN2O2 m/z 317.1 (M+H).
A solution of 2-((5-bromopyridin-3-yl)methyl)isoindoline-1,3-dione (LXIII) (1.9 g, 6.0 mmol, 1 eq) and hydrazine hydrate (2.0 g, 40 mmol, 6 eq) in EtOH (20 mL) was heated at 70° C. for 3 h. The mixture was filtered through a Celite® pad and the filtrate was concentrated in vacuo, the crude product was dissolved in 1N HCl solution (15 mL) and concentrated to dryness, then it was washed with acetone (10 mL×3), the precipitate was collected by filtration, dried in vacuo to give (5-bromopyridin-3-ylmethanamine (LXIV) (1.3 g, 6.95 mmol, 97.7% yield) as a white solid. 1H NMR (D2O, 500 MHz) δ ppm 4.34 (s, 2H), 8.56 (s, 1H), 8.75 (d, J=1.2 Hz, 1H), 8.91 (d, J=1.6 Hz, 1H). ESIMS found for C6H7BrN2 m/z 187.0 (M+H).
A solution of (5-bromopyridin-3-ylmethanamine (LXIV) (1.30 g, 5.8 mmol, 1.0 eq), cyclopentanecarbaldehyde (0.57 g, 5.8 mmol, 1.0 eq) and TEA (0.60 g, 5.8 mmol, 1.0 eq) in MeOH (15 mL) was stirred at room temperature for 2 h. Then NaBH2CN (1.98 g, 34.6 mmol, 6.0 eq) was added and the mixture was stirred at the same temperature for another 3 h. The solvent was removed under reduced pressure and the residue was diluted in water (20 mL) and extracted with DCM (10 mL×3), combined organic layers were dried over MgSO4 and concentrated in vacuo to give 1-(5-bromopyridin-3-yl)-N-(cyclopentylmethyl)methanamine (LXV) (1.23 g, 4.57 mmol, 79.3% yield) as a yellow oil. 1H NMR (CDCl3, 400 MHz) δ ppm 1.07-1.23 (m, 2H), 1.47-1.67 (m, 4H), 1.70-1.84 (m, 2H), 2.02 (spt, J=7.6 Hz, 1H), 2.53 (d, J=7.2 Hz, 2H), 3.80 (s, 2H), 7.86 (s, 1H), 8.47 (s, 1H), 8.56 (d, J=2.0 Hz, 1H); ESIMS found for C12H17BrN2 m/z 269.1 (M+H).
To a solution of l-(5-bromopyridin-3-yl)-N-(cyclopentylmethyl)methanamine (LXV) (1.00 g, 3.7 mmol, 1 eq) and TEA (0.93 g, 9.2 mmol, 2.5 eq) in DCM (20 mL) was added portion wise Boc2O (0.85 g, 4.0 mmol, 1.1 eq) at 0° C., the reaction mixture was stirred at room temperature for 1 h. The mixture was washed with water (10 mL), brine (10 mL), the organic layer was separated, dried over MgSO4 and concentrated in vacuo to give tert-butyl (5-bromopyridin-3-yl)methyl(cyclopentylmethyl) carbamate (LXVI) (1.25 g, 3.38 mmol, 91.9% yield) as a white solid. ESIMS found for C17H25BrN2O2 m/z 369.1 (M+H).
Preparation of intermediate 3-bromo-5-(cyclohexyloxy)pyridine (LXIX) is depicted below in Scheme 13.
To a solution of 5-bromopyridin-3-ol (LXVII) (523 mg, 3.01 mmol) in THF (30 mL) cooled to 0° C. were added triphenylphosphine (867 mg, 3.31 mmol) and cyclohexanol (LXVIII) (331 mg, 3.31 mmol) followed by (E)-bis(4-chlorobenzyl) diazene-1,2-dicarboxylate (1.21 g, 3.31 mmol), added portion wise. The reaction mixture was then stirred at 25° C. overnight. The reaction was worked-up with an EtOAc—NaHCO3 extraction and the solid filtered off. The solvent was removed and the residue was purified by ISCO (20% EtOAc-hexanes) to give 3-bromo-5-(cyclohexyloxy)pyridine (LXIX) (209 mg, 0.82 mmol, 27.2% yield) as a yellow oil. 1H NMR (DMSO-d6, 500 MHz) δ ppm 1.21-1.31 (m, 1H) 1.34-1.48 (m, 4H) 1.49-1.57 (m, 1H) 1.70 (br dd, J=9.74, 4.25 Hz, 2H) 1.88-1.96 (m, 2H) 2.50 (dt, J=3.70, 1.72 Hz, 5H) 4.46-4.54 (m, 1H) 7.72 (t, J=2.20 Hz, 1H) 8.24 (d, J=1.92 Hz, 1H) 8.27 (d, J=2.47 Hz, 1H).
The following intermediate was prepared in accordance with the procedure described in the above Scheme 13.
tert-Butyl 4-((5-bromopyridin-3-yl)oxy)piperidine-1-carboxylate (LXX): Yellow oil (244 mg, 0.683 mmol, 23.2% yield). ESIMS found for C15H21BrN2O3 m/z 358.3 (M+H).
Preparation of intermediate 3-(benzyloxy)-5-bromopyridine (LXXII) is depicted below in Scheme 14.
To a solution of 5-bromopyridin-3-ol (LXVII) (174 mg, 1.0 mmol) in DMF (3 mL) was added potassium carbonate (415 mg, 3.0 mmol). The slurry was heated at 90° C. for 1 h and then cooled to 25° C. The (bromomethyl)benzene (LXXI) (171 mg, 1.0 mmol) was added and the mixture was stirred at 25° C. overnight. The reaction was worked-up using a saturated sodium bicarbonate and EtOAc extraction. The product was purified by ISCO column (40-100% EtOAc-hexanes). The 3-(benzyloxy)-5-bromopyridine (LXXII) (105 mg, 0.398 mmol, 39.8% yield) was obtained as yellow oil. ESIMS found for C12H10BrNO m/z 266.1 (M+H).
The following intermediates were prepared in accordance with the procedure described in the above Scheme 14.
3-Bromo-5-(2-(pyrrolidin-1-yl)ethoxy)pyridine (LXXIII): Yellow oil (97 mg, 0.358 mmol, 15.56% yield). ESIMS found for C11H15BrN2O m/z 272.2 (M+H).
2-((5-Bromopyridin-3-yl)oxy)-N,N-dimethylethan-1-amine (LXXIV): Yellow oil (97 mg, 0.396 mmol, 28.9% yield). ESIMS found for C9H13BrN2O m/z 245.1 (M+H).
1-(2-(3-Bromo-5-fluorophenoxy)ethyl)pyrrolidine (LXXV): Yellow oil (370 mg, 1.284 mmol, 85.8% yield). ESIMS found for C12H15BrNO m/z 289.0 (M+H).
2-(3-Bromo-5-fluorophenoxy)-N,N-dimethylethan-1-amine (LXXVI): Yellow oil (364 mg, 1.389 mmol, 50.2% yield). ESIMS found for C10H11BrFNO m/z 263.9 (M+H).
Preparation of intermediate/e/V-butyl 4-(2-((5-bromopyridin-3-yl)amino)-2-oxoethyl)piperidine-1-carboxylate (LXXVIII) is depicted below in Scheme 15.
To a solution of 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)acetic acid (LXXVII) (3.4 g, 13.97 mmol) in DCM (10 mL) was added DMF (1 mL). The solution was cooled in ice-water to 0° C. Oxalyl chloride (1.835 mL, 20.96 mmol) was then added dropwise. The mixture was stirred for 1 h at 25° C. The organic volatile was then removed under vacuum. The residue was dissolved in DCM (10 mL). DMAP (0.171 g, 1.397 mmol) and 5-bromopyridin-3-amine (XXXVI) (2.418 g, 13.97 mmol) were added to the solution and cooled to 0° C. DIPEA (4.88 ml, 27.9 mmol) was then added dropwise and the mixture was stirred for 2 h at 25° C. The reaction was worked-up with DCM and saturated NaHCO3. The product was purified by ISCO (0-100% EtOAc-hexanes). The tert-butyl 4-(2-((5-bromopyridin-3-yl)amino)-2-oxoethyl)piperidine-1-carboxylate (LXXVIII) (2.82 g, 7.08 mmol, 50.7% yield) was obtained as a yellow oil. ESIMS found for C17H24BrN3O3 m/z 343.1 (M−56).
The following intermediate was prepared in accordance with the procedure described in the above Scheme 15.
N-(5-Bromopyridin-3-yl)-2-(dimethylamino)acetamide (LXXIX): Yellow oil (528 mg, 2.05 mmol, 19.0% yield). ESIMS found for C9H12BrN3O m/z 259.3 (M+H).
Preparation of intermediate tert-butyl (1-(6-chloropyrazin-2-yl)azetidin-3-ylcarbamate (LXXXII) is depicted below in Scheme 16.
To a solution of tert-butyl azetidin-3-ylcarbamate hydrochloride (LXXX) (2 g, 9.58 mmol) in dry DMF (19.2 mL) was added DIPEA (8.37 ml, 47.9 mmol). To this mixture was added 2,6-dichloropyrazine (LXXXI) (1.428 g, 9.58 mmol) and the reaction was stirred at 95° C. for 3 h. The reaction was quenched with water (20 mL) and extracted with EtOAc. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography (40 g) (100% hexanes→hexanes: EtOAc 1:1) to yield tert-butyl (1-(6-chloropyrazin-2-yl)azetidin-3-ylcarbamate (LXXXII) (2.2882 g, 8.04 mmol, 84% yield) as a white solid. ESIMS found for C12H17ClN4O2 m/z 285.1 (M+H).
Preparation of intermediate N-(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-ylbenzyl) methanesulfonamide (LXXXVI) is depicted below in Scheme 17.
A solution of 3-bromo-5-fluorobenzonitrile (LXXXIII) (44.0 g, 220.0 mmol, 1.0 eq) was dissolved in THF (30 mL). BH3-Me2S (33.43 g, 440.0 mmol, 2.0 eq) was added to the solution at 20° C. Then it was stirred at 80° C. for 2 h, HCl (6 N, 100 mL) was added to the mixture slowly at 20° C. The mixture was stirred at 80° C. for 1 h, then it was washed with EtOAc (300 mL). The water phase was basified with 50% aqueous NaOH and it was extracted with EtOAc (300 mL×3). The combined organic layers were dried over anhydrous Na2SO4 and concentrated in vacuo to produce (3-bromo-5-fluoro-phenyl)methanamine (LXXXIV) (24.0 g, 117.62 mmol, 53.5% yield). 1H NMR (CDCl3, 300 MHz) ppm 3.86 (s, 2H), 7.01 (d, J=8 Hz, 1H), 7.12 (d, J=8 Hz, 1H), 7.28 (s, 1H); ESIMS found C7H7BrFN m/z 203.9 (Br79M+H).
A solution of (3-bromo-5-fluoro-phenyl)methanamine (LXXXIV) (23.0 g, 112.7 mmol, 1.0 eq) was dissolved in DCM (15 mL), TEA (34.22 g, 338.2 mmol, 3.0 eq) was added to the mixture. Then MsCl (13.44 g, 117.3 mmol, 1.04 eq) was added slowly to the solution at 0° C. It was stirred at 0-30° C. for 2 h. The reaction was washed with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na2SO4 and concentrated to give N-(3-bromo-5-fluorobenzyl)methanesulfonamide (LXXXV) (34.0 g, 102.44 mmol, 90.9% yield, 85% purity) as an oil. 1H NMR (CDCl3, 300 MHz) ppm 2.88 (s, 3H), 4.24 (d, J=4.5 Hz, 2H), 6.99 (d, J=9 Hz, 1H), 7.13 (dt, J=8.1 Hz, J=2 Hz, 1H), 7.25 (s, 1H); ESIMS found C8H9BrFNO2S m/z 282.0 (Br79M+H).
A solution of N-(3-bromo-5-fluorobenzyl)methanesulfonamide (LXXXV) (34.0 g, 102.4 mmol, 1.0 eq) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (52.02 g, 204.9 mmol, 2.0 eq), KOAc (20.11 g, 204.9 mmol, 2.0 eq) was dissolved in dioxane (20 mL). Then Pd(dppf)Cl2 (7.60 g, 10.2 mmol, 0.1 eq) was added to the mixture. It was stirred at 90° C. for 2 h. Then the solvent was removed to get the residue which was purified by silica gel column (PE:EtOAc=10:1→100% EtOAc) to get N-(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)methanesulfonamide (LXXXVI) (30.0 g, crude). 1H NMR (CDCl3, 400 MHz) δ ppm 1.37 (s, 12H), 2.92 (s, 3H), 4.34 (d, J=6.3 Hz, 2H), 7.19 (dt, J=9.3 Hz, J=2.1 Hz, 1H), 7.44 (dd, J=8.7 Hz, J=2.4 Hz, 1H), 7.54 (s, 1H); ESIMS found C14H21BFNO4S m/z 330.1 (M+H).
Preparation of intermediate N-(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-ylbenzyl) methanesulfonamide (XC) is depicted below in Scheme 18.
To mixture of 1,3-dibromo-5-fluorobenzene (LXXXVII) (100 g, 393 mmol) and N′,N′-dimethylethane-1,2-diamine (173 g, 1.97 mol, 214 mL) was added t-BuOK (88 g, 787 mmol) in one portion at 25° C. under N2. The mixture was stirred at 25° C. for 30 min, then heated to 110° C. and stirred for 11.5 h. The mixture was cooled to 25° C. and concentrated in reduced pressure at 45° C. The residue was purified by silica gel chromatography (column height: 250 mm, diameter: 100 mm, 100-200 mesh silica gel, PE/EtOAc=2:1, Rf=0.6) to give N1-(3-bromo-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine (LXXXVIII) (30 g, 114.9 mmol, 29.2% yield) as a yellow oil. ESIMS found for C10H14BrFN2 m/z 261.1 (M+H).
To a mixture of N1-(3-bromo-5-fluorophenyl)-N2,N2-dimethylethane-1,2-diamine (LXXXVIII) (30 g, 114 mmol) in DCM (200 mL) was added (Boc)2O (37.6 g, 172 mmol), TEA (34.8 g, 344 mmol) and DMAP (7 g, 57.4 mmol) in one portion at 25° C. under N2. The mixture was stirred at 25° C. for 12 h. The mixture was concentrated in reduced pressure at 45° C. The residue was purified by silica gel chromatography (column height: 250 mm, diameter: 100 mm, 100-200 mesh silica gel, PE/EtOAc=2:1, Rf=0.43) to give tert-butyl (3-bromo-5-fluorophenyl)(2-(dimethylamino)ethyl)carbamate (LXXXIX) (20 g, 55.4 mmol, 48.2% yield) as yellow oil. 1H NMR (CDCl3, 400 MHz) δ ppm 1.43 (s, 9H), 2.21 (s, 6H), 2.41 (t, J=7 Hz, 2H), 3.67 (t, J=7.2 Hz, 2H), 6.96 (d, J=9.6 Hz, 1H), 7.06 (d, J=6 Hz, 1H), 7.22 (s, 1H); ESIMS found for C15H22BrFN2O2 m/z 361.0 (M+H).
To a mixture of tert-butyl (3-bromo-5-fluorophenyl)(2-(dimethylamino)ethyl) carbamate (LXXXIX) (19 g, 52.6 mmol) and bis(pinacolato)diboron (20 g, 78.9 mmol) in dioxane (60 mL) was added Pd(dppf)Cl2 (3.8 g, 5.26 mmol) and KOAc (30.9 g, 315.6 mmol) in one portion at 25° C. under N2. The mixture was stirred at 25° C. for 30 min, then heated to 110° C. and stirred for 11.5 h. The mixture was cooled to 25° C. and concentrated in reduced pressure at 45° C. The residue was purified by silica gel chromatography (column height: 250 mm, diameter: 100 mm, 100-200 mesh silica gel, /EtOAc=1:1, Rf=0.24) to give tert-butyl (2-(dimethylamino)ethyl)(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate (XC) (15 g, 36.7 mmol, 69.8% yield) as yellow oil. ESIMS found for C21H34BFN2O4 m/z 327.2 (M+H as the boronic acid).
Preparation of intermediate (1-tert-butoxycarbonyl)-4-(3-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-ylboronic acid (XCV) is depicted below in Scheme 19.
To a solution of 4-bromo-1H-pyrrolo[2,3-c]pyridine (XCI) (10 g, 50.8 mmol, 1 eq.), DMAP (622 mg, 5.1 mmol, 0.1 eq.) and TEA (10.6 mL, 76.1 mmol, 3 eq.) in DCM (200 mL) was added Boc2O (14.4 mL, 61 mmol, 1.2 eq.) at 0° C. The reaction was warmed to room temperature and stirred for 2 h. Water (200 mL) was added and extracted with DCM (×2). Removal solvents gave tert-butyl 4-bromo-1H-pyrrolo[2,3-c]pyridine-1-carboxylate (XCII) as white solid (11.4 g, 38.4 mmol, 76.5% yield). ESIMS found for C12H11BrN2O2 m/z 297.1 (M+H).
To a solution of tert-butyl 4-bromo-1H-pyrrolo[2,3-c]pyridine-1-carboxylate (XCII) (9.0 g, 30.2 mmol, 1.0 eq) and (3-fluorophenylboronic acid (XCIII) (4.66 g, 33.3 mmol, 1.1 eq) in a mixture solvent of dioxane (90 mL) and water (30 mL) was added K3PO4 (1.6 g, 75.7 mmol, 2.5 eq). The suspension was purged with nitrogen (×3) followed by addition of Pd(dppf)Cl2 (2.2 g, 3.03 mmol, 0.1 eq). The reaction was stirred at 80° C. for 12 h. The suspension was poured into water (100 mL) and extracted with EtOAc (100 mL×2). The combined organic layer was washed with brine (50 mL), dried over Na2SO4 and concentrated under reduced pressure. Then the crude product was purified by column chromatography on silica gel to afford tert-butyl 4-(3-fluorophenyl)-1H-pyrrolo[2,3-c]pyridine-1-carboxylate (XCIV) as a yellow solid (8.0 g, 25.6 mmol, 84.6% yield). ESIMS found for C18H17FN2O2 m/z 313.1 (M+H).
To a solution of tert-butyl 4-(3-fluorophenyl)-1H-pyrrolo[2,3-c]pyridine-1-carboxylate (XCIV) (3.83 g, 12.3 mmol, 1.0 eq) and triisopropyl borate (3.7 g, 19.6 mmol, 1.6 eq) in THF (100 mL), was added dropwise LDA (2 M, 12.3 mL, 24.5 mmol, 2.0 eq) at −30° C. under N2. The reaction was stirred at this temperature for 30 min. The reaction was quenched at −30° C. with buffer (pH=7, NaH2PO4/Na2HPO4) and then poured into water (100 mL). The light yellow aqueous phase was extracted with EtOAc (200 mL×3). The combined organic phase was washed with saturated brine (500 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to afford light yellow solid. Then the solid was washed with methyl tertiary butyl ether to give (1-(tert-butoxycarbonyl)-4-(3-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-ylboronic acid (XCV) as a white solid (4.0 g, 11.2 mmol, 91.6% yield). 1H NMR (MeOD 400 MHz) δ ppm 1.73 (s, 9H), 6.87 (s, 1H), 7.21 (t, J=8 Hz, 1H), 7.40 (d, J=11.2 Hz, 1H), 7.48 (d, J=7.6 Hz, 1H), 7.54-7.60 (m, 1H), 8.38 (s, 1H), 9.35 (s, 1H); ESIMS found for C18H18BFN2O4 m/z 357.0 (M+H).
The following intermediates were prepared in accordance with the procedure described in the above Scheme 19.
(1-(tert-Butoxycarbonyl)-4-(4-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-ylboronic acid (XCVI): Yellow solid (1.5 g, 4.2 mmol, 14.6% yield). 1H NMR (MeOD, 400 MHz) δ ppm 1.72 (s, 9H), 6.84 (s, 1H), 7.28 (t, J=8.8 Hz, 1H), 7.66 (dd, J=5.6 Hz, J=14 Hz, 2H), 8.34 (s, 2H), 9.31 (s, 1H); ESIMS found for C18H18BFN2O4 m/z 357.0 (M+H).
(1-(tert-Butoxycarbonyl)-4-(2-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)boronic acid (XCVII): White solid (6.0 g, 16. mmol, 87.7% yield). 1H NMR (MeOD, 400 MHz) δ ppm 1.73 (s, 9H), 6.64 (d, J=2 Hz, 1H), 7.77-7.92 (m, 2H), 7.47-7.63 (m, 2H), 8.35 (s, 1H), 9.35 (s, 1H); ESIMS found for C18H18BFN2O4 m/z 357.0 (M+H).
(1-(tert-Butoxycarbonyl)-4-(pyridin-3-yl)-1H-pyrrolo[2,3-c]pyridin-2-yl)boronic acid (XCVIII): Yellow solid (5.3 g, 15.6 mmol, 57.6% yield). 1H NMR (MeOD, 400 MHz) δ ppm 1.73 (s, 9H), 6.87 (s, 1H), 7.63 (t, J=6 Hz, 1H), 8.16 (d, J=6 Hz, 1H), 8.42 (s, 1H), 8.64 (d, J=3.6 Hz, 1H), 8.84 (s, 1H), 9.38 (s, 1H); ESIMS found C17H18BN3O4 m/z 340.0 (M+H).
(1-(tert-Butoxycarbonyl)-4-(pyridin-4-yl)-1H-pyrrolo[2,3-c]pyridin-2-yl)boronic acid (XCIX): White solid (5.5 g, 16.2 mmol, 65.6% yield). 1H NMR (MeOD, 400 MHz) δ ppm 1.74 (s, 9H), 6.97 (s, 1H), 7.78 (d, J=6.4 Hz, 2H), 8.50 (s, 1H), 8.71 (d, J=6.4 Hz, 2H), 9.42 (s, 1H); ESIMS found C17H18BN3O4 m/z 339.9 (M+H).
(1-(tert-Butoxycarbonyl)-4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-pyrrolo[2,3-c]pyridin-2-ylboronic acid (C): Off-white solid (3.0 g, 6.47 mmol, 45.3% yield). 1H NMR (MeOD, 400 MHz) δ ppm 1.72 (s, 9H), 2.95 (s 3H), 4.36 (s, 2H), 6.91 (s, 1H), 7.24 (d, J=9.2 Hz, 1H), 7.32 (d, J=8.8 Hz, 1H), 7.51 (s, 1H), 8.38 (s, 1H), 9.33 (s, 1H); ESIMS found C20H23BFN3O6S m/z 464.0 (M+H).
(1-(tert-Butoxycarbonyl)-4-(furan-3-yl)-1H-pyrrolo[2,3-c]pyridin-2-ylboronic acid (CI): Yellow solid (2.5 g, 7.6 mmol, 43.3% yield). ESIMS found for C16H17BN2O5 m/z 362.1 (M+H+MeOH).
(1-(tert-Butoxycarbonyl)-4-(thiophen-2-yl)-1H-pyrrolo[2,3-c]pyridin-2-ylboronic acid (CII): Yellow solid (1.1 g, 3.2 mmol, 96.0% yield). ESIMS found for C16H11BN2O4S m/z 378.1 (M+H+MeOH).
Preparation of intermediate (1-(tert-butoxycarbonyl)-4-(4-methylpiperazin-1-yl)-1H-pyrrolo[2,3-c]pyridin-2-ylboronic acid (CV) is depicted below in Scheme 20.
To a solution of tert-butyl 4-bromo-1H-pyrrolo[2,3-c]pyridine-1-carboxylate (XCII) (7.0 g, 23.6 mmol, 1.0 eq), XPhos (1.1 g, 2.36 mmol, 0.1 eq), Cs2CO3 (2.0 eq) and 1-methylpiperazine (CIII) (2.36 g, 23.6 mmol, 1.0 eq) in anhydrous toluene (150 mL) was added Pd2(dba)3 (2.2 g, 2.36 mmol, 0.1 eq). The reaction mixture was stirred at 100° C. for 15 h under N2. The mixture was filtered through a Celite® pad, and the filtrate was concentrated to give crude product. The crude product was purified by silica gel chromatography to give tert-butyl 4-(4-methylpiperazin-1-yl)-1H-pyrrolo[2,3-c]pyridine-1-carboxylate (CIV) as a yellow solid (2.0 g, 6.32 mmol, 26.8% yield). ESIMS found for C17H24N4O2 m/z 317.0 (M+H).
To a mixture of tert-butyl 4-(4-methylpiperazin-1-yl)-1H-pyrrolo[2,3-c]pyridine-1-carboxylate (CIV) (2.0 g, 6.32 mmol, 1.0 eq) and isopropyl borate (3.6 g, 19.0 mmol, 3.0 eq) in anhydrous THF (50 mL) cooled to −30° C. was added dropwise LDA (2M, 9.5 mL, 19.0 mmol, 3.0 eq). The reaction was stirred at −30° C. for 0.5 h under N2. The reaction was added to aq. NH4Cl (250 mL). The combined aqueous layers were extracted with EtOAc (100 mL×3) to remove neutral impurities. The combined organic layers were dried over Na2SO4 and concentrated to give crude product. EtOAc (80 mL) was added to the crude product. The mixture was stirred at 20° C. for 15 mins. The mixture was filtered and filter cake was washed by EtOAc (50 mL) and dried to give (1-(tert-butoxycarbonyl)-4-(4-methylpiperazin-1-yl)-1H-pyrrolo[2,3-c]pyridin-2-ylboronic acid (CV) (1.0 g, 2.78 mmol, 43.9% yield) as white solid. ESIMS found for C17H25BN4O4 m/z 394.2 (M+H+MeOH).
The following intermediate was prepared in accordance with the procedure described in the above Scheme 20.
(1-tert-Butoxycarbonyl)-4-(piperidin-1-yl)-1H-pyrrolo[2,3-c]pyridin-2-yl)boronic acid (CVI): White solid (2.2 g, 6.3 mmol, crude). 1H NMR (MeOD, 400 MHz) δ ppm 1.67 (s, 9H), 1.59-1.70 (m, 2H), 1.74-1.83 (m, 4H), 3.13-3.22 (m, 4H), 6.73 (s, 1H), 7.83 (s, 1H), 8.93 (s, 1H); ESIMS found C17H24BN3O4 m/z 346.2 (M+H).
Preparation of 3-(4-(2-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazole (544) is depicted below in Scheme 21.
A mixture of K3PO4 (1.07 g, 5.04 mmol, 3.0 eq), tert-butyl 4-((5-bromopyridin-3-yl)oxy)piperidine-1-carboxylate (LXX) (600 mg, 1.55 mmol, 1.0 eq), 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (XVII) (606.4 mg, 1.85 mmol, 1.1 eq) and Pd(PPh3)4 (194.1 mg, 0.168 mmol, 0.10 eq) in 1,4-dioxane (10 mL) and water (2 mL) was purged with nitrogen. The mixture was heated at 120° C. using microwave energy for 0.5 h. The reaction was cooled to room temperature and concentrated. The crude product was purified by flash column chromatography (0-100% EtOAc-Hexanes). The fractions containing the product were concentrated and the residue triturated in ether to produce tert-butyl 4-((5-(1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yl)pyridin-3-yl)oxy)piperidine-1-carboxylate (CVII) (600 mg, 1.25 mmol, 74.6% yield) as an off-white solid. ESIMS found for C27H34N4O4 m/z 479.0 (M+H).
To a solution of tert-butyl 4-((5-(1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yl)pyridin-3-yl)oxy)piperidine-1-carboxylate (CVII) (880 mg, 1.84 mmol) in DCM (3 mL) was added TFA (4.5 mL, 58.4 mmol). The reaction was stirred at 25° C. for 3 h. The reaction was worked-up with a 2 N NaOH-EtOAc extraction. The organic layer was combined, dried over MgSO4, evaporated under high vacuum to produce 5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazole (CVIII) (780 mg, 2.65 mmol, crude) which was used for next reaction without further purification. ESIMS found for C17H18N4O m/z 295.0 (M+H).
To a solution of 5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazole (CVIII) (600 mg, 2.04 mmol, 1.0 eq) in DMF (10 mL) was added iodine (620.8 mg, 2.45 mmol, 1.2 eq) and KOH (571.9 mg, 10.2 mmol, 5.0 eq). The suspension was stirred at 25° C. overnight. The reaction suspension was poured into water (200 mL) and extracted with EtOAc (300 mL×3). The combined organic layer was washed with saturated Na2SO3 solution (100 mL), brine (100 mL), dried over sodium sulfate and concentrated to give crude 3-iodo-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazole (CIX) (810 mg, 1.93 mmol, 94.6% yield) as a brown solid which was used directly without further purification. ESIMS found for C17H17IN4O m/z 420.8 (M+H).
To a solution of 3-iodo-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazole (CIX) (810 mg, 1.93 mmol, 1.0 eq) in DCM (100 mL) was added di-tert-butyl dicarbonate (631 mg, 2.89 mmol, 1.5 eq), DMAP (23.5 mg, 0.193 mmol, 0.1 eq) and TEA (0.806 mL, 5.78 mmol, 3.0 eq). The reaction was stirred at 25° C. for 4 h. The reaction was washed with sat. NaHCO3-EtOAc, brine, dried over sodium sulfate and concentrated. The residue was purified by column chromatography (0-100% EtOAc-Hexanes) to give tert-butyl 5-(5-((1-(tert-butoxycarbonyl) piperidin-4-yl)oxy)pyridin-3-yl)-3-iodo-1H-indazole-1-carboxylate (CX) (0.210 g, 0.338 mmol, 17.6% yield) as a yellow oil. 1H NMR (499 MHz, DMSO-d6) δ ppm 1.41 (s, 9H), 1.59 (ddt, J=12.83, 8.51, 4.15, 4.15 Hz, 2H), 1.67 (s, 9H), 1.96 (br dd, J=5.90, 3.43 Hz, 2H), 3.17-3.27 (m, 2H), 3.65-3.71 (m, 2H), 4.84 (tt, J=7.79, 3.60 Hz, 1H), 7.79-7.84 (m, 2H), 8.06 (dd, J=8.64, 1.78 Hz, 1H), 8.15 (d, J=8.78 Hz, 1H), 8.35 (d, J=2.47 Hz, 1H), 8.56 (d, J=1.65 Hz, 1H); ESIMS found for C27H33IN4O5 m/z 620.8 (M+H).
A mixture of tert-butyl 5-(5-((1-tert-butoxycarbonyl) piperidin-4-yl)oxy)pyridin-3-yl)-3-iodo-1H-indazole-1-carboxylate (CX) (82 mg, 0.132 mmol, 1.0 eq), (1-(tert-butoxycarbonyl)-4-(2-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-ylboronic acid (XC VII) (51.8 mg, 0.145 mmol, 1.1 eq), K2CO3 (54.8 mg, 0.397 mmol, 3.0 eq) and Pd(dppf)Cl2 (21.6 mg, 0.026 mmol, 0.2 eq) in 1,4-dioxane (10 mL) and water (2 mL) was purged with nitrogen. The mixture was heated at 90° C. using microwave energy for 0.5 h. The reaction was cooled to room temperature and concentrated. The crude product was purified by flash column chromatography (0-100% EtOAc-Hexanes). The fractions containing the product were concentrated and the residue triturated in ether to produce tert-butyl 3-(1-(tert-butoxycarbonyl)-4-(2-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)-5-(5-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)pyridin-3-yl)-1H-indazole-1-carboxylate (CXI) (99 mg, 0.123 mmol, 93.1% yield) was obtained as an off-yellow solid. ESIMS found for C45H49FN6O7 m/z 804.9 (M+H).
To a suspension of tert-butyl 3-(1-(tert-butoxycarbonyl)-4-(2-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)-5-(5-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)pyridin-3-yl)-1H-indazole-1-carboxylate (CXI) (99 mg, 0.123 mmol, 1.0 eq) in DCM (1 mL) was added TFA (94.8 μL, 1.23 mmol, 10 eq). The resulting solution was stirred at 25° C. for 4 h. The reaction was washed with 2N NaOH-EtOAc brine, dried over sodium sulfate and concentrated. The residue was purified by silica gel chromatography (0-100% MeOH/CHCl3). The fractions containing the product were concentrated to afford 3-(4-(2-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-indazole (544) (12.5 mg, 0.025 mmol, 20.1% yield) as an orange solid. 1H NMR (500 MHz, DMSO-d6) δ ppm 1.46-1.56 (m, 2H), 1.93-2.00 (m, 2H), 2.55-2.63 (m, 2H), 2.96 (dt, J=12.62, 4.25 Hz, 2H), 4.61-4.69 (m, 1H), 7.12 (d, J=1.65 Hz, 1H), 7.36-7.40 (m, 1H), 7.40-7.44 (m, 1H), 7.49-7.56 (m, 1H), 7.70-7.78 (m, 3H), 7.79-7.84 (m, 1H), 8.18 (d, J=1.10 Hz, 1H), 8.28 (d, J=2.47 Hz, 1H), 8.36 (s, 1H), 8.55 (d, J=1.92 Hz, 1H), 8.83 (s, 1H), 12.28 (br s, 1H), 13.66 (br s, 1H); ESIMS found for C30H25FN6O m/z 504.9 (M+1).
The following compounds were prepared in accordance with the procedures described herein. See, for example, Schemes 1a and 1-21.
1H NMR (400 MHz, DMSO-d6) δ ppm 1.12 (t, J=7.50 Hz, 3H), 2.40 (q, J=7.64 Hz, 2H), 7.23-7.30 (m, 1H), 7.34 (s, 1H), 7.59-7.67 (m, 2H), 7.71 (d, J=7.72 Hz, 1H), 7.73-7.77 (m, 1H), 7.77-7.83 (m, 1H), 8.28 (s, 1H), 8.38-8.43 (m, 2H), 8.71 (d, J=1.98 Hz, 1H), 8.74 (d, J=2.43 Hz, 1H), 8.82 (s, 1H), 10.22 (s, 1H), 12.40 (br s, 1H), 13.76 (s, 1H); ESIMS found for C28H21FN6O m/z 477.2 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 7.42-7.49 (m, 1H), 7.62-7.75 (m, 2H), 7.77-7.83 (m, 3H), 7.89 (d, J=3.91 Hz, 2H), 8.37-8.44 (m, 1H), 8.50 (s, 1H), 8.64 (s, 1H), 8.65-8.71 (m, 1H), 9.01 (s, 1H), 9.14-9.19 (m, 1H), 13.72 (br s, 1H); ESIMS found for C25H16FN5 m/z 406.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 2.26 (s, 6H), 3.61 (s, 2H), 7.24-7.34 (m, 1H), 7.38 (d, J=0.66 Hz, 1H), 7.57-7.62 (m, 1H), 7.62-7.68 (m, 1H), 7.69-7.74 (m, 1H), 7.75-7.80 (m, 1H), 7.80-7.85 (m, 1H), 8.10 (s, 1H), 8.28 (s, 1H), 8.45 (s, 1H), 8.51 (d, J=1.76 Hz, 1H), 8.82 (s, 1H), 8.95 (d, J=2.21 Hz, 1H), 12.39 (br s, 1H), 13.75 (br s, 1H); ESIMS found for C28H23FN6 m/z 463.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 0.95 (t, J=139 Hz, 3H), 1.61-1.72 (m, 2H), 2.39 (br t, J=7.28 Hz, 2H), 7.42 (td, J=8.88, 2.32 Hz, 2H), 7.68-7.83 (m, 4H), 7.89 (br d, J=8.82 Hz, 1H), 8.50 (s, 1H), 8.53 (br s, 1H), 8.57 (s, 1H), 8.83 (br d, J=1.32 Hz, 2H), 9.01 (s, 1H), 10.43 (br s, 1H), 13.73 (br d, J=0.66 Hz, 1H), 14.22 (br s, 1H); ESIMS found for C29H23FN6O m/z 491.2 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 7.26-7.33 (m, 1H), 7.38 (s, 1H), 7.60-7.69 (m, 2H), 7.69-7.74 (m, 1H), 7.79 (br d, J=8.82 Hz, 1H), 7.84-7.93 (m, 3H), 8.29 (s, 1H), 8.54 (br d, J=0.66 Hz, 1H), 8.66 (br d, J=6.17 Hz, 2H), 8.83 (s, 1H), 12.40 (br s, 1H), 13.77 (br s, 1H); ESIMS found for C25H16FN5 m/z 406.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 0.84-0.97 (m, 4H), 1.90-2.00 (m, 1H), 7.43 (td, J=8.54, 2.32 Hz, 1H), 7.67-7.79 (m, 3H), 7.79-7.86 (m, 2H), 7.89-7.94 (m, 1H), 8.49 (s, 1H), 8.70 (br s, 1H), 8.75 (brs, 1H), 9.01 (br s, 1H), 9.04 (s, 1H), 9.05 (br s, 1H), 11.29 (br s, 1H), 13.87 (br s, 1H), 14.32 (br s, 1H); ESIMS found for C29H21FN6O m/z 489.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.21-1.37 (m, 3H), 1.40-1.50 (m, 2H), 1.65-1.72 (m, 1H), 1.80 (dt, J=12.29, 2.45 Hz, 2H), 1.83-1.92 (m, 2H), 2.35-2.42 (m, 1H), 7.41 (td, J=8.49, 1.76 Hz, 2H), 7.64-7.77 (m, 3H), 7.78-7.84 (m, 2H), 7.88 (br d, J=8.60 Hz, 1H), 8.50 (br d, J=4.85 Hz, 2H), 8.53 (s, 1H), 8.78 (br dd, J=4.63, 2.21 Hz, 1H), 9.00 (s, 1H), 10.25 (br s, 1H), 13.69 (br s, 1H), 14.19 (br d, J=0.66 Hz, 1H); ESIMS found for C32H27FN6O m/z 531.2 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 2.19-2.31 (m, 2H), 2.75 (t, J=6.73 Hz, 2H), 2.94 (br t, J=13.34 Hz, 2H), 3.76 (s, 2H), 7.23-7.32 (m, 1H), 7.39 (s, 1H), 7.56-7.64 (m, 1H), 7.64-7.69 (m, 1H), 7.71 (br d, J=7.50 Hz, 1H), 7.75-7.80 (m, 1H), 7.80-7.85 (m, 1H), 8.06-8.11 (m, 1H), 8.28 (s, 1H), 8.46 (s, 1H), 8.52 (d, J=1.76 Hz, 1H), 8.82 (s, 1H), 8.95 (d, J=1.98 Hz, 1H), 12.39 (br s, 1H), 13.74 (s, 1H); ESIMS found for C30H23F3N6 m/z 525.3 (M+H).
1H NMR (400 MHz, DMSO-d6) δ ppm 7.27-7.33 (m, 2H), 7.36 (ddd, J=6.78, 5.46, 0.99 Hz, 1H), 7.59-7.68 (m, 2H), 7.68-7.73 (m, 1H), 7.75 (d, J=8.82 Hz, 1H), 7.92 (td, J=7.72, 1.76 Hz, 1H), 8.12 (s, 1H), 8.23 (dd, J=8.82, 1.54 Hz, 1H), 8.29 (s, 1H), 8.66-8.72 (m, 1H), 8.79 (s, 1H), 8.83 (s, 1H), 12.43 (br s, 1H), 13.74 (br s, 1H); ESIMS found for C25H16FN5 m/z 406.2 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.29 (s, 9H), 7.50 (br t, J=8.71 Hz, 2H), 7.73 (br d, J=1.10 Hz, 1H), 7.82-7.91 (m, 2H), 8.01 (br dd, J=8.82, 5.51 Hz, 2H), 8.46 (s, 1H), 8.51-8.57 (m, 2H), 8.78 (br d, J=1.76 Hz, 1H), 8.86-8.91 (m, 1H), 8.98 (s, 1H), 9.63 (br s, 1H), 13.67 (br s, 1H), 14.19 (s, 1H); ESIMS found for C30H25FN6O m/z 505.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 2.82 (br d, J=3.97 Hz, 6H), 4.52 (br d, 7=4.19 Hz, 2H), 7.50 (t, J=8.93 Hz, 2H), 7.72 (d, J=1.32 Hz, 1H), 7.89 (d, J=8.82 Hz, 1H), 7.99-8.08 (m, 3H), 8.46 (s, 1H), 8.85 (br s, 1H), 8.88 (br s, 1H), 9.00 (br s, 1H), 9.06 (s, 1H), 9.34 (br d, J=1.32 Hz, 1H), 13.83 (s, 1H), 14.32 (br s, 1H); ESIMS found for C28H23FN6 m/z 463.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 0.96 (br t, J=7.50 Hz, 3H), 1.63-1.75 (m, 2H), 2.36-2.42 (m, 2H), 7.47-7.57 (m, 2H), 7.71 (br s, 1H), 7.82 (br d, J=9.92 Hz, 1H), 7.88 (br d, J=8.82 Hz, 1H), 7.96-8.05 (m, 2H), 8.45 (br s, 1H), 8.49-8.58 (m, 2H), 8.75 (br d, J=10.36 Hz, 2H), 8.98 (br s, 1H), 10.31 (br s, 1H), 13.66 (br s, 1H), 14.18 (br s, 1H); ESIMS found for C29H23FN6O m/z 491.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.82-1.91 (m, 1H), 2.01 (dt, J=19.35, 8.85 Hz, 1H), 2.12-2.22 (m, 2H), 2.23-2.31 (m, 2H), 3.29-3.39 (m, 1H), 7.47-7.57 (m, 3H), 7.62-7.70 (m, 1H), 7.79-7.87 (m, 2H), 7.88-7.93 (m, 1H), 8.45 (s, 1H), 8.58 (br s, 1H), 8.62 (br s, 1H), 8.90 (br s, 1H), 8.92 (br s, 1H), 9.05 (s, 1H), 10.46 (br s, 1H), 13.75 (s, 1H), 14.26 (br s, 1H); ESIMS found for C30H23FN6O m/z 503.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 5.43 (br s, 2H), 7.24 (br d, J=1.32 Hz, 1H), 7.31 (br s, 1H), 7.38-7.45 (m, 2H), 7.69 (br d, J=8.38 Hz, 1H), 7.76 (br d, J=8.38 Hz, 1H), 7.83-7.92 (m, 2H), 7.95 (br s, 1H), 8.16 (br s, 1H), 8.25 (s, 1H), 8.31 (br s, 1H), 8.82 (br s, 1H), 12.44 (br s, 1H), 13.72 (br s, 1H); ESIMS found for C25H17FN6 m/z 421.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.30 (brt, J=7.28 Hz, 3H), 3.01-3.11 (m, 2H), 4.26-4.35 (m, 2H), 7.50 (brt, J=8.82 Hz, 2H), 7.73 (br d, J=1.10 Hz, 1H), 7.86-7.92 (m, 1H), 7.92-7.98 (m, 1H), 8.03 (br dd, J=8.71, 5.40 Hz, 2H), 8.46 (s, 1H), 8.67 (br s, 1H), 8.70-8.79 (m, 2H), 9.04 (s, 1H), 9.16 (br d, J=1.98 Hz, 1H), 13.72 (br d, J=1.32 Hz, 1H), 14.24 (br s, 1H); ESIMS found for C28H23FN6, m/z 463.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.17 (br d, J=6.62 Hz, 6H), 3.16 (br d, J=5.07 Hz, 1H), 7.31 (br s, 1H), 7.37-7.47 (m, 2H), 7.78 (br s, 2H), 7.85-7.94 (m, 2H), 8.24 (br s, 1H), 8.37 (br s, 1H), 8.48 (br s, 1H), 8.70 (br d, J=4.41 Hz, 1H), 8.72 (br d, J=1.98 Hz, 1H), 8.79 (br s, 1H), 10.17 (br s, 1H), 12.34 (br s, 1H), 13.72 (br s, 1H); ESIMS found for C29H23FN6O m/z 491.2 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.63-1.89 (m, 6H), 2.85-3.02 (m, 4H), 4.42 (br d, J=2.87 Hz, 2H), 7.49 (br t, J=8.82 Hz, 2H), 7.75 (br s, 1H), 7.89 (br d, J=8.82 Hz, 1H), 7.92-7.96 (m, 1H), 8.01 (br dd, J=8.71, 5.40 Hz, 2H), 8.45 (s, 1H), 8.59 (br s, 1H), 8.70 (br s, 1H), 8.71 (brd, J=1.76 Hz, 1H), 9.01 (s, 1H), 9.16 (br d, J=1.99 Hz, 1H), 13.65 (br s, 2H), 14.21 (br s, 1H); ESIMS found for C31H27FN6 m/z 503.2 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.07 (s, 9H), 2.34 (s, 2H), 7.51 (br t, J=8.82 Hz, 2H), 7.71 (d, J=1.32 Hz, 1H), 7.83-7.89 (m, 1H), 7.89-7.96 (m, 1H), 8.01 (dd, J=8.82, 5.29 Hz, 2H), 8.46 (s, 1H), 8.67 (s, 1H), 8.78 (br s, 1H), 9.01 (br s, 1H), 9.05 (br s, 2H), 10.87 (br s, 1H), 13.81 (s, 1H), 14.31 (br s, 1H); ESIMS found for C31H27FN6O m/z 519.2 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 0.93 (br t, J=7.50 Hz, 3H), 1.33-1.44 (m, 2H), 1.59-1.70 (m, 2H), 2.36-2.43 (m, 2H), 7.48 (br t, J=8.82 Hz, 2H), 7.55-7.62 (m, 1H), 7.77-7.83 (m, 1H), 7.83-7.88 (m, 1H), 7.96 (br dd, J=8.71, 5.40 Hz, 2H), 8.38 (br s, 1H), 8.45 (br s, 1H), 8.49 (br d, J=1.98 Hz, 1H), 8.70 (br d, J=2.20 Hz, 1H), 8.71 (br d, J=2.21 Hz, 1H), 8.91 (s, 1H), 10.23 (s, 1H), 14.01 (br s, 2H); ESIMS found for C30H25FN6O m/z 505.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.54-1.65 (m, 2H), 1.66-1.86 (m, 4H), 1.88-1.98 (m, 2H), 2.91 (dt, J=15.99, 8.10 Hz, 1H), 7.51 (br t, J=8.93 Hz, 2H), 7.72 (br d, J=1.32 Hz, 1H), 7.81-7.88 (m, 1H), 7.88-7.94 (m, 1H), 8.01 (dd, J=8.71, 5.40 Hz, 2H), 8.46 (s, 1H), 8.62 (s, 1H), 8.72 (br s, 1H), 8.93 (br s, 2H), 9.00 (s, 1H), 10.67 (br s, 1H), 13.76 (s, 1H), 14.26 (br s, 1H); ESIMS found for C31H25FN6O m/z 517.2 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 2.19-2.30 (m, 2H), 2.73-2.81 (m, 2H), 2.94 (br t, J=13.34 Hz, 2H), 3.77 (s, 2H), 7.33-7.44 (m, 3H), 7.76-7.84 (m, 2H), 7.89 (br dd, J=8.38, 5.73 Hz, 2H), 8.09 (s, 1H), 8.24 (s, 1H), 8.44 (s, 1H), 8.53 (s, 1H), 8.80 (s, 1H), 8.94 (s, 1H), 12.36 (br s, 1H), 13.72 (s, 1H); ESIMS found for C30H23F3N6 m/z 525.2 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 7.40 (br dd, J=7.06, 5.51 Hz, 2H), 7.52 (brt, J=8.93 Hz, 2H), 7.66 (br s, 1H), 7.84 (br d, J=8.82 Hz, 1H), 7.94-8.03 (m, 2H), 8.18 (br d, J=7.94 Hz, 1H), 8.29 (br d, J=7.50 Hz, 1H), 8.45 (s, 1H), 8.70-8.74 (m, 1H), 8.85 (s, 1H), 8.99 (s, 1 II). 13.66 (br s, 1H), 14.13 (br s, 1H); ESIMS found for C25H16FN5 m/z 406.1 (M+1).
1H NMR (400 MHz, DEUTERIUM OXIDE) δ ppm 7.34 (br s, 1H), 7.70 (s, 2H), 7.96-8.07 (m, 2H), 8.22 (br d, J=6.39 Hz, 2H), 8.63 (br d, J=7.50 Hz, 1H), 8.70 (br d, J=5.73 Hz, 1H), 8.71-8.80 (m, 2H), 8.83 (s, 1H), 8.98 (br d, J=6.39 Hz, 2H); ESIMS found for C24H16N6 m/z 389.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.12-1.21 (m, 6H), 2.70-2.84 (m, 1H), 7.80-7.97 (m, 4H), 8.61 (br s, 2H), 8.76 (brs, 1H), 8.83 (brs, 1H), 8.89 (br d, J=4.30 Hz, 1H), 9.10 (br d, J=5.09 Hz, 3H), 9.24 (br s, 1H), 10.99 (br s, 1H), 13.95 (br s, 1H); ESIMS found for C28H23N7O m/z 474.2 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 7.57-7.65 (m, 2H), 7.67 (br d, J=7.28 Hz, 1H), 7.79-7.87 (m, 2H), 7.92 (q, J=8.75 Hz, 2H), 8.11 (br d, J=7.28 Hz, 2H), 8.60 (s, 2H), 8.77 (s, 1H), 8.84 (br d, J=3.31 Hz, 1H), 9.01 (br s, 1H), 9.08 (s, 1H), 9.11 (br s, 1H), 9.22 (br d, J=5.73 Hz, 2H), 11.07 (br s, 1H), 13.90 (br s, 1H), 14.35 (br s, 1H); ESIMS found for C31H21N7O m/z 508.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.22 (d, J=6.17 Hz, 6H), 3.88-3.99 (m, 1H), 7.14 (br s, 1H), 7.83 (br d, J=1.10 Hz, 1H), 7.88-7.96 (m, 2H), 8.05 (s, 2H), 8.61 (br d, J=10.36 Hz, 2H), 8.68 (br d, J=7.94 Hz, 1H), 8.82 (s, 1H), 8.91 (br d, J=3.75 Hz, 1H), 9.13 (s, 1H), 9.26 (br d, J=1.54 Hz, 1H), 14.11 (br s, 1H), 14.39 (br s, 1H); ESIMS found for C27H23N7 m/z 446.2 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.35-1.47 (m, 1H), 1.70-1.79 (m, 1H), 1.79-1.89 (m, 4H), 2.90-3.00 (m, 2H), 3.35-3.43 (m, 2H), 4.45 (br d, J=5.09 Hz, 2H), 7.83-7.88 (m, 1H), 7.88-7.93 (m, 2H), 7.97-8.03 (m, 1H), 8.59 (s, 1H), 8.62 (dt, J=8.80, 1.66 Hz, 1H), 8.77 (d, J=1.57 Hz, 1H), 8.84-8.89 (m, 3H), 9.09 (s, 1H), 9.22 (d, J=1.96 Hz, 1H), 9.24 (d, J=1.96 Hz, 1H), 13.85 (s, 1H); ESIMS found for C30H27N7 m/z 486.2 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.55-1.65 (m, 2H), 1.65-1.74 (m, 2H), 1.74-1.84 (m, 2H), 1.94 (br d, J=8.38 Hz, 2H), 2.97 (dt, J=15.60, 7.75 Hz, 1H), 7.82 (s, 1H), 7.83-7.89 (m, 1H), 7.89-7.98 (m, 2H), 8.62 (s, 1H), 8.69 (br d, J=8.16 Hz, 1H), 8.79 (s, 1H), 8.90 (br s, 2H), 9.09 (s, 1H), 9.15 (br s, 1H), 9.16 (br s, 1H), 9.26 (s, 1H), 11.14 (br s, 1H), 13.98 (s, 1H), 14.39 (br s, 1H); ESIMS found for C30H25N7O m/z 500.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 2.60-2.71 (m, 2H), 3.59 (br s, 2H), 3.83-3.94 (m, 2H), 4.63 (br s, 2H), 7.87-7.93 (m, 2H), 7.94-7.99 (m, 1H), 8.02 (br d, J=8.82 Hz, 1H), 8.62 (s, 1H), 8.74 (br d, J=7.72 Hz, 1H), 8.85 (s, 1H), 8.90 (br s, 2H), 8.96 (br s, 1H), 9.10 (s, 1H), 9.29 (br s, 1H), 9.30 (br s, 1H), 13.92 (s, 1H), 14.36 (br s, 1H); ESIMS found for C29H23F2N7 m/z 508.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 7.78-7.84 (m, 1H), 7.84-7.92 (m, 2H), 7.92-7.99 (m, 1H), 8.49-8.55 (m, 1H), 8.57 (br s, 1H), 8.77 (br s, 1H), 8.85 (br d, J=1.54 Hz, 1H), 9.06 (br s, 1H), 9.20 (br d, J=0.66 Hz, 1H), 9.22 (br s, 1H), 9.34 (br s, 2H), 13.87 (br s, 1H), 14.31 (br s, 1H); ESIMS found for C23H15N7 m/z 390.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 0.98 (d, J=6.39 Hz, 6H), 2.14 (dt, J=13.51, 6.81 Hz, 1H), 2.27 (d, J=7.06 Hz, 2H), 7.49 (s, 1H), 7.74-7.79 (m, 1H), 7.79-7.84 (m, 1H), 7.89 (d, J=5.95 Hz, 2H), 8.41 (s, 1H), 8.42-8.48 (m, 2H), 8.72 (br d, J=1.98 Hz, 1H), 8.74 (br d, J=1.98 Hz, 1H), 8.76 (br d, J=5.73 Hz, 2H), 8.89 (s, 1H), 10.21 (s, 1H), 12.65 (br s, 1H), 13.83 (s, 1H); ESIMS found for C29H25N7O m/z 488.2 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 3.73 (s, 2H), 7.24-7.31 (m, 1H), 7.31-7.45 (m, 4H), 7.76 (s, 1H), 7.79 (br dd, J=8.82, 1.54 Hz, 1H), 7.84-7.88 (m, 1H), 7.96 (d, J=6.17 Hz, 2H), 8.45 (br t, J=2.09 Hz, 1H), 8.54 (d, J=10.14 Hz, 2H), 8.75 (d, J=1.98 Hz, 2H), 8.84 (br d, J=5.95 Hz, 2H), 9.01 (s, 1H), 10.55 (s, 1H), 13.54 (br s, 1H), 14.13 (s, 1H); ESIMS found for C32H23N7O m/z 522.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 3.32 (s, 6H), 3.95 (br s, 2H), 7.47 (s, 1H), 7.77-7.86 (m, 2H), 7.86-7.92 (m, 2H), 8.21 (br s, 1H), 8.38 (s, 1H), 8.50 (s, 1H), 8.59 (br s, 1H), 8.69-8.77 (m, 2H), 8.87 (s, 1H), 9.04 (br s, 1H), 12.46 (br s, 1H), 13.78 (s, 1H); ESIMS found for C27H23N7 m/z 446.2 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.85-1.95 (m, 2H), 2.03-2.12 (m, 2H), 3.14-3.24 (m, 2H), 3.45-3.52 (m, 2H), 4.48-4.55 (m, 2H), 7.80 (s, 1H), 7.89 (s, 2H), 7.95-8.00 (m, 2H), 8.38 (t, J=2.20 Hz, 1H), 8.57 (s, 1H), 8.62 (s, 1H), 8.73 (d, J=1.98 Hz, 1H), 8.81-8.85 (m, 2H), 9.02 (s, 1H), 9.17 (d, J=2.21 Hz, 1H), 13.54 (br s, 1H), 14.18 (br s, 1H); ESIMS found for C29H25N7 m/z 472.2 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 0.96 (t, J=139 Hz, 3H), 1.67 (dq, J=14.75, 7.29 Hz, 2H), 2.37 (br t, J=7.28 Hz, 2H), 7.51 (s, 1H), 7.74-7.79 (m, 1H), 7.79-7.85 (m, 1H), 7.87-7.93 (m, 2H), 8.42 (s, 1H), 8.43-8.49 (m, 2H), 8.72 (dd, J=3.53, 2.20 Hz, 2H), 8.77 (br d, J=5.95 Hz, 2H), 8.90 (s, 1H), 10.22 (s, 1H), 12.72 (br s, 1H), 13.85 (s, 1H); ESIMS found for C28H23N7O m/z 474.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 7.87-7.94 (m, 2H), 7.98-8.06 (m, 3H), 8.12-8.19 (m, 2H), 8.60 (s, 1H), 8.75 (s, 1H), 8.80 (br dd, J=4.30, 1.65 Hz, 2H), 8.85-8.90 (m, 2H), 9.06 (s, 1H), 13.73 (br s, 2H), 14.28 (s, 1H); ESIMS found for C24H16N6 m/z 389.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 0.85-0.93 (m, 4H), 1.81-1.88 (m, 1H), 7.46 (s, 1H), 7.73-7.78 (m, 1H), 7.78-7.83 (m, 1H), 7.87-7.91 (m, 2H), 8.40 (s, 1H), 8.44 (s, 2H), 8.72 (dd, J=3.64, 2.09 Hz, 2H), 8.74-8.78 (m, 2H), 8.88 (s, 1H), 10.54 (s, 1H), 12.58 (br s, 1H), 13.81 (s, 1H); ESIMS found for C28H21N7O m/z 472.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.19-1.38 (m, 3H), 1.40-1.55 (m, 2H), 1.68 (br d, J=11.03 Hz, 1H), 1.75-1.83 (m, 2H), 1.87 (br d, J=11.91 Hz, 2H), 2.35-2.43 (m, 1H), 7.44 (s, 1H), 7.74-7.84 (m, 2H), 7.88 (br d, J=5.51 Hz, 2H), 8.39 (br s, 1H), 8.44 (s, 1H), 8.47 (d, J=1.76 Hz, 1H), 8.71 (s, 1H), 8.72-8.79 (m, 3H), 8.88 (br s, 1H), 10.15 (s, 1H), 12.49 (br s, 1H), 13.78 (s, 1H); ESIMS found for C31H27N7O m/z 514.2 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 7.34-7.40 (m, 1H), 7.55 (brd, J=5.07 Hz, 1H), 7.79 (brd, J=8.38 Hz, 1H), 7.88-7.99 (m, 3H), 8.13 (br s, 1H), 8.15 (br d, J=7.28 Hz, 1H), 8.24-8.30 (m, 1H), 8.46 (br s, 1H), 8.71 (br d, J=3.97 Hz, 1H), 8.81 (br d, J=6.17 Hz, 2H), 8.95 (br s, 1H), 13.91 (s, 2H); ESIMS found for C24H16N6 m/z 389.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 0.97 (br d, J=6.53 Hz, 6H), 1.61 (br d, J=4.52 Hz, 2H), 1.78 (br s, 4H), 2.09-2.19 (m, 1H), 2.27 (brd, J=6.90 Hz, 2H), 3.21-3.27 (m, 4H), 7.08 (s, 1H), 7.68 (brs, 1H), 7.78 (s, 2H), 8.37 (s, 1H), 8.44 (s, 1H), 8.51 (br s, 1H), 8.71 (br d, J=3.01 Hz, 2H), 10.21 (s, 1H), 12.02 (br s, 1H), 13.63 (br s, 1H); ESIMS found for C29H31N7O m/z 494.3 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.59 (br s, 2H), 1.75 (br s, 4H), 3.17 (br s, 4H), 6.58 (s, 1H), 7.04 (br d, J=8.53 Hz, 1H), 7.12 (s, 1H), 7.21 (br s, 1H), 7.45 (br d, J=8.41 Hz, 1H), 7.81 (s, 1H), 8.08 (s, 1H), 8.18 (s, 2H); ESIMS found for C24H23N7 m/z 410.3 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.62 (br d, J=3.64 Hz, 2H), 1.72 (br s, 4H), 1.78 (br s, 4H), 3.24 (br s, 4H), 3.34-3.37 (m, 4H), 3.71 (s, 2H), 7.12 (s, 1H), 7.68 (s, 1H), 7.73-7.79 (m, 1H), 7.79-7.86 (m, 1H), 8.11 (s, 1H), 8.42 (br s, 1H), 8.44 (br s, 1H), 8.51 (s, 1H), 8.92 (s, 1H), 12.03 (br s, 1H), 13.62 (br s, 1H); ESIMS found for C29H31N7 m/z 478.3 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.62 (br s, 2H), 1.78 (br s, 4H), 3.24 (br s, 4H), 7.18 (br s, 1H), 7.69 (br s, 1H), 7.76-7.84 (m, 1H), 7.84-7.92 (m, 1H), 8.46 (br s, 1H), 8.56 (br s, 1H), 9.21 (br s, 1H), 9.31 (br s, 2H), 12.00 (br s, 1H), 13.67 (br s, 1H); ESIMS found for C23H21N7 m/z 396.2 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 2.28 (s, 3H), 2.60 (br s, 4H), 3.27 (br s, 4H), 5.41 (s, 2H), 7.03 (s, 1H), 7.25 (s, 1H), 7.60 (br d, J=8.53 Hz, 1H), 7.66 (s, 1H), 7.72 (br d, J=8.66 Hz, 1H), 7.94 (d, J=2.26 Hz, 1H), 8.17 (d, J=1.51 Hz, 1H), 8.28 (s, 1H), 8.45 (s, 1H); ESIMS found for C24H24N8 m/z 425.2 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 2.30 (s, 3H), 2.62 (br s, 4H), 3.29 (br s, 4H), 7.12 (s, 1H), 7.37 (dd, J=7.22, 4.96 Hz, 1H), 7.70 (s, 1H), 7.73 (d, J=8.78 Hz, 1H), 7.94 (brt, J=7.65 Hz, 1H), 8.15 (d, J=7.91 Hz, 1H), 8.23 (d, J=8.91 Hz, 1H), 8.48 (s, 1H), 8.71 (br d, J=4.39 Hz, 1H), 8.80 (s, 1H), 12.09 (s, 1H), 13.62 (s, 1H); ESIMS found for C24H23N7 m/z 410.3 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.06 (s, 9H), 2.27 (br s, 2H), 2.28 (br s, 3H), 2.60 (br s, 4H), 3.27 (br s, 4H), 7.01 (s, 1H), 7.61-7.68 (m, 2H), 7.75 (d, J=8.66 Hz, 1H), 8.32 (s, 1H), 8.39-8.47 (m, 2H), 8.70 (s, 1H), 8.74 (d, J=1.76 Hz, 1H), 10.16 (br s, 1H); ESIMS found for C30H34N8O m/z 523.3 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 2.24 (s, 3H), 2.58 (br s, 4H), 3.27 (br s, 4H), 3.76 (br s, 2H), 3.81 (br s, 2H), 7.16 (s, 1H), 7.19-7.25 (m, 1H), 7.31 (br t, J=7.47 Hz, 2H), 7.35-7.41 (m, 2H), 7.67 (s, 1H), 7.78 (q, J=8.66 Hz, 2H), 8.18 (s, 1H), 8.45 (d, J=6.90 Hz, 2H), 8.52 (s, 1H), 8.91 (s, 1H); ESIMS found for C32H32N8 m/z 529.3 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 2.32 (s, 3H), 7.39 (br d, J=4.77 Hz, 1H), 7.44 (s, 1H), 7.51 (br d, J=8.53 Hz, 1H), 7.66 (br d, J=5.15 Hz, 1H), 7.76 (d, J=8.53 Hz, 1H), 8.15 (br d, J=5.52 Hz, 1H), 8.23 (s, 1H), 8.48 (br d, J=4.52 Hz, 1H), 8.52 (s, 1H), 8.82 (s, 1H), 12.45 (br s, 1H), 13.79 (s, 1H); ESIMS found for C20H15N5 m/z 326.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 0.95 (t, J=7.34 Hz, 3H), 1.66 (sxt, J=7.33 Hz, 2H), 2.37 (br t, J=7.28 Hz, 2H), 7.31 (s, 1H), 7.55 (d, J=5.27 Hz, 1H), 7.67-7.74 (m, 1H), 7.76-7.81 (m, 1H), 8.10 (d, J=5.40 Hz, 1H), 8.36 (br s, 1H), 8.41 (br s, 1H), 8.73 (d, J=1.38 Hz, 1H), 8.77 (s, 1H), 8.81 (d, J=1.63 Hz, 1H), 10.23 (br d, J=1.13 Hz, 1H); ESIMS found for C23H20N6O m/z 397.2 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.21 (br d, J=1.17 Hz, 2H), 1.43-1.59 (m, 4H), 1.71 (br s, 2H), 1.96-2.07 (m, 1H), 3.84 (br s, 2H), 7.39 (br s, 1H), 7.56 (br d, J=2.89 Hz, 1H), 7.74-7.80 (m, 1H), 7.80-7.87 (m, 1H), 8.12 (br s, 1H), 8.17 (br s, 1H), 8.47 (br s, 1H), 8.53 (br s, 1H), 8.79 (br s, 1H), 8.92 (br s, 1H), 12.11 (br s, 1H), 13.67 (br s, 1H); ESIMS found for C26H26N6 m/z 423.3 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 7.61 (s, 1H), 7.77-7.84 (m, 3H), 7.86-7.94 (m, 3H), 8.23-8.28 (m, 1H), 8.47 (s, 1H), 8.61 (s, 1H), 8.68 (br d, J=5.77 Hz, 2H), 8.81 (s, 1H), 12.71 (br s, 1H), 13.90 (s, 1H); ESIMS found for C23H15N5S m/z 394.2 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 3.05 (s, 6H), 7.22 (s, 1H), 7.47 (br d, J=5.77 Hz, 2H), 7.72-7.78 (m, 1H), 7.79-7.84 (m, 1H), 7.85 (s, 1H), 8.14 (d, J=2.38 Hz, 1H), 8.35 (s, 1H), 8.40 (s, 1H), 8.53 (s, 1H), 8.61 (s, 1H), 8.71 (s, 1H), 12.26 (br s, 1H), 13.67 (br s, 1H); ESIMS found for C25H20N6O m/z 421.2 (M+1).
1H NMR (499 MHz, DMSO-d6) δ ppm 1.38-1.44 (m, 2H), 1.53 (dt, J=11.18, 5.52 Hz, 4H), 2.41 (br s, 4H), 3.59 (s, 2H), 6.86 (dd, J=3.43, 1.78 Hz, 1H), 7.49 (d, J=4.94 Hz, 1H), 7.53-7.58 (m, 1H), 7.71-7.76 (m, 2H), 7.76-7.81 (m, 1H), 8.03 (s, 1H), 8.27 (d, J=4.94 Hz, 1H), 8.44 (s, 1H), 8.50 (d, J=1.65 Hz, 1H), 8.64 (s, 1H), 8.90 (d, J=2.20 Hz, 1H), 11.73 (br s, 1H), 13.48 (br s, 1H); ESIMS found for C29H26N6O m/z 474.9 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 0.92 (t, J=7.34 Hz, 3H), 1.30-1.42 (m, 2H), 1.62 (quin, J=7.40 Hz, 2H), 2.39 (br t, J=7.40 Hz, 2H), 7.28 (s, 1H), 7.60 (s, 1H), 7.72-7.80 (m, 1H), 7.80-7.85 (m, 1H), 7.90 (s, 1H), 8.41 (s, 1H), 8.47 (s, 1H), 8.58 (s, 1H), 8.71 (s, 1H), 8.76 (br d, J=1.63 Hz, 1H), 8.78 (br d, J=2.01 Hz, 1H), 8.79 (br s, 1H), 10.23 (s, 1H), 12.81 (br s, 1H), 13.90 (s, 1H); ESIMS found for C28H24N6O2 m/z 4113 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 0.82-0.93 (m, 4H), 1.80-1.90 (m, 1H), 7.25-7.31 (m, 1H), 7.46 (s, 1H), 7.67 (d, J=5.02 Hz, 1H), 7.69-7.75 (m, 1H), 7.75-7.84 (m, 2H), 8.37-8.46 (m, 3H), 8.72 (s, 1H), 8.74 (br s, 1H), 8.76 (br s, 1H), 10.56 (br s, 1H); ESIMS found for C27H20N6OS m/z 4112 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 3.78 (s, 2H), 3.85 (s, 2H), 7.20-7.26 (m, 2H), 7.31 (brt, J=7.47 Hz, 2H), 7.36-7.41 (m, 2H), 7.52 (s, 1H), 7.64 (d, J=4.89 Hz, 1H), 7.77-7.87 (m, 3H), 8.17 (s, 1H), 8.43 (s, 1H), 8.47 (s, 1H), 8.55 (s, 1H), 8.76 (s, 1H), 8.92 (d, J=1.63 Hz, 1H), 12.40 (br s, 1H), 13.76 (brs, 1H); ESIMS found for C31H24N6S m/z 513.2 (M+1).
1H NMR (400 MHz, METHANOLS) δ ppm 1.09-1.28 (m, 3H), 2.42-2.53 (m, 2H), 2.82 (br s, 3H), 4.39 (br s, 2H), 7.25-7.33 (m, 1H), 7.49 (br d, J=7.94 Hz, 1H), 7.64 (br s, 1H), 7.80 (br d, J=14.99 Hz, 2H), 8.14-8.19 (m, 1H), 8.31 (br s, 1H), 8.44 (br s, 1H), 8.49 (br d, J=1.76 Hz, 1H), 8.63 (br d, J=0.88 Hz, 1H), 8.69 (br s, 1H), 8.88 (br s, 1H); ESIMS found for C30H26FN7O3S m/z 584.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.28 (brt, J=7.06 Hz, 3H), 3.04 (brd, J=5.07 Hz, 2H), 4.31 (br s, 2H), 4.38 (br d, J=5.95 Hz, 2H), 7.39 (br d, J=8.82 Hz, 1H), 7.68 (br d, J=9.04 Hz, 1H), 7.75-7.85 (m, 2H), 7.90 (br d, J=8.60 Hz, 1H), 7.96 (br d, J=8.60 Hz, 1H), 8.49 (s, 1H), 8.68-8.84 (m, 3H), 9.08 (s, 1H), 9.21 (br s, 1H), 13.80 (br s, 1H), 14.29 (br s, 1H); ESIMS found for C30H28FN7O2S m/z 570.1 (M+1),
1H NMR (400 MHz, DMSO-d6) δ ppm 2.86 (s, 3H), 3.75 (s, 2H), 4.35 (br d, J=6.17 Hz, 2H), 7.25-7.31 (m, 1H), 7.33-7.40 (m, 4H), 7.66 (br d, J=9.26 Hz, 1H), 7.73-7.83 (m, 4H), 7.88 (br d, J=8.82 Hz, 1H), 8.49 (br d, J=9.04 Hz, 2H), 8.57 (br s, 1H), 8.86 (br s, 2H), 9.01 (s, 1H), 10.78 (s, 1H), 13.73 (br s, 1H), 14.23 (br s, 1H); ESIMS found for C35H28FN7O3S m/z 646.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.20 (d, J=6.39 Hz, 6H), 2.90 (s, 3H), 3.82-3.91 (m, 1H), 4.37 (br d, J=6.39 Hz, 2H), 6.72 (br s, 1H), 7.35-7.42 (m, 1H), 7.61-7.73 (m, 2H), 7.75 (s, 1H), 7.77-7.90 (m, 4H), 8.02 (br s, 1H), 8.48 (br s, 2H), 8.66 (s, 1H), 9.05 (s, 1H), 13.84 (br s, 1H), 14.31 (br s, 1H); ESIMS found for C30H28FN7O2S m/z 570.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 0.91 (t, J=139 Hz, 3H), 1.21-1.31 (m, 2H), 1.31-1.41 (m, 2H), 1.61 (dt, J=14.77, 7.39 Hz, 2H), 2.41 (br t, J=7.50 Hz, 2H), 2.88 (s, 3H), 4.36 (d, J=5.95 Hz, 2H), 7.38 (br d, J=9.04 Hz, 1H), 7.64-7.70 (m, 1H), 7.76 (s, 1H), 7.77-7.83 (m, 2H), 7.85-7.92 (m, 1H), 8.49 (s, 1H), 8.53 (br s, 1H), 8.60 (s, 1H), 8.87 (s, 2H), 9.03 (s, 1H), 10.55 (br d, J=0.66 Hz, 1H), 13.79 (s, 1H), 14.29 (s, 1H); ESIMS found for C32H30FN7O3S m/z 612.1 (M+1)
1H NMR (400 MHz, DMSO-d6) δ ppm 1.81-1.90 (m, 1H), 1.94-2.05 (m, 1H), 2.11-2.23 (m, 2H), 2.23-2.31 (m, 2H), 2.88 (s, 3H), 4.37 (br d, J=5.95 Hz, 2H), 7.38 (br d, J=9.04 Hz, 1H), 7.67 (br d, J=9.26 Hz, 1H), 7.73-7.86 (m, 3H), 7.90 (br d, J=8.82 Hz, 1H), 8.49 (s, 1H), 8.62 (br d, J=5.95 Hz, 2H), 8.95 (br d, J=5.07 Hz, 2H), 9.03 (s, 1H), 10.47 (br s, 1H), 13.79 (br s, 1H), 14.28 (br s, 1H); ESIMS found for C32H28FN7O3S m/z 610.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 2.93 (s, 3H), 4.38 (d, J=6.17 Hz, 2H), 7.39 (br d, J=9.48 Hz, 1H), 7.68 (br d, J=9.26 Hz, 1H), 7.79-7.86 (m, 2H), 7.86-7.91 (m, 1H), 7.91-7.97 (m, 1H), 8.49 (s, 1H), 8.74 (s, 1H), 9.03 (s, 1H), 9.21 (s, 1H), 9.33 (s, 2H), 13.84 (br d, J=1.32 Hz, 1H), 14.31 (br s, 1H); ESIMS found for C26H20FN7O2S m/z 514.0 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.55-1.66 (m, 2H), 1.69-1.77 (m, 2H), 2.61 (br t, J=11.54 Hz, 2H), 2.73-2.83 (m, 1H), 3.04 (br d, J=10.92 Hz, 2H), 7.17 (s, 1H), 7.30 (br t, J=7.59 Hz, 1H), 7.36 (br d, J=8.53 Hz, 1H), 7.55-7.65 (m, 3H), 7.68 (br t, J=7.15 Hz, 1H), 7.91 (s, 1H), 8.25 (s, 1H), 8.79 (s, 1H); ESIMS found for C25H22FN5 m/z 412.3 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 2.84 (br s, 2H), 3.83 (br s, 2H), 6.31 (br s, 1H), 7.49 (br t, J=8.72 Hz, 2H), 7.54 (s, 1H), 7.66-7.77 (m, 2H), 7.98 (dd, J=8.22, 5.46 Hz, 2H), 8.16 (s, 1H), 8.45 (s, 1H), 9.03 (s, 1H), 13.61 (br s, 1H), 14.13 (s, 1H); ESIMS found for C25H20FN5 m/z 410.2 (M+1).
1H NMR (499 MHz, DEUTERIUM OXIDE) δ ppm 4.51 (s, 6H), 4.95 (t, J=5.63 Hz, 2H), 6.52 (t, J=5.76 Hz, 2H), 9.59-9.66 (m, 3H), 10.01 (d, J=8.51 Hz, 1H), 10.05-10.08 (m, 1H), 10.10 (dd, J=8.65, 1.51 Hz, 1H), 10.12-10.18 (m, 2H), 10.49 (s, 1H), 10.54 (d, J=2.74 Hz, 1H), 10.71 (s, 1H), 10.85 (d, J=1.92 Hz, 1H), 11.06 (s, 1H), 14.51 (br s, 1H), 15.90 (br s, 1H); ESIMS found for C29H25FN6O m/z 492.9 (M+1).
1H NMR (499 MHz, DMSO-d6) δ ppm 7.06 (s, 1H), 7.39-7.46 (m, 2H), 7.50-7.58 (m, 1H), 7.63 (d, J=8.51 Hz, 1H), 7.69-7.77 (m, 2H), 7.99 (br s, 1H), 8.20 (br d, J=13.17 Hz, 2H), 8.25 (br s, 1H), 8.83 (s, 1H), 12.20 (s, 1H), 12.88 (br s, 1H), 13.49 (s, 1H); ESIMS found for C23H15FN6 m/z 394.9 (M+1).
1H NMR (500 MHz, DMSO-d6) δ ppm 1.46-1.56 (m, 2H), 1.93-2.00 (m, 2H), 2.55-2.63 (m, 2H), 2.96 (dt, J=12.62, 4.25 Hz, 2H), 4.61-4.69 (m, 1H), 7.12 (d, J=1.65 Hz, 1H), 7.36-7.40 (m, 1H), 7.40-7.44 (m, 1H), 7.49-7.56 (m, 1H), 7.70-7.78 (m, 3H), 7.79-7.84 (m, 1H), 8.18 (d, J=1.10 Hz, 1H), 8.28 (d, J=2.47 Hz, 1H), 8.36 (s, 1H), 8.55 (d, J=1.92 Hz, 1H), 8.83 (s, 1H), 12.28 (br s, 1H), 13.66 (br s, 1H); ESIMS found for C30H25FN6O m/z 504.9 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 3.89 (s, 3H), 7.30 (br s, 1H), 7.59-7.68 (m, 3H), 7.97 (s, 1H), 8.21 (s, 1H), 8.24 (s, 1H), 8.26-8.32 (m, 2H), 8.68 (dd, J=4.64, 1.38 Hz, 1H), 8.82 (s, 1H), 9.04 (d, J=1.88 Hz, 1H); ESIMS found for C23H17N7 m/z 392.4 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 2.71 (s, 3H), 3.71 (s, 3H), 7.65 (br d, J=8.78 Hz, 1H), 7.79 (br d, J=7.53 Hz, 2H), 7.93 (br d, J=8.66 Hz, 1H), 8.31 (br s, 2H), 8.51 (s, 1H), 8.73 (s, 1H), 9.02 (br d, J=4.39 Hz, 2H), 9.17 (s, 1H), 14.00 (br s, 1H), 14.49 (br s, 1H); ESIMS found for C24H19N7 m/z 406.2 (M+1).
1H NMR (499 MHz, DMSO-d6) δ ppm 1.61-1.68 (m, 2H), 1.76-1.83 (m, 4H), 3.23-3.28 (m, 4H), 3.77 (dd, J=8.23, 6.04 Hz, 2H), 3.89-3.97 (m, 1H), 4.33 (t, J=7.68 Hz, 2H), 7.06 (s, 1H), 7.69 (s, 1H), 7.73 (d, J=8.78 Hz, 1H), 7.84 (s, 1H), 8.17 (dd, J=8.78, 1.37 Hz, 1H), 8.45 (s, 1H), 8.58 (s, 1H), 8.82 (s, 1H), 12.03 (br s, 1H), 13.62 (br s, 1H); ESIMS found for C26H27N9 m/z 466.0 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.34 (br d, J=6.27 Hz, 1H), 1.46 (br d, J=8.91 Hz, 2H), 1.57 (br s, 3H), 1.66 (br s, 2H), 1.81 (br s, 6H), 2.01 (br d, J=2.13 Hz, 2H), 3.39 (br s, 4H), 4.88 (br s, 1H), 7.69 (br s, 1H), 7.74 (br s, 1H), 7.89 (br d, J=8.16 Hz, 1H), 8.01 (br d, J=8.03 Hz, 1H), 8.62 (br s, 1H), 8.72 (br s, 3H), 9.06 (br s, 1H), 13.38 (br s, 1H); ESIMS found for C30H32N6O m/z 493.3 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.83-1.93 (m, 1H), 2.28 (br s, 4H), 2.38-2.46 (m, 2H), 2.60 (br s, 4H), 2.90 (br d, J=1.67 Hz, 2H), 3.16 (s, 3H), 3.23-3.30 (m, 4H), 6.95 (br s, 1H), 7.57 (br d, J=7.78 Hz, 1H), 7.64 (s, 1H), 7.72 (br d, J=8.53 Hz, 1H), 8.30 (br s, 1H), 8.42 (br s, 1H), 8.46 (br s, 1H), 8.70 (br d, J=6.02 Hz, 2H), 10.28 (br d, J=1.25 Hz, 1H); ESIMS found for C31H35N9O m/z 550.3 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.70 (br s, 4H), 2.55 (br s, 4H), 2.85 (t, J=5.77 Hz, 2H), 4.29 (t, J=5.77 Hz, 2H), 7.42 (s, 1H), 7.57 (d, J=5.27 Hz, 1H), 7.73-7.78 (m, 1H), 7.80 (br s, 1H), 7.82-7.88 (m, 1H), 8.12 (d, J=5.40 Hz, 1H), 8.31 (d, J=2.51 Hz, 1H), 8.49 (s, 1H), 8.64 (d, J=1.38 Hz, 1H), 8.79 (s, 1H), 12.09 (br s, 1H), 13.64 (br s, 1H); ESIMS found for C25H24N6O m/z 425.4 (M+1).
1H NMR (499 MHz, DMSO-d6) δ ppm 3.97 (s, 3H), 7.51 (s, 1H), 7.72-7.79 (m, 3H), 7.80-7.83 (m, 1H), 7.85 (dd, J=8.64, 1.51 Hz, 1H), 8.19 (dd, J=2.74, 1.37 Hz, 1H), 8.31 (d, J=2.74 Hz, 1H), 8.41 (s, 1H), 8.53 (s, 1H), 8.65 (d, J=1.65 Hz, 1H), 8.75 (s, 1H), 12.27 (br s, 1H), 13.69 (br s, 1H); ESIMS found for C24H17N5OS m/z 424.1 (M+1).
1H NMR (499 MHz, DMSO-d6) δ ppm 3.97 (s, 3H), 7.22 (d, J=1.10 Hz, 1H), 7.48 (s, 1H), 7.74-7.80 (m, 1H), 7.81-7.83 (m, 1H), 7.83-7.87 (m, 2H), 8.32 (d, J=2.74 Hz, 1H), 8.40 (s, 1H), 8.58 (s, 1H), 8.61 (s, 1H), 8.67 (d, J=1.65 Hz, 1H), 8.72 (s, 1H), 12.25 (br s, 1H), 13.68 (br s, 1H); ESIMS found for C24H17N5O2 m/z 408.2 (M+1).
1H NMR (499 MHz, DMSO-d6) δ ppm 2.86 (s, 3H), 4.31 (br d, J=6.31 Hz, 2H), 5.31 (s, 2H), 7.21 (br d, J=8.78 Hz, 1H), 7.35 (br d, J=7.41 Hz, 1H), 7.40 (brt, J=7.41 Hz, 2H), 7.44 (s, 1H), 7.51 (br d, J=7.14 Hz, 2H), 7.56 (br d, J=9.33 Hz, 1H), 7.68 (brt, J=6.31 Hz, 1H), 7.72 (s, 1H), 7.75-7.79 (m, 1H), 7.81-7.85 (m, 1H), 7.86-7.89 (m, 1H), 8.30 (s, 1H), 8.36 (br d, J=2.74 Hz, 1H), 8.47 (s, 1H), 8.64 (br d, J=1.37 Hz, 1H), 8.84 (s, 1H), 12.37 (br s, 1H), 13.70 (s, 1H); ESIMS found for C34H27FN6O3S m/z 618.9 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 2.81 (br s, 6H), 4.50 (br s, 2H), 7.42 (td, J=8.54, 2.09 Hz, 1H), 7.71 (dd, J=7.83, 1.87 Hz, 1H), 7.74 (s, 1H), 7.78 (dt, J=9.87, 2.01 Hz, 1H), 7.84 (d, J=7.72 Hz, 1H), 7.93-8.01 (m, 1H), 8.51 (s, 1H), 8.73 (s, 1H), 8.83 (d, J=1.32 Hz, 1H), 8.98 (br s, 1H), 9.10 (s, 1H), 9.34 (d, J=1.76 Hz, 1H), 13.94 (s, 1H), 14.81 (br s, 1H); ESIMS found for C28H22F2N6 m/z 481.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 2.82 (s, 6H), 4.54 (br s, 2H), 7.39 (td, J=8.65, 2.32 Hz, 1H), 7.63 (s, 1H), 7.64-7.71 (m, 2H), 7.73 (br d, J=9.92 Hz, 1H), 7.80 (d, J=7.72 Hz, 1H), 8.46 (s, 1H), 8.76 (d, J=7.06 Hz, 1H), 8.81 (br s, 1H), 8.94 (s, 1H), 9.03 (s, 1H), 9.11 (s, 1H), 13.84 (s, 1H), 14.41 (br s, 1H); ESIMS found for C28H22F2N6 m/z 481.1 (M+1).
1H NMR (400 MHz, DMSO-d6) δ ppm 2.80 (br s, 6H), 4.56 (br s, 2H), 7.34-7.41 (m, 1H), 7.41-7.47 (m, 1H), 7.62-7.71 (m, 4H), 7.74-7.83 (m, 1H), 8.40-8.47 (m, 1H), 8.74-8.83 (m, 1H), 8.90-8.95 (m, 1H), 8.98 (br s, 1H), 9.11 (br s, 1H), 13.65 (br s, 1H), 14.76 (br s, 1H); ESIMS found for C28H22F2N6 m/z 481.1 (M+1).
The screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) with a lentiviral construct that includes a Wnt-responsive promoter driving expression of the firefly luciferase gene.
SW480 colon carcinoma cells were transduced with a lentiviral vector expressing luciferase with a human Sp5 promoter consisting of a sequence of eight TCF/LEF binding sites. SW480 cells stably expressing the Sp5-Luc reporter gene and a hygromycin resistance gene were selected by treatment with 150 μg/mL of hygromycin for 7 days. These stably transduced SW480 cells were expanded in cell culture and used for all further screening activities. Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:3, 10-point dose-response curves starting from 10 μM) and compound transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, Calif.) into 384-well white solid bottom assay plates (Greiner Bio-One) with appropriate DMSO backfill for a final DMSO concentration of 0.1%. For Sp5-Luc reporter gene assays, the cells were plated at 4,000 cells/well in 384-well plates with medium containing 1% fetal bovine serum and incubated overnight at 37° C. and 5% CO2. Following incubation, 20 μl of BrightGlo luminescence reagent (Promega) was added to each well of the 384-well assay plates. The plates were placed on an orbital shaker for 2 min and then luminescence was quantified using the Envision (Perkin Elmer) plate reader. Readings were normalized to DMSO only treated cells, and normalized activities were utilized for EC50 calculations using the dose-response log (inhibitor) vs. response-variable slope (four parameters) nonlinear regression feature available in GraphPad Prism 5.0 (or Dotmatics). For EC50 of >10 μM, the percent inhibition at 10 μM is provided.
Table 2 shows the measured activity for representative compounds of Formula I as described herein.
Representative compounds were screened using the following assay procedure to assess the effect on cell viability as described below.
Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:3, 8-point dose-response curves from 10 μM to 0.0045 μM) and compound transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, Calif.) into 96-well clear bottom, black-walled plates (Corning-Costar).
Approximately 2×103 SW480 colon cancer cells were seeded into each well and allowed to incubate in the presence or absence of compound for four days at 37° C./5% CO2. Eight replicates of DMSO-treated cells served as controls and cells treated with compound were performed in duplicate.
After incubation, 20 μL of CellTiter-Blue (Promega) was added to each well allowed to incubate for approximately 3 hours. This reagent was a buffered solution which contains resazurin, metabolically active cells were able to reduce rezarurin (blue) into resorufin (pink) which was highly fluorescent. This measured fluorescence was used as a readout for cell viability.
After incubation, the plates were read at Ex 560 nm Em 590 nm (Cytation 3, BioTek). Dose-response curves were generated and EC50 concentration values were calculated using non-linear regression curve fit in the GraphPad Prism (San Diego, Calif.) or Dotmatics' Studies Software (Bishops Stortford, UK). For EC50 of >10 μM, the percent inhibition at 10 μM is provided.
Table 3 shows the activity of representative compounds of Formula I as provided herein.
Representative compounds were screened using primary human fibroblasts (derived from IFF patients) treated with TGF-β1 to determine their ability to inhibit the fibrotic process.
Human Fibroblast Cell Culture:
Primary human fibroblasts derived from IPF patients (LL29 cells) [1Xiaoqiu Liu, et.al., “Fibrotic Lung Fibroblasts Show Blunted Inhibition by cAMP Due to Deficient cAMP Response Element-Binding Protein Phosphorylation”, Journal of Pharmacology and Experimental Therapeutics (2005), 315(2), 678-687; 2Watts. K. L., et.al., “RhoA signaling modulates cyclin D1 expression in human lung fibroblasts; implications for idiopathic pulmonary fibrosis”, Respiratory Research (2006), 7(1), 88] were obtained from American Type Culture Collection (ATCC) and expanded in F12 medium supplemented with 15% Fetal Bovine Serum and Penicillin/Streptomycin.
Compound Screening:
Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point dose-response curves from 10 μM to 1.87 nM) and compound transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, Calif.) into 384-well clear bottom assay plates (Greiner Bio-One) with appropriate DMSO backfill for a final DMSO concentration of 0.1%. LL29 cells are plated at 1,500 cells/well in 80 μL/well F12 medium supplemented with 1% Fetal Bovine Serum. One hour after addition of the cells, TGF-β1 (Peprotech; 20 ng/mL) was added to the plates to induce fibrosis (ref. 1 and 2 above). Wells treated with TGF-β1 and containing DMSO were used as controls. Cells were incubated at 37° C. and 5% CO2 for 4 days. Following incubation for 4 days, SYTOX green nucleic acid stain (Life Technologies [Thermo Fisher Scientific]) was added to the wells at a final concentration of 1 μM and incubated at room temperature for 30 min. Cells were then fixed using 4% formaldehyde (Electron Microscopy Sciences), washed 3 times with PBS followed by blocking and permeabilization using 3% Bovine Serum Albumin (BSA; Sigma) and 0.3% Triton X-100 (Sigma) in PBS. Cells were then stained with antibody specific to α-smooth muscle actin (αSMA; Abeam) (ref. 1 and 2 above) in 3% Bovine Serum Albumin (BSA; Sigma) and 0.3% Triton X-100 (Sigma) in PBS, and incubated overnight at 4° C. Cells were then washed 3 times with PBS, followed by incubation with Alexa Flor-647 conjugated secondary antibody (Life Technologies [Thermo Fisher Scientific]) and DAPI at room temperature for 1 hour. Cells were then washed 3 times with PBS and plates were sealed for imaging. αSMA staining was imaged by excitation at 630 nm and emission at 665 nm and quantified using the Compartmental Analysis program on the CellInsight CX5 (Thermo Scientific). Dead or apoptotic cells were excluded from analysis based on positive SYTOX green staining. % of total cells positive for αSMA were counted in each well and normalized to the average of 11 wells treated with TGF-β1 on the same plate using Dotmatics' Studies Software. The normalized averages (fold change over untreated) of 3 replicate wells for each compound concentration were used to create dose-responses curves and EC50 values were calculated using non-linear regression curve fit in the Dotmatics' Studies Software. For EC50 of >10 μM, the percent inhibition at 10 μM is provided.
Table 4 shows the activity of representative compounds of Formula I as provided herein.
Representative compounds were screened using primary human mesenchymal stem cells (hMSCs) to determine their ability to induce chondrogenesis (process by which cartilage is developed).
Human Mesenchymal Stem Cell Culture:
Primary human mesenchymal stem cells (hMSCs) were purchased from Lonza (Walkersville, Md.) and expanded in Mesenchymal Stem Cell Growth Media (Lonza). Cells between passage 3 and 6 were used for the experiments.
Compound Screening:
Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. For the 96 well assay, serial dilution (1:3, 6-point dose-response curves from 2700 nM to 10 nM) and compound transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, Calif.) into 96-well clear bottom assay plates (Greiner Bio-One) with appropriate DMSO backfill for a final DMSO concentration of 0.03%. hMSCs were plated at 20,000 cells/well in 250 μL/well Incomplete Chondrogenic Induction Medium (Lonza; DMEM, dexamethasone, ascorbate, insulin-transferrin-selenium [ITS supplement], gentamycin-amphotericin [GA-1000], sodium pyruvate, proline and L-glutamine). TGF-β3 (10 ng/mL) was used as a positive control for differentiation while negative control wells were treated with 75 nL DMSO for normalization and calculating EC50 values. For the 384 well assay, serial dilution (1:3, 8-point dose-response curves from 5000 nM to 2.2 nM) and compound transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, Calif.) into 384-well clear bottom assay plates (Greiner Bio-One) with appropriate DMSO backfill for a final DMSO concentration of 0.03%. hMSCs were plated at 8,000 cells/well in 80 μL/well Incomplete Chondrogenic Induction Medium (Lonza; DMEM, dexamethasone, ascorbate, insulin-transferrin-selenium [ITS supplement], gentamycin-amphotericin [GA-1000], sodium pyruvate, proline and L-glutamine). TGF-β3 (10 ng/mL) was used as a positive control for differentiation while negative control wells were treated with 25 nL DMSO for normalization and calculating EC50 values. Cells were incubated at 37° C. and 5% CO2 for 6 days. To image chondrogenic nodules, the cells were fixed using 4% formaldehyde (Electron Microscopy Sciences), and stained with 2 μg/mL Rhodamine B (Sigma-Aldrich) and 20 μM Nile Red (Sigma-Aldrich) [Johnson K., et.al, A Stem Cell-Based Approach to Cartilage Repair, Science, (2012), 336(6082), 717-721], The nodules imaged (25 images per well for 96 well plates and 9 images per well for 384 well plates at 10× magnification) by excitation at 531 nm and emission at 625 nm and quantified using the CellInsight CX5 (Thermo Scientific). Area of nodules in each well was normalized to the average of 3 DMSO treated wells on the same plate using Excel (Microsoft Inc.). The normalized averages (fold change over DMSO) of 2 or 3 replicate wells for each compound concentration were calculated. Due to solubility limitations of some of the compounds, curve fitting was incomplete leading to inaccurate EC50 determinations.
Using TGF-β3 as a positive control, the concentration of representative compounds required to induce 50% levels of chondrogenesis is reported. In addition, the maximum activity of each compound and the respective dose that each compound reached maximum chondrogenesis activity is reported. Table 5 shows the activity of representative compounds as provided herein.
Representative compounds were screened using the following assay procedure to determine their ability to inhibit IL-6 and therefore demonstrate their anti-inflammatory properties.
Human Monocyte Cell Culture:
Human monocyte cell line (THP-1 cells; Catalog # TIB-202, ATCC, Manassas, Va.) were cultured in Roswell Park Memorial Institute (RPMI) 1640 Medium (Catalog #21870-100, Buffalo, N.Y.) with 1% L-glutamine, 1% HEPES, 1% Sodium Pyruvate, 2% Sodium Bicarbonate supplemented with 100 units/mL penicillin, 50 μg/mL streptomycin, 2-mercaptoethanol (0.05 mM) [basal medium] and 10% fetal bovine serum (Catalog #16140089, Life Technologies, Carlsbad, Calif.) at 37° C. and 5% CO2
Compound Screening: THP-1 cells were cultured in basal media with 1% FBS for 24 hours before the start of the assay. Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:3, 10-point dose-response curves starting from 10 μM) and compound transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, Calif.) into 384-well white low volume assay plates (Greiner Bio-One) with appropriate DMSO backfill for a final DMSO concentration of 0.1%. THP-1 cells were plated at 5000 cells/well in the 384-well plates and incubated at 37° C. for 2 h. 500 ng/mL of EPS was added after 2 hours and cells were incubated for another 22 hours at 37° C. Plates were spun in a centrifuge for 1 minute at 10,000 rpm and a mixture of anti-IL6 XL665, and anti-IL6 Cryptate diluted in reconstitution buffer (Cisbio Inc.) was added to each well. Following incubation for 3 hrs at room temperature, Homogeneous Time-Resolved Fluorescence (HTRF) was measured using the Envision (Perkin Elmer) at 665 nm and 620 nM. The ratio of fluorescence at 665 nm to 620 nm was used as a readout for IL6 quantification. All samples were processed in duplicate. Readings were normalized to DMSO treated cells and normalized activities were utilized for EC50 calculations using the dose-response log (inhibitor) vs. response-variable slope (four parameters) nonlinear regression feature available in GraphPad Prism 5.0 (or Dotmatics). For EC50 of >10 μM, the percent inhibition at 10 μM is provided.
Table 6 shows the activity of representative compounds of Formula I as provided herein.
This application claims the benefit of U.S. Provisional Application No. 62/200,229, filed Aug. 3, 2015, which is incorporated herein by reference in its entirety.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US16/45309 | 8/3/2016 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62200229 | Aug 2015 | US |
